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ABSTRACT 
 
Zhen  Xu 
Heterogeneous Particle Deaggregation and Its Implication for Therapeutic  
Aerosol Performance 
(Under the direction of Dr. Anthony J. Hickey, Ph.D, D.Sc.) 
 
The delivery of aerosol drugs using dry powder inhalers (DPIs) greatly improves the 
treatment of diseases such as Asthma. The major hurdles for effective treatment using DPIs 
relate to the formulation performance efficiency and reproducibility. The relationship 
between the physicochemical nature of powder formulation and the behavior of particles in 
the aerosolization process are still poorly understood. 
In order to improve performance prediction and optimization of DPI formulation, we 
should have a comprehensive understanding of the physicochemical properties of the 
powders at rest and after being aerosolized. We hypothesize that: 1) The application of 
standardized entrainment tubes (SETs) for formulation performance evaluation can minimize 
the confounding factors caused by inhaler devices and reveal the relationship of airflow 
conditions and carrier-based dry powder formulation performance. 2) The models of 
molecular surface association described by adsorption expressions can be adapted to fit shear 
displacement observations. 3) The carrier surface treatment can reduce the surface 
heterogeneity and improve the performance efficiency of dry powder aerosol formulation. 
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 A set of SETs was used to allow focus on the relationship between formulation and 
their aerosolization performance. A novel interpretation using powder aerosol deaggregation 
equation (PADE) was developed based on comprehensive studies of carrier-based 
formulation performance. 
 The PADE led to a fundamental understanding that the forces acting at the particle 
interface are analogous to those at the molecular level, and the models of molecular surface 
association described by the adsorption theory are analogous to shear displacement. The 
analogy from surface adsorption/desorption led to a completely novel way of looking at 
particle interactions. Several related surface phenomena were compared from their physical 
meanings to the fundamental theories. 
 The PADE was further challenged by coating of lactose carrier particles with fatty 
acids. The coating was found to effectively improve the aerosolization performance, 
presumably by means of reducing surface heterogeneity and masking high surface energy 
density regions. Using SETs in which particle separation occurs in response to shear stress, 
we have developed a basic understanding of aerosolization performance described by PADE. 
This observation may serve as a link between macroscopic statistical thermodynamics and 
microscopic individual particle deaggregation. 
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CHAPTER 1 GENERAL INTRODUCTION 
1.1 Pharmaceutical Aerosols 
An aerosol is defined as a collection of solid or liquid particles suspended in a gas. 
Therapeutic aerosols are directly delivered into the respiratory tract for local or systemic 
action. Of the various pharmaceutical dosage forms and routes of administration, the delivery 
of aerosols by inhalation frequently offers advantages with respect to oral or parenteral routes 
(Figure 1-1).[1] Briefly, it is a method of non-invasive and local delivery, which may 
improve efficacy and reduce unwanted systemic side effect. The large surface area and thin 
alveolar epithelium of the lungs allow rapid absorption and onset of action to the target site. 
The absence of first-pass metabolism ensures high bioavailability compared to other route of 
administration.  
There is a long history of anecdotal inhalation therapy that can be traced back 4~5 
thousand years. However, the commercialization of inhalation products with manufacturing 
standards and stringent test procedure occurred only recently.[2] During the development of 
modern inhalation therapy, three distinct categories of delivery systems including nebulizer, 
propellant driven metered dose inhaler (pMDI), and dry powder inhaler (DPI) evolved.[3] 
Among them, the nebulizer has the longest history of use for delivery of therapeutic agents.[4] 
pMDIs and DPIs emerged for the treatment of asthma in the mid-1950s and 1960s, 
respectively.[5, 6] More recently there has been an increased interest in the development of 
DPIs due to the phase-out of ozone depleting propellants used in pMDIs.[7, 8] Delivery of 
small molecular weight drugs for the treatment of diseases such as asthma and chronic 
obstructive pulmonary disease (COPD) is the major application for this technology.[9] The 
drugs used for these purpose are mainly classified as β2-adrenergic receptor agonists, mast 
cell stabilizers, cholinergic receptor antagonists, and corticosteroids.[6] The pulmonary drug 
delivery is also being used for respiratory tract and lung infections using antibiotics or 
vaccines, or the delivery of protein, peptides and macromolecules for local and systemic 
diseases.[10, 11]  
Asthma therapy is the major application of drugs in these therapeutic categories. These drugs 
may delivered directly to the lungs to treat the cause and symptoms of disease which are 
outlined in the following section  
 
1.2 Therapeutic Implications 
1.2.1 Asthma 
Asthma is a chronic inflammatory airway disease. It is characterized by bronchoconstriction 
and inflammation of the airways, which is partially or completely reversible either 
spontaneously or with treatment. Acute exacerbations of asthma result in symptoms 
including wheezing, cough, and dyspnea. However, limited symptoms associate with asthma 
between acute exacerbations and even pulmonary function tests may be normal. Whereas 
past definitions emphasized obstruction, more accurate definition focuses on asthma as a 
primary inflammatory disease which is the major cause of bronchial hyperreactivity and 
airflow obstruction.[12] Approximately 7.2% of U.S. adults have asthma and in 2006 
accounted for 3613 deaths in the United States.[13] Asthma can be triggered by airway 
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inflammation caused by allergens, respiratory infections, occupational and environmental 
stimuli, cigarette smoke, pharmacological agents such as methacholine, histamine, and 
aspirin along with non-steroidal anti-inflammatory agents, and many unknown inflammatory 
mediators.[14, 15]  Asthma often occurs at night (Nocturnal asthma) because of sleep-
induced airway smooth muscle tone change and reduced circulating catecholamine levels. 
Inflammation also causes an associated increase in bronchial hyperresponsiveness to stimuli. 
Mucus hypersecretion can occur in acute and chronic feature of asthma accompanying 
airway inflammation, which, in severe asthma, lead to fatal airway obstruction.[14] Asthma 
is mediated by antibodies (IgE) found on mast cells in the airway mucosa. On exposure to 
antigens, there is an increase in CD4+ T lymphocytes that orchestrate the degranulation of 
mast cells to release primary mediators including histamine, eosinophilic, and neutrophilic 
chemotactic factors, which cause rapid and episodic bronchoconstriction and increased 
vascular permeability. In asthma, cytokines such as interleukin (IL)-4, IL-5, and IL-13 may 
be important, because they are necessary for IgE formation and eosinophilic 
inflammation.[14] The secondary mediators including leukotrienes and prostaglandins may 
result in prolonged bronchoconstrictor response.[16] Several inflammatory enzymes such as 
mast cell tryptase may play important role in hyperreactivity and in some aspects of airway 
remodeling in asthma.[17] 
 
1.2.2 Drugs and Receptors 
Pharmacological control of the airway is mediated by receptors found on bronchial airway 
and vessel smooth muscle, secretory cells, bronchial epithelium, and pulmonary and 
bronchial blood vessels.[18] The receptors for β-adrenergic agonists are distributed 
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throughout the lung, but are more accumulated in the periphery of respiratory systems. Both 
sympathetic (adrenergic) and parasympathetic (cholinergic) receptors control the lung 
airflow. The sympathetic postganglionic fibers primarily secrete norepinephrine. The adrenal 
glands release epinephrine when they receive sympathetic signals from the spinal cord. Both 
epinephrine and norepinephrine bind to α-adrenergic receptors of blood vessels to cause 
constriction and to β-adrenergic receptors of the bronchial airway and vessel smooth muscle 
to cause dilation of the airways and blood vessels. The parasympathetic postganglionic fibers 
secrete acetylcholine as primary neutrotransmitter. Acetylcholine binds to M3 muscarinic 
cholinergic receptors and cause airway smooth muscle constriction, blood vessel dilation, 
and glandular secretion. 
Classes of drugs commonly prescribed for asthma therapy include: 1) Bronchodilators 
(i.e. drugs that result in bronchodilation of the airway smooth muscle) such as β-adrenergic 
agonists, anticholinergics, and phosphodiesterase inhibitors (xanthine derivatives); 2) Drugs 
that reduce or control of inflammatory mediator release/synthesis such as corticosteroid; 3) 
Cromone derivatives that prevent mast cell degranulation. A schematic representation of the 
various pathways leading to bronchoconstriction, and the classes of inhaled anti-asthmatic 
drugs that are utilized to act at specific stages are shown in Figure 1-1.[19] These therapeutic 
agents are mainly aerosolized and delivered by inhalation to respiratory tract.  
1.2.2.1 β-Adrenergic agonists 
β-Adrenergic agonists are a group of catecholamine derivatives that stimulate sympathetic 
nervous system and allow relaxation of airway smooth muscle in the presence of reversible 
airflow obstruction. The trend in this type of bronchodilators has been toward development 
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from nonspecific (such as epinephrine) to β2 specific agents, in order to reduce side-effect 
exerted by stimulation of undesired adrenergic receptors (such as cardiac effect). β2-agonists 
are a primary group of bronchodilators used in asthma treatment. Based on the duration of 
action in the lung following delivery, they are classified as very short-acting such as 
isoetharine; short-acting such as albuterol (GlaxoSmithKline, 3M, Schering Plough), 
terbutaline (AstraZeneca), and fenoterol (Boehringer Ingelheim); and long-acting 
bronchodilators such as salmeterol (GlaxoSmithKline) and formoterol (Boehringer 
Ingelheim).[19]  Treatment with regular β-agonist therapy in severe asthma does not address 
the underlying inflammatory process. Quite a few studies have implicated the use of short-
acting β-agonist causes increased hyperreactivity, worsening clinical outcomes, and mortality, 
which is known as asthma paradox.[20] Co-administration with anticholinergics or 
corticosteroids could achieve additive bronchodilation or anti-inflammation effect. 
1.2.2.2 Anticholinergics 
This class of drugs induce bronchodilation and inhibit mucus secretion by competitive 
inhibition of cholinergic receptors, causing blockade of acetylcholine-induced stimulation of 
guanyl cyclase, which, in turn, reduces the formation of cyclic guanosine monophosphate 
(cGMP), a mediator of bronchoconstriction.[21] They are bronchodilators for treatment of 
asthma. The representative drugs include ipratropium (Boehringer Ingelheim), a non-
selective, short-acting bronchodilator; oxitropium; and tiotropium (Boehringer Ingelheim). 
Ipratropium has been co-administered with albuterol (Combivent®) to achieve additive 
bronchodilator effect and prevent β2-agonist induced bronchospasm.[22]  
1.2.2.3 Corticosteroids 
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Corticosteroids are the most effective medication currently available for the treatment of 
asthma. Although their exact mechanism of action is still unclear, they are effectively used 
for suppressing airway inflammation that usually decrease bronchial hyperreactivity and 
airflow obstruction associated with asthma.[23] They also inhibit prostaglandins and 
leukotrienes, as well as cyclooxygenases (both COX-1 and COX-2) expression, providing 
long-term control of persistent asthma symptoms. The systemic use of corticosteroids causes 
significant systemic immunosuppression, while local delivery with aerosol corticosteroids 
has far fewer side effects. This class of drugs include beclomethasone dipropionate 
(GlaxoSmithKline, 3M, and Schering Plough), triamcinolone acetonide (Aventis), 
budesonide (AstraZeneca), flunisolide, fluticasone (GSK), and Mometasone furoate 
(Schering Plough).[19]  
1.2.2.4 Cromone derivatives 
Cromones are a unique class of compounds that prevent the onset and development of asthma 
through inhibition of chemical mediators of inflammation. The representative drug, disodium 
cromoglycate (Aventis), was formulated as the first marketed dry powder inhalation product 
for the treatment of asthma.[2] The mechanism of action of this class of drugs has yet to be 
fully elucidated. Generally, they are mast cell stabilizers that prevent histamine release 
involved in local hypersensitivity of the lungs.[19]  
1.2.2.5 Xanthine derivatives 
Xanthine derivatives such as theophylline have the effect of diuresis and smooth muscle 
relaxation.[24] They are used as bronchodilator for the treatment of both asthma and stable 
state COPD. The exact mechanism of action of xanthines is still debatable. It is generally 
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proposed that xanthines cause smooth muscle relaxation by inhibition of phosphodiesterase, 
leading to an increase in intracellular cyclic adenosine 3’,5’-monophosphate (cAMP). An 
increase in cAMP results in bronchial smooth muscle relaxation.[24]. Xanthine derivitives 
are not delivered as aerosols but are included as this completes the pharmacology of locally 
acting agents in the lungs. 
Once the pharmacological targets have been identified delivering the drugs to the site 
of action requires consideration of the anatomy and physiology of the lungs. 
 
1.2.3 Respiratory Deposition 
Airflow in the respiratory system is complex. The understanding of the local aerodynamics 
derives mainly from experimental studies using physical models of lung airways. The 
respiratory system can be divided into three regions: the head airway (nasopharyngeal) 
region, tracheobronchial region, and alveolar region.[25] Each region covers several 
anatomical units exhibiting distinct difference in structure, airflow pattern, and function. In 
Weibel’s model, 23 generations of the airway from trachea to alveolar sacs were 
designated.[26] An estimate of an average adult’s airflow indicates that flows in the upper 
airway are turbulent to transition region, while the 16 generation and below are laminar flow, 
as is indicated by the Reynolds number (Re) of the airway.[26] For the majority of 
pharmaceutical aerosols, the dynamics of particles in the airways fall in the Stokes’ regime 
for particle diameters larger than 1.3 μm.[27] Particle movement in this size regime follows 
Stokes’s law (Eq. 1-1). The individual curvilinear particle motion can be characterized 
including the terminal settling velocity (VTS), relaxation time (τ), and Reynolds number of 
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particles (Rep).[28] Equating the aerodynamic drag force with the Stokes’s law result in the 
terminal settling velocity in a laminar condition and neglecting slip correction:[25] 
VdFD πη3=  (Eq. 1-1) 
)1Re(
18
2
<= forgdV epTS ηχ
ρ
    (Eq. 1-2) 
where ρp is the particle density; de is the equivalent volume diameter (diameter of a sphere 
having the same volume as that of the irregular particle); η is the dynamic viscosity of air 
(1.81 × 10-5 kg/(ms) at 20 oC); χ is the dynamic shape factor. Reynolds number of particle is 
defined as: 
η
ρ Vd pp
p =Re     (Eq. 1-3) 
where dp is the particle diameter, V is the relative velocity between particle and airflow. 
 The airflow in the lower respiratory tract and alveolar region is generally laminar. 
Turbulent deposition may happen in the upper respiratory tract, but will not be discussed here. 
Particles dispersed in airflow follow curvilinear motion. The trajectory of a particle departs 
from the streamline airflow due to a variety of physical forces. Mechanisms of particle 
deposition in the respiratory tract include: 1) inertial impaction; 2) gravitational settling; 3) 
Brownian motion; 4) interception; 5) electrostatic forces. These mechanisms will be briefed 
below. It should be noted that the deposition occurs when several mechanisms act 
simultaneously. A brief discussion is shown below. Discussion of all the deposition 
mechanisms has been included in several books in details.[25, 29, 30] 
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1.2.3.1 Deposition by inertial impaction 
Deposition by inertial impaction is the main mechanism for larger particles (> 5 μm) with 
high velocity. This mechanism occurs at the curvature when the airflow is deflected. While 
smaller and slower particles can move along the streamline, the larger and faster particles are 
unable to follow the streamline due to inertia. A parameter that determines the deposition 
efficiency is the Stokes number:[25, 29] 
D
VCd
D
VStk cpp η
ρτ
92/
2
==    (Eq. 1-4) 
where τ is the relaxation time, dp and V are the particle diameter and velocity, respectively; 
Cc is the Cunningham correction factor. 
1.2.3.2 Deposition by sedimentation 
Gravitational settling (sedimentation) is governed by Stokes’s law (Eq. 1-1). Particle 
diameters between 0.5-3 μm are deposited in the bronchial and alveolar regions by this 
mechanism. Both inertial impaction and gravitational settling are dependent on the relaxation 
time (τ) of the particle, which is defined as:[25] 
η
ρτ
18
2
ppd=     (Eq. 1-5) 
Increased gravitational settling occurs by either breathholding or slow tidal breathing.[29] 
1.2.3.3 Deposition by Brownian motion 
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Brownian motion (diffusion) dominates the deposition of particles smaller than 0.1 μm. The 
rate of diffusion, according to the Stokes-Einstein equation, is proportional to the temperature 
and inversely proportional to the particle size and air viscosity. 
1.2.3.4 Deposition by interception 
Interception is mainly relevant to particles with high aspect ratio (elongated). While flowing 
in the airway, elongated particles are predominantly aligned with streamlines with their long 
axis. Therefore, they have aerodynamic diameters (da) that are predominantly related to their 
short axis (cross-sectional diameter). It is well known that elongated particles such as 
asbestos and mineral fibers are able to deposit in deep lung (alveolar region) because of their 
small aerodynamic diameters and the mechanism of interception. Once deposited, they have 
less chance of being cleared by macrophage due to their length.[25] Because of these 
characteristics, the use of elongated particles for drug delivery has attracted much attention. 
There are quite a few reports that elongated drug [31-34] or carrier [35, 36] particles enhance 
aerosolization performance exemplified as increase in fine particle fraction. However, the 
enhanced performance relies on the loose agglomeration of the fiber to facilitate fluidization 
and deaggregation during actuation. The performance could be poor when the fibrous 
particles are in contact along their length.[28] Powder flow is adversely influenced by 
increasing elongation ratio, which may also cause processing problems such as reduced 
content uniformity. 
1.2.3.4 Deposition by other mechanisms 
Besides the above mentioned mechanisms of respiratory deposition, several additional 
mechanisms may come into play. The electrostatic deposition may occur due to surface 
  10
charges present on particles and the airway surfaces. Hygroscopic particle growth at elevated 
relative humidity and temperature in the respiratory tract may increase or decrease deposition 
velocity.[30] 
It should be noted that deposited particles do not reside permanently in the respiratory 
systems, but are removed by respiratory clearance. The particles (i.e. drugs) are solubilized 
and taken up into blood circulation if they are soluble in bodily fluid. Otherwise, they are 
cleared by alveolar macrophage or mucociliary escalation (the upward movement of mucus 
due to coordinated cilia beating. 
In order to enter the respiratory tract particles must be generated as aerosols. One of 
the major categories of aerosol delivery systems, dry powder inhaler, briefly mentioned 
earlier is described in detail below. 
 
1.3 Dry Powder Inhaler (DPI) 
  The first commercial DPI was the Spinhaler® for the delivery of disodium cromoglycate to 
treat asthma.[37] Unlike pMDIs, passive DPIs actuated by the inspiratory flow of the patient 
require little inhalation coordination. In addition, the propellant-free dosage forms offer 
advantages of formulation stability and low environment impact. DPIs have become an 
important alternative to pMDIs for pulmonary drug delivery.[38-43] In the U.S., several 
successful DPI products, such as Turbuhaler® and Diskus®, were launched in the market in 
the late 1980s and 1990s, respectively.[38] Currently, there are more than twenty passive 
(breath actuated) DPIs commercially available.[6, 43] As the advances of powder technology 
and device design occurred, next generation passive and active DPIs are expected to be 
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approved by Food and Drug Administration. It has been predicted that they may supersede 
pMDIs as the most popular devices.[44, 45] The evolution of DPI is shown is shown in 
Appendix 1-A. 
All DPIs contain three basic features: device, formulation, and dose-metering system. 
For passive DPIs, the inspiratory flow is the only source of energy for particle resuspension 
from static powder bed. The device is designed to allow efficient resuspension through 
distinct fluidization and deaggregation mechanisms.[46] The formulation contains either 
respirable drug particles alone (having the aerodynamic diameter about 1-5 μm depending on 
the target site), or respirable drug with a carrier powder, usually α-lactose monohydrate.[47] 
The carrier (typically > 30 μm [48]) functions primarily to increase powder flow and 
facilitate drug aerosol formation, and act as a bulking agent for uniform capsule filling. There 
are mainly three types of metering systems including the pre-metered individual capsules, 
multiple dose blisters or strips, or dose reservoirs.[42] The device, formulation, and patient’s 
inspiratory maneuver, determine the efficiency and reproducibility of delivery of therapeutic 
aerosols and, consequently, the probability of their reaching the desired site of action.[41, 49-
51] The next generation DPIs under development includes extra mechanisms that facilitate 
drug aerosolization. They include, but are not limited to impellors (Spiros), compressed air 
assist (Nektar), vibration (Oriel, Microdose), and impact hammers (3M, DelSys).[19] Novel 
dry powder inhaler (DPI) technology and particle engineering has yet to lead to the 
fundamental understanding required for predictable and reproducible pulmonary delivery of 
therapeutic aerosol in an airflow independent manner. 
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1.3.1 Aerosol Formulation 
The aerosol formulation consists of interactive physical mixtures of particles (drugs, carriers, 
and surface fines) maintained by thermodynamically favorable interfacial interactions at the 
solid-solid interface. The interparticulate interactions are a combination of van der Waals 
forces, capillary forces, electrostatic forces, and mechanical interlocking.[46] The aerosol 
formation requires the static powder to overcome these interparticulate interactions and 
resuspend the drug particle in an air stream. Besides the adhesion and cohesion, the 
interparticulate friction may also play an important role at the initiation of powder 
aerosolization.[52] Surface analytical approaches have demonstrated the importance of the 
interparticulate forces and formulation performance. The formulation performance may be 
considered in four transition states designated as dilation, flow, fluidization and 
deaggregation, which are most easily contemplated as sequential steps but from a practical 
standpoint are likely to be, more or less, instantaneous phenomena (Figure 1-2C). [46]  
 
1.3.2 Device 
1.3.2.1 DPI device 
DPI device development,[6, 38, 40, 53-55] innovation,[43] mechanism of particle 
separation,[6] and the influence of inhaler selection [50] have been reviewed extensively. 
Each commercial DPI device has distinct dimensions and internal geometries. Thus, each has 
its distinct airflow parameters (e.g. specific resistance, RD) and combination of aerosol 
generation mechanisms to enhance drug resuspension. The mechanisms of DPI fluidization 
include shear, capillary, and mechanical forces; and the mechanisms of particle 
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deaggregation include relative motion, turbulence, shear stress and collision [46]. These 
mechanisms occur to a different extent in each inhaler device, but their relative importance in 
the device is not well understood yet.[6, 46] The airflow pathways of commercial DPIs are 
usually short, tortuous, and sometimes include grids or baffles to maximize delivery 
efficiency, so their airflow conditions are usually not fully developed.[46] The device design 
is usually tailored to achieve maximum drug aerosolization efficiency of a specific powder 
formulation. The combination of the formulation and device is considered the “drug product”. 
Therefore, once a product has been developed the efficiency and reproducibility of aerosol 
delivery by a DPI device-drug formulation combination are measured as the component 
characteristics give rise to a single performance outcome. However, during preliminary 
studies intended to focus on formulation effects alone to aid in optimization, the effect of 
device, required to generate the aerosol, is often underestimated or simply ignored. Due to 
the large variation caused by incompletely developed airflow condition and diverse 
dispersion mechanisms upon inhalation, the evaluation of the formulation performance effect 
is often inconsistent and confounded by the device effect. The use of different devices by 
different researchers prevents the comparison of performance results even if the same airflow 
rate, or pressure drop, is applied. It would be desirable to assess and understand the elements 
of the formulation that contribute to improved performance independently of the unique 
inhaler design. Therefore, it is desirable to adopt standardized devices that will allow 
comparison of formulations between laboratories independently of specific inhalers. 
1.3.2.2 Standardized entrainment tubes (SETs) 
SETs were designed and made in order to respond to the needs for standardized devices to 
evaluate formulations.[56] These SETs were made of polished stainless steel and designed as 
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device-independent tools that encompass a wide range of pressure drops used in commercial 
DPIs at defined airflow rate.[56] The geometry and dimension of the SETs are shown in 
Table 1-1. The principal aerosol generation mechanisms of the SETs are turbulent shear 
force fluidization and deaggregation [56]. Unique features, often found in DPIs, such as grids, 
tortuous channels and other forms of baffles, are not present in the SETs, as they are 
characteristic device design elements matched to particular formulations intended for specific 
drug products and do not easily lend themselves to standardization. Unlike the commercial 
DPI devices, the SETs have fully developed (Poiseuille’s law in a flow field through a 
cylindrical pipe) and well-characterized airflow parameters designated as shear stress (τs), 
Reynold’s number (Re), pressure drop (ΔP) and power [56], which allow focus on the 
formulation effect. Among these parameters, the viscous turbulent stress is directly related to 
the fluid energy dissipation rate, which is influenced by aerodynamic acceleration, shear flow 
as well as by impaction or other mechanical forces.[57] This parameter varies within the flow 
cross-section and also depends on the flow geometry and Reynolds number.[57] In addition 
to turbulent shear forces, the impaction and momentum transfer are perhaps the most 
important mechanisms for deaggregation because they are volume (or weight) related.[58, 59] 
However, it is reasonable to suggest that particles which can be separated by shear forces 
may more readily be removed under the influence of impaction and momentum transfer.[60]  
 
1.4 Fundamental Intermolecular and Surface Forces 
1.4.1 Adhesion and Cohesion Forces 
The intermolecular forces are essentially electrostatic in origin and their rigorous treatment 
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requires consideration of quantum electrodynamics in which the spatial distribution of the 
electron clouds is described by Schrödinger equation.[61] For practical operation, these 
forces are roughly classified into commonly encountered forms including: (1) van der Waals 
forces which are attributed to polarization forces that arise from the dipole moments induced 
in atoms or molecules; (2) hydrogen bonds which are a special dipole–dipole interaction of 
polarized hydrogen atom with an electronegative atom; (3) chemical bonding including 
covalent bonds and ionic bonds at shorter range; (4) Coulomb force arising between charged 
molecules which are purely electrostatic in nature, although all of these forces have the same 
fundamental origin.[62] In the pharmaceutical sciences, these attractive physical forces are 
manifested in different forms such as surface adsorption, protein binding, hydrophobic 
interaction, solvation, crystallization, self-assembly, due to the difference in molecular 
properties at different force range. These forces are often discussed in connection with 
intermolecular surface physics and chemistry. [63, 64]  
 In principle, the fundamental physical forces involved in macrobodies such as 
colloids, microparticles and surfaces, namely the interparticulate or surface forces, are similar 
to those at the molecular level.[62, 65] These attractive physical forces in dry powder aerosol 
formulations are mainly classified as van der Waals, electrostatic, and capillary forces. Other 
forces including frictional forces, mechanical interlocking, and hydrogen bonding are not 
frequently studied, yet still important.[66] They are the manifestation of combining relations 
of the above described intermolecular forces acting between larger particles or extended 
surfaces and should be operative between both molecules and particles.[67] They lead to 
particle aggregation (adhesion/cohesion).[68] Among them, van der Waals forces are 
typically dominant in uncharged dry powders.[69] The magnitude (Figure 1-3) of the van der 
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Waals, electrostatic, and capillary forces between ideal binary system (ideal assumes to be 
atomically flat, surface homogeneous, and rigid bodies) was estimated by calculation 
previously.[58, 66] The van der Waals forces are approximately two orders of magnitude 
greater than electrostatic forces and capillary forces. The latter arising from capillary 
condensation will prevail only at high relative humidity. The majority of publications show 
calculations of the adhesion/cohesion forces in uncharged dry powders based only on the 
contribution of van der Waals forces. Through interaction potential of the form w(r) = – C/h6 
(Lennard-Jones attractive potential, where C is the coefficient of intermolecular pair potential, 
h is the separation distance) and non-retardation assumption, the van der Waals forces can be 
semi-quantitatively described as below:[62, 65, 67, 70] 
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where A is the Hamaker constant (typically ~10-19 J) depending on the molecular properties 
of the materials involved [62], R is the particle radius (m), and h is the separation distance 
(m). Eqs. 1-6 and 1-7 are useful for understanding the origin and magnitude of 
adhesion/cohesion forces as they are proportional to the particle size. Because gravitational 
forces diminish quicker than van der Waals force when particle size is small, the magnitude 
of van der Waals forces become appreciable and the dry powder becomes adhesive/cohesive, 
when the particle sizes are less than 10 μm.[69]  
 The description of interparticulate forces can also be achieved by adopting a 
thermodynamic approach because the work of adhesion/cohesion is closely related to surface 
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energetics. The theoretical treatment that correlates the interparticulate forces between two 
rigid spheres and thermodynamic work of adhesion is known as Derjaguin approximation 
(valid when the range of interaction is much less than the local radii of particle curvature) 
(Eq. 1-8).[71] 
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where Fad is the adhesion force (N); Wab is the work of adhesion between two particles (N/m); 
γa, γb, and γab are the surface free energy of substance a, b, and interfacial energy between a 
and b (J/m2).  
 Although the quantification of van der Waals forces between ideal particles appears 
to be straightforward, the measured forces are not directly translatable to aerosol 
performance. This may be attributed to the complexity of real particles, which are inherently 
heterogeneous. Van der Waals forces between actual pharmaceutical particles require 
consideration of heterogeneity which can be roughly classified from geometric and energetic 
perspectives. The former includes particle size distribution (including the presence of a 
ternary component), morphology, surface asperities, meso- or micro-pores, and particle 
deformation, and the latter, the energy density difference caused by surface imperfection 
such as amorphous content, polymorphic state, or surface impurities. Even perfectly 
crystalline materials have different energy distributions due to their molecular orientation and 
crystal habit. The form of distribution varies with different dry powder material. They will 
influence the interparticulate forces, heat capacity, mechanical stress, etc. The practical 
approach to describing energy heterogeneity is to average local thermodynamic quantities 
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and treat them statistically (i.e. distribution function).[72] Several distribution functions have 
been used in the literature, such as uniform distribution, normal distribution, log-normal 
distribution, exponential distribution, and Rayleigh distribution. They are generally discussed 
in the literature of surface adsorption or surface chemistry.[67, 72] Moreover, the surface 
heterogeneity feature is a characteristic of mutual interaction between particles rather than an 
independent particle. 
Van der Waals forces decay rapidly with increasing separation distance and are 
effective only within a separation distance less than 100 nm [67], so they are quite sensitive 
to particle shape and surface roughness change.[73] Eqs 1-6 and 1-7 for van der Waals forces 
prediction are often poor for pharmaceutical powders because the particle surfaces are 
normally covered by asperities. Roughness arises from numerous small steps, kinks, defects 
or flat regions. They can be evaluated mathematically in terms of irregular oscillations 
around a mean value.[74] Different models such as Fourier, fractal, and chaos analysis have 
been used.[74] The change of surface roughness can change van der Waals forces by several 
orders of magnitude. The magnitude of the interparticulate forces is also affected by the 
number of mutual points of contact (the coordination number).[66] The adhesion/cohesion 
can be overestimated or underestimated based on the effective contact area caused by surface 
roughness.[27]  
 Electrostatic forces can be attractive or repulsive. They occur by means of contact 
charging, coulombic interaction, and induced charging. Contact charging occurs during 
contact between uncharged and unlike particles by electron transfer until equilibrium state of 
the Fermi level is achieved. The magnitude of the contact potential force (Fc) may be 
expressed as:[27]  
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where q is the particle charge on detachment from a substrate; A is the contact area between 
the particle and the substrate.  
Coulombic forces occur when two charged particles are brought together. Either 
attraction or repulsion is possible depending on the electrical charge signs. The magnitude of 
Coulombic forces may be expressed as:[75]  
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where q1 and q2 are the electrical charges on the two particles, respectively; ε is the 
permittivity and h is the separation distance.  
The induced charging occurs when a charged particle, q, approaches an uncharged 
particle of radius R. The magnitude of induced charging forces may be calculated as:[75] 
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where h is the separation distance; ε0 is the permittivity. 
 Capillary forces rise between particles following capillary condensation of water 
vapor at high relative humidity (RH). The Laplace pressure develops due to the water 
meniscus formed in the contact zone pulls particles together. The capillary forces between 
two spherical particles may be described as [62]: 
SLLc RRF γπθγπ *4cos*4 +=     (Eq. 1-12) 
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where Fc is the capillary force; R* is the harmonic mean of the particle radii; γL is the surface 
tension of water (72.8 mN/m at 20 oC); γSL is the solid-liquid interfacial energy; θ is the 
measured contact angle that water is supposed to form with the particle surface. 
Real particles will deform (change in shape and asperities) because of the attractive 
interparticulate forces, resulting in a finite contact area even without external force load.[62] 
The physicochemical and viscoelastic properties of the particles will influence the 
deformation and effective contact area. The determination of the pull-off force between 
deformable bodies has been subjected to several theoretical treatments. Pharmaceutical 
powder aerosols are in general described by adhesive elastic contact using the Johnson-
Kendall-Roberts (JKR)(Eq. 1-13) [76] or the Derjaguin-Muller-Toporov (DMT)(Eq. 1-14) 
[77] models.  
adad WRF
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∗= π2   (Eq. 1-14) 
where Fad is the adhesion force (N), R* is the harmonic mean of the particle radii (m), Wad is 
the work of adhesion (N/m). The choice of the model depends on the interacting materials 
and the particle geometries. The DMT model is applicable for hard material with low surface 
energies and high elastic moduli (Young’s modulus > 109 N/m2), and considers attractive 
force beyond the contact region. The JKR model is for softer material and neglects the 
attractive force outside the contact circle, which indicates the existence of a neck of finite 
height.[27] The transition of DMT to JKR model can be interpreted by a dimensionless 
parameter known as Tabor parameter.[78]  
  21
1.4.2 Deaggregation (Separation) Forces 
Two-phase systems, the solid particles and air molecules with which they interact, play 
important roles in powder dynamics. As mentioned above, the whole aerosolization can be 
roughly categorized into four phases starting from static powder bed, dilation, fluidization, to 
drug resuspension.[79] When the airflow entrains through a DPI, it transfers the kinetic 
energy of the continuous bombardment of air molecules into the powder bed for powder 
entrainment and deaggregation. According to Rumpf’s theory, the particle separation occurs 
when the adhesion forces are supplanted by the applied removal force; whereas Kendall’s 
theory state that the separation occurs when the energy consumption is proportional to the 
formation of new surfaces.[80] For carrier-based DPIs, the separation forces include 1) drag 
and lift, 2) shear and friction, and 3) inertial forces. The aerodynamic drag and shear 
displacement are proportional to the particle cross-sectional area (Fdrag ∝ d2; area related) (Eq. 
1-15).[66] It is increasingly difficult to fluidize smaller particles because adhesive/cohesive 
forces are generally dependent on their diameter, d. Whereas the inertial forces are related to 
kinetic energy function such as collision, rotation, and vibration (Ek ∝ d3; volume related) 
(Eq. 1-16),[66] where Cd is the drag coefficient; d is the diameter of the particle (m); V is the 
airflow velocity (m/s); ρa is the density of the air (kg/m3); and ρp is the density of the particle 
(kg/m3). Shear and friction forces between drugs and carriers are also proportional to d3.[58] 
A more detailed equation that describes the components of predominating forces affecting 
the relative motion of a particle can be found in the literature.[66]  
22
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The airflow in the DPI device may be laminar, transitional, or turbulent, which can be 
described by Reynolds number of the device (Red).[66] The majority of DPIs are designed to 
have turbulent airflow to facilitate particle deaggregation (Red > 4000 for fully developed 
airflow in cylindrical tube), or a turbulent core surrounded by a laminar envelope.[66] 
Besides Red, factors affecting particle entrainment and deaggregation in an air stream include 
shear stress (τs, N/m2), pressure drop (ΔP, N/m2), and power (Nm/s).[56] The volume airflow 
rate required to produce particle deaggregation force to overcome van der Waals forces was 
estimated previously and can be expressed as Q > 110 dp-4/7 (L/min) , dp is the diameter of the 
particle (μm).[81] 
The drug aerosolization efficiency of a dry powder aerosol formulation is generally 
characterized by in vitro performance evaluation, typically an inertial method is employed 
such as liquid impinger sampling or Andersen cascade impaction.[46] 
 
1.5 Aerosolization Performance 
1.5.1 Definition of terms 
With respect to dry powder aerosol performance efficiency and reproducibility, the terms 
emitted dose, fine particle mass or fraction, and mass median aerodynamic diameter are 
frequently used. The emitted dose (ED) represents the proportion of the nominal dose 
delivered, the rest remaining in the device. The fine particle mass (FPM) or fraction (FPF) is 
the mass, or proportion with respect to the nominal dose in a size range considered 
sufficiently small to enter the lungs. The numerical cut-off size defining the FPM or FPF is 
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dictated by the sampling airflow rate and the calibrated cutoff of the inertial sampling device 
with which aerodynamic size is measured. It is frequently the case that the FPM or FPF are 
defined with respect to proportion of mass or faction of the total in particles below an 
aerodynamic diameter of approximately 5 μm (dependent on the sampler and operating 
conditions). The mass median aerodynamic diameter (MMAD) represents the aerodynamic 
particle size for which 50% of the total aerosol by mass has smaller aerodynamic diameters. 
Both FPM (or FPF) and MMAD represents the degree of deaggregation, where larger FPM 
and smaller MMAD values represent greater deaggregation.[56]  
 
1.5.2 Aerosolization performance  
The aerosolization performance of DPI systems depends on different perspectives mentioned 
above. The effect of lactose monohydrate carrier on the aerosolization has been explored 
extensively.[49, 82] An overview of strategies involving lactose monohydrate modification 
to change drug-carrier interaction and improve aerosolization performance is shown in Table 
1-2.[83] Increased drug aerosolization was often observed with smaller carrier size, because 
the proper size of carrier particles may effectively disrupt the drug self-agglomerates.[60, 84] 
However, it was also reported that increasing the carrier size had little influence [52] or 
increase FPF [85] in some formulations. The addition of fine excipients (<10 μm) generally 
increases FPF, and an optimum concentration of fines exist.[86, 87] The carrier shape affects 
the formulation performance, but both increased [35] and decreased FPF [36] were reported 
when the elongation ratio of lactose monohydrate increased. The increased FPF could 
possibly be explained as the increasing aerodynamic drag forces to the elongated carriers, 
whereas the decreased performance in another system was possibly affected by poorer 
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powder flow due to poorer blend content uniformity and irreproducible ED. The influence of 
polymorphism could confound the performance results caused by elongation ratio. The 
surface roughness could influence powder performance in two ways. Lower FPF was 
obtained from carriers with macroscopic surface roughness or smooth surfaces, whereas 
higher FPF was obtained from carriers with microscopic surface roughness.[88, 89] The key 
is the effective drug-carrier contact areas which determine the magnitude of adhesion. 
Particle surface coating with force control agents (e.g. leucine, magnesium stearate) could 
effectively reduce the cohesive-adhesive ratio (characterized by AFM cohesive-adhesive 
balance approach) and improve aerosolization performance.[90] Surface modification by 
etching of carrier lactose monohydrate improved performance, due to the change in surface 
roughness and reduced drug-carrier adhesion.[91, 92] The particle engineering techniques 
[93, 94] provide versatile methods to change particle size, morphology, surface roughness, 
envelope density, crystallinity, and surface electrostatic charge, all of which may have 
significant impact on the aerosolization performance efficiency. 
The goals of these aerosol performance studies are straightforward. They include: 1) 
to improve the aerosolization performance efficiency by maximizing the FPF (or FPM, 
defined in Section 1.5.1 above); 2) to develop device independent formulation (i.e. the same 
FPF across different aerodynamic shear) and; 3) to achieve formulation prediction. However, 
in spite of extensive research in manipulation of interparticulate interactions by above 
mentioned methods, the list of parameters analyzed and the performance properties measured 
indicates the unfortunate nature of research in this field, since it is not evident that the 
phenomenology that naturally precedes the framing of hypotheses to facilitate an 
understanding of underlying scientific principles has evolved beyond its empirical origins. 
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New regulatory initiatives in Quality by Design will facilitate concordance of experimental 
design, and development of standardized materials and methods supporting progress in this 
field.  
 
1.5.3 Current trend for performance prediction of aerosol formulation 
The relationship between the physicochemical properties of dry powder aerosols and the 
aerodynamic aerosolization performance efficiency could be rather complex because a 
myriad of influencing factors described above. Real pharmaceutical fine powders are affected 
by both their intrinsic characteristics and environmental factors. They are susceptible to 
change over time. Each change will result in a formulation with new physicochemical 
properties that may influence performance.[95] Unique inhaler devices and aerosolization 
conditions further confound the aerosol performance evaluation and limit the potential to 
predict behavior. The aerosolization performance prediction remains a challenge due to the 
limited fundamental understanding of interparticulate interactions in heterogeneous condition 
and how they can be related to the deaggregation processes even in the simplest dry powder 
aerosol system. It is imperative to extend qualitative observations to obtain quantitative 
reproducible measurements. Currently, the performance prediction can be roughly classified 
into two categories: The correlation of performance data with 1) formulation properties and 2) 
airflow properties. 
 Performance prediction of a DPI formulation is, to a large extent, achieved by 
correlation of performance data (such as ED, FPF, MMAD) with formulation properties. The 
performance is generally evaluated at fixed airflow condition (e.g. fixed airflow rate, 
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pressure drop, etc). A straightforward approach frequently used is the correlation of 
performance with interparticulate interactions. Traditional techniques for interparticulate 
force measurement include particle detachment following centrifugation, vibration, impact 
separation, and the rapidly developed atomic force microscopy (AFM) technique.[96] The 
AFM colloid probe and pull-off force techniques allow interparticulate force measurement at 
single particle level. It is well known that geometric and energetic heterogeneity often cause 
log-normal distribution of the pull-off forces.[97] However, practically, it has been observed 
that dry powder formulations having similar adhesion/cohesion do not necessarily result in 
similar aerodynamic behavior of the drug when lactose monohydrate based formulations 
were studied.[52, 98] This deviation may be attributed to different sites of adhesion.[52] 
Moreover, increased cohesion was correlated with decreased FPF [99, 100] or increased FPF 
[101] when using drug-only formulation. These paradoxical correlation results can possibly 
be explained by variation in the fluidization and the effectiveness of aerodynamic 
deaggregation exerted on the agglomerates.[101] It is clear that the pull-off force alone may 
not be a reliable parameter for performance prediction. There are reports of the influence of 
the contribution of individual interparticulate forces (van der Waals, capillary, electrostatic 
forces) on performance. However, the correlation of formulation performance with individual 
component of these fundamental forces was rare. 
 In recent years, for the purpose of performance efficiency optimization, indirect 
correlations of performance data with particle size,[102-104] carrier type,[105, 106] particle 
morphology,[107] surface roughness,[92, 100, 108] surface energy,[109-112] ternary 
component,[104, 113, 114] relative humidity (RH%) [115, 116] have been explored. These 
parameters have a great influence on the particulate interaction. Caution should still be 
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exercised when applying some of these parameters. For example, the correlation of 
performance with the increasing surface roughness, was known to either increase [35, 108] or 
decrease [92, 100, 117] the interparticulate forces depending on the true area of contact. 
Different surface analytical techniques have been applied to evaluate the change in 
correlation between particle parameters and performance. AFM is a powerful and versatile 
technique that is playing an important role in surface characterization of various components 
related to the fundamental forces and geometrical features that contribute to 
adhesion/cohesion under a variety of environmental conditions.[118] This technique has been 
used extensively for formulation screening and performance prediction. It is worth 
mentioning that performance efficiency of micronized drug particles is dependent on the 
drugs’ cohesive and adhesive properties and optimum performance is achieved when the 
ratio of cohesion to adhesion is balanced. An approach, designated the cohesive-adhesive 
balance (CAB) method has been described [119, 120] and the aerosol performance was 
correlated with the ratio of cohesive and adhesive forces.[101, 105] Although factors such as 
surface roughness can significantly influence the performance, this method avoids the need 
for measurement of the area of contact, by a normalization technique. Overall this method 
has been useful for formulation screening [121] and correlation with the results of 
aerosolization performance mechanism studies in the more sophisticated ternary blending 
system.[113] A slightly cohesive drug-carrier CAB ratio was suggested for optimum 
formulation performance.[121] Although rapid development of the AFM technique has 
occurred, it should be noted that the correlation using one technique may not always be 
reliable. AFM substrates are usually prepared by recrystallization or high-pressure 
compaction, which may not be a true representation of a relevant pharmaceutical formulation. 
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Other surface analytical techniques such as inverse gas chromatography (IGC) and contact 
angle measurement can provide complementary data for surface energy analysis.  
 Other correlations have been explored for performance data with respect to 
alternative aerosol powder properties such as milling effect,[104] Hildebrand solubility 
parameter,[122] drug-carrier ratio,[123] Carr’s flowability index,[124] elongation ratio,[35] 
avalanche time,[98] and the amount of particle surface coating.[125, 126] These parameters 
are more or less indirectly related to the fundamental interparticulate forces or surface 
energetics. 
 Conversely, the correlation of performance with the airflow properties (e.g. shear 
stress) is much less frequently reported than the relationship to formulation properties. This 
may be attributed to: 1) the requirement for a performance study to control a variety of 
influencing factors, and the airflow is the easiest to fix once the inhaler devices and airflow 
rate are determined; 2) The performance efficiency among different formulations is usually 
compared qualitatively and categorically (i.e. rank order comparison); 3) Many of the studies 
of aerodynamic behavior under various air flow conditions focus on the inhaler device 
development. (For example, the computation fluid dynamics (CFD) aided inhaler device 
design); 4) The formulation effect is often confounded by the inhaler device effect. More 
than twenty inhalers [43, 66] are currently marketed with a variety of mechanisms of drug 
aerosolization, the results and findings in one system cannot be extrapolated directly to 
another system. Nevertheless, the formulation performance as a function of airflow 
parameters is very important because the optimum formulation cannot be determined unless 
its performance under the airflow conditions within a relevant inspiratory range is evaluated. 
For example, the optimized formulation used in Inhalator® (high shear stress) may not 
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necessarily disperse efficiently in Rotahaler® (low shear stress) at the same airflow rate. 
Moreover, most of the commercial DPIs require patients’ inspiration for pulmonary drug 
delivery. The airflow parameters are dependent on the airflow rate (patients’ maneuver) 
which may vary greatly. Performance reproducibility in a wide respirable range is a key to 
the successful formulation development and FDA approval for pulmonary delivery. 
Currently, the conventional formulation optimization and reproducibility study remains an 
empirical estimation based on iteration by trial and error. 
 Performance efficiency is directly related to specific resistance (RD), which is 
dependent on the geometry and dimension of the inhaler devices.[127] At given airflow rate, 
inhaler devices with higher RD are expected to generate greater turbulence and result in 
higher FPF.[128] However, higher RD will result in lower volumetric airflow rate due to the 
capability of patients’ maneuver. Powder flow is correlated directly with ease of particle 
separation and aerosol performance at given RD (same inhaler device).[129] This indicates 
that increasing inspiratory effort corresponds to increase in FPF. More recently, Chan et al 
[130] studied the influence of airflow at 8 different airflow rates on the performance using 
mannitol powder. They observed that an increase in “FPFImpinger” (FPFImpinger represents FPF 
that separate from the influence of capsule, device and throat retention) occurred at lower 
airflow rate between 30 and 75 L/min but reached a plateau at higher airflow rate. They also 
applied a CFD approach to track the fate of 1000-5000 particles through the airstream 
generated inside the Aerolizer®, and concluded that device flow field generated from simpler 
geometry is necessary for deaggregation mechanism studies such as turbulence and 
impaction levels.[130, 131] It should be noted that the airflow rate based on a patient’s 
inhalation covers a very narrow range of inspiratory capacity, while RD tolerates a wider 
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range which can be achieved by device innovation.[128] Recently, a CFD approach was used 
to model airflow path and particle trajectories using ~1000 particles. The particles were 
assumed to deaggregate when the fluid based torque exceeded the separation torque.[59] 
Both fluid-based and impact-based effects were evaluated.[59] Due to the complexity of the 
deaggregation process, the CFD approach is only capable of describing a small population of 
particles but not the entire pharmaceutical powder. In 2006, de Boer et al [132] evaluated the 
relationship of FPF and pressure drop (ΔP) using four commercial inhaler devices with 
distinct mechanisms of deaggregation upon which the performance was highly dependent. 
The complexity of deaggregation makes it difficult to separate the effects of formulation 
heterogeneity and the confounding airflow conditions other than ΔP. A global nonideality of 
the experimental system was observed instead of attempting to deconvolute the confounded 
separate effects.[132] Also in 2006, Louey et al [56] described standardized entrainment 
tubes (SETs). These SETs were characterized using four airflow parameters including 
pressure drop (ΔP), power, Reynold’s number (Re), and shear stress (τs) at airflow rates of 
28.3 and 60 L/min. An increase in these parameters across the device at the same airflow rate 
corresponds to increased drug deaggregation. The airflow conditions of these SETs 
encompass those of commercial inhalers, and the application of well-defined SETs for 
performance studies eliminates the confounding factors caused by inhaler devices and allows 
focus on formulation effect. A semi-quantitative correlation of performance data including 
fine particle mass (FPM) and mass median aerodynamic diameter (MMAD) with these 
airflow parameters was then evaluated. For VentolinTM rotacaps (a lactose based albuterol 
sulfate formulation), hyperbolic relationship and exponential decay were suggested for FPM-
airflow parameters and MMAD-airflow parameters correlation, respectively.[56] Yet, no 
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regression analyses were performed to further quantify these relationships due to the limited 
quantity of initial data. 
 
1.6 Problem Statement: Delivery Efficiency and Reproducibility 
Despite the emergence of novel particle engineering and device technology, efficient and 
reproducible pulmonary delivery of dry powder aerosols in an airflow independent response 
to shear stress still represent a great challenge. This is partly due to a lack of fundamental 
understanding of the behavior of drug microparticles in heterogeneous environments arising 
from a variety of factors (e.g. surface heterogeneity of adsorption sites [133]). Analytical 
approaches such as AFM cohesive-adhesive balance have demonstrated the importance of 
the interplay of the particulate forces and deaggregation. However, a direct correlation of 
pharmaceutical particulate interaction (microscopic) with the aerosol performance 
(macroscopic) data is not readily available, because of the heterogeous nature of both drug 
and carrier surfaces, and multiple assumptions (e.g. Derjaguin approximation) for direct 
interparticulate interaction measurement. The formulation design and optimization are often 
confounded by non-standardized devices, the heterogeneous nature of drug and carrier 
surfaces, and assumptions with respect to force (or surface energy) measurement. 
Performance prediction remains an empirical estimation based on iteration by trial and error. 
In addition to the collecting and analyzing existing results from the literature, we should 
evolve methods that convey the fundamental interparticulate interactions and applied such 
ideas for the formulation evaluation and prediction. Understanding of the fundamental 
adhesion/cohesion and heterogeneous particle deaggregation is still the key for the scientific 
development of DPIs. 
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1.7 Hypothesis and Objectives 
The phase-out of ozone depleting propellants from pharmaceutical aerosol products has 
created a demand for alternative methods of delivering locally acting drugs for the treatment 
of asthma and COPD. Dry powder aerosol formulations consist largely of blends of drug 
with lactose monohydrate. These formulations are frequently inefficient and irreproducible in 
their delivery of drugs. In order to improve performance prediction and optimization of DPI 
formulations, we will characterize the physicochemical properties of carrier-based DPI 
formulations at rest and investigate the heterogeneous nature of these formulations to the 
aerosolization performance using SETs.  Towards these aims, and based on our knowledge 
that the fundamental forces that govern the particle-particle interactions are similar to 
intermolecular and surface interactions, we hypothesize that: 
1) The application of SETs for formulation performance evaluation can minimize the 
confounding factors caused by inhaler devices and reveal the relationship of airflow 
conditions and carrier-based dry powder formulation performance 
2) The models of molecular surface association described by adsorption expressions can be 
adapted to fit shear displacement observations. 
3) The carrier surface treatment can reduce the surface heterogeneity and improve the 
performance efficiency of dry powder aerosol formulation. 
The arrangement of the major objectives that address the hypotheses is shown below:  
1) Discriminatory assessment of dry powder aerosol performance using SETs and carrier-
based formulations. In Chapter 2, we started with the physicochemical characterization of 
lactose monohydrate batches and their interactive physical mixtures with micronized model 
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drug albuterol sulfate. Then, in Chapter 3, we presented an important and comprehensive 
experimental investigation of formulations (4 drugs × 4 lactose monohydrate carriers) which 
led to the discovery of a novel predictive correlation method, namely the powder aerosol 
deaggregation equation (PADE). The performance evaluation of sixteen lactose-based 
formulations using novel PADE method was analyzed using conventional method (by 
DesignExpert analysis) and compared with the PADE method. 
2) Chapter 4 and 6 represented two recent trends for the next generation DPI formulation 
development that either alternative carriers (Chapter 4) or surface modification of existing 
lactose monohydrate (Chapter 6) were explored for formulation optimization. The 
robustness of the PADE method was examined and extended to these systems.  
3) Mechanistic evaluation of performance data by PADE. A theoretical interpretation and 
comparison of surface physical phenomena including surface adsorption, protein binding, 
and powder deaggregation were demonstrated in Chapter 5. The predictive PADE 
regression analyses were exemplified by the evaluation of SETs vs. commercial DPIs and 
storage effect. It is assumed that the particle deaggregation has a statistical origin associated 
with turbulent flow character. The selection of adapted surface adsorption models as the 
possible link between macroscopic statistical thermodynamics and microscopic individual 
particle deaggregation was rationalized. Also in Chapter 5, extra SETs were characterized 
and aerosolization performance was evaluated when more accurate data fittings were 
explored that consider surface heterogeneity of dry powder systems. The adapted surface 
adsorption models were further compared by introducing the heterogeneity factors associated 
with the selected adsorption theories. Several applications of the PADE were included. 
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4) The surface modification of lactose monohydrate (Chapter 6) also served as a probe for 
the study of PADE mechanism. 
5) Finally, in Chapter 7, in addition to a summary of the newly developed theory, some 
guidance for future development of DPI formulation was discussed. 
 
1.8 Summary 
In this chapter, important definitions and a brief history of pharmaceutical inhalation therapy 
have been presented. A short discussion of the therapeutic implications in respiratory drug 
delivery, including the mechanisms of particle deposition in the respiratory tract, a chronic 
airway disease, asthma, and the mechanisms of drug action for treatment of this disease were 
outlined. Two major components of DPI, the dry powder formulation and the aerosolization 
device, were elaborated. The DPI devices were compared with the SETs from their 
mechanisms of fluidization and deaggregation. An obvious advantage of SETs that allowed 
focus on formulation optimization was highlighted. The fundamental interparticulate and 
surface forces that govern the static powder behavior, and the fundamental forces responsible 
for powder aerosolization were recapitulated. These interparticulate interactions served as the 
foundation of all the following dry powder formulation studies. A mini-review of the 
aerosolization performance studies and current trend for formulation prediction and 
optimization was then on introduced, which led to the problem statement about improving 
the aerosolization efficiency and reproducibility. Finally, the hypotheses and the objectives 
of each following chapters were stated. 
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Table 1-1. SET Specifications (Dimensions and Airflow Parameters at Q = 60 L/min). [56] 
 
Dimensions (mm) ** Airflow parameters 
SET 
External 
outlet 
length 
(a) 
Inlet 
length 
(b) 
Internal 
outlet 
length 
(c) 
Inlet outer 
diameter 
(e) 
Inlet inner 
diameter 
(f) 
Reynold’s 
No., Re, 
Shear Stress 
(N/m2) 
A 150 300 140 6.3 4.5 18443 13.143 
B 135 300 125 7.9 6.2 13440 4.342 
C 127 600 117 9.5 7.7 11066 2.199 
D 100 600 90 12.7 11.0 7720 
 
0.624 
* The SET-A and B use peripherally-located dosage table. 
# The SET-C and D use centrally-located dosage table. 
** The powder dosage length (d) is set at 10 mm. 
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Table 1-2. Overview of Strategies that Control Drug-Carrier Interactions for In Vitro 
Aerosolization Optimization 
Modification Major Influencing Factors References 
 Dose (%w/w conc.), drug carrier ratio [84], [103], [123]  
 Drug properties: cohesiveness, adhesiveness [101], [103], [134]  
 Size and size distribution, polydispersity [135, 136] 
 Morphology, polymorph [31], [36], [107], [137] 
Surface roughness [138], [139], [109], [140-142] 
Crystallinity, surface amorphous content [102], [143] 
Physicochemic
al properties 
Crystal habit [144] 
Surface coating Force control agents: magnesium stearate, leucine, lecithin, polymer [90], [109], [125], [137] 
 Nanoparticles [145-147] 
D
ru
g 
 Additive: e.g. amino acid, lactose fine, surfactant [122], [148-150] 
  Co-spray drying [126], [151, 152] 
 Micronization by milling, spray drying, spray-freeze drying, in-situ-micronization [102, 103], [143], [153-156] 
 
Particle 
engineering Direct crystallization [157] 
  Antisolvent precipitation, micro- or nano-size [158-160] 
  Solution enhanced dispersion by supercritical fluids [115], [161] 
Size and size distribution, polydispersity, fine excipient [84], [162-165] 
Morphology [35, 36], [88], [108] 
Surface roughness [117], [166] 
Surface area [110] 
Physicochemic
al properties 
Surface energy [110, 111], [167] 
Surface coating Force control agents [90], [111], [116], [168, 169] 
Surface etching Surface smoothing, surface area reduction [91, 92] 
Particle 
engineering 
Lactose composite, crystallization, spray-drying, 
ultrasound assisted crystallization [100], [36], [170-174] 
C
ar
rie
r 
　
-la
ct
os
e 
m
on
oh
yd
ra
te
 
 Particle engineering review, e.g. spray drying [93], [172], [94] 
Alternative 
carrier 
Physicochemic
al properties 
Reducing or non-reducing sugar: mannitol, glucose, 
erythritol, xylitol, raffinose, sucrose, maltitol, 
maltodextran 
[105, 106], [112], [121], [144], 
[117], [175-177] 
   Sugar fines [86], [176]  
A 
combination 
of above 
Review or 
overview 
Relevant variables for in vitro aerosol resuspension from 
adhesive mixture 
[178], [52], [49](review), 
[179](review), [180, 181], 
[182](review) 
 Milling [104] 
 Mixing [111], [167], [183, 184] Pharmaceutical processing 
 Filling [185] 
Intrinsic fines Introduced by pharmaceutical processing [98] 
[87](review), [176], [114], [186-
188] Added fines Lactose, alternative sugar, drug 
“Active” site Carrier surface occupancy preferred at “active” sites [189-191] 
Ternary 
inclusion 
agglomeration Drug-fine large agglomerates easy to resuspense [86], [113], [162], [192-194] 
Relative 
humidity 
Storage effect, 
humidity Influence of moisture adsorption and ingress [116], [170, 175], [194-196],  
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Figure 1-1. Mechanisms of Action of Drugs for Asthma Therapy.[19] 
 
 
 
 
 
 
 
 
 
 
 
  38
Figure 1-2. Schematic Diagrams of the Dry Powder Inhalers: (A) Rotahaler, a unit-dose low 
shear device; (B) Inhalator, a unit-dose high shear device; and (C) The various transition 
stages of powder aerosolization, through dilated, free flowing, and finally dispersed powder. 
(Courtesy of Dr. A.J. Hickey) 
 
(A) 
 
(B) 
(C) 
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Figure 1-3. The Magnitude of Interparticulate Forces: (A) Adhesion forces; (B) 
Aerodynamic deaggregation forces.[73] 
 
(A) 
 
(B) 
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 CHAPTER 2 LACTOSE CHARACTERIZATION 
2.1 Introduction 
2.1.1 Lactose Monohydrate as Carrier 
Lactose [1] is the most widely used pharmaceutical excipient in solid and liquid dosage 
forms and is the only approved DPI carrier in the US, although the investigation of 
alternative DPI carriers is ongoing. As a carrier in DPI formulation, it functions as a 
fluidizing agent in the drug aerosolization and as a bulking agent for accurate powder 
filling and metering. Lactose has a well established safety profile, is inexpensive, and 
abundant since it is derived from milk and the dairy industry. It has several desirable 
physicochemical properties (monohydrate crystalline form) such as relative smooth 
surface, non-hygroscopic (critical relative humidity ~99% at 24 oC [2]), moderate 
interparticulate interactions and flow properties.[3]  
Lactose is a disaccharide that consists of galactose and glucose bonded through a 
β-1→4 glycosidic linkage. The most common chemical form of lactose used as 
pharmaceutical excipient is the crystalline α-lactose monohydrate (C12H22O11·H2O), 
which is prepared by crystallization from supersaturated aqueous solution below 93.5 
oC.[4] The other two chemical forms of lactose are anhydrous α-lactose and β-lactose. 
The former can be obtained by removing the bound water of α-lactose monohydrate, 
which can be achieved either by heat treatment or anhydrous methanol treatment of 
α-lactose monohydrate.[5] The latter is the anomer of α-form because of mutarotation in 
solution, the stereoisomers inter-conversion at anomeric position. The equilibrium 
concentration of the two anomers is dependent on temperature, solvent, and pH. It should 
be noted that all pharmaceutical crystalline α-lactose monohydrate contain inherent 
β-lactose impurity to a different extent, because the nucleation and growth of the former 
under nonequilibrium concentrations of the latter.[6] On the basis of modeling calculation, 
it has been proposed that the characteristic tomahawk shape of crystalline α-lactose 
monohydrate arises as a consequence of non-uniform incorporation of the β-lactose into 
the growing interface of particular growth sectors.[6, 7] The accurate quantification of 
β-lactose can be achieved by derivatization of anomeric proton by trimethylsilyl group 
followed by gas chromatography.[8] As a source of milk product, the surface of the 
crystalline α-lactose monohydrate may contain tiny amount of residual contaminants such 
as protein (casein, lactoalbumin, and whey) and lipid (triglycerides and fatty acids),[1, 9] 
which may be beneficial or become drawbacks for use. 
For the same chemical form of lactose, the thermal properties including melting 
point, heat of fusion, and heat capacity could be different. For example, the thermal 
properties of anhydrous α-lactose produced by methanol treatment of crystalline 
α-lactose monohydrate are different from that formed by heat.[5] This is the behavior of 
different molecular packing to form different the solid state. Lactoses with different 
degrees of molecular disorder can be prepared by a few methods. For example, a 
molecularly smooth surface, with Miller indices for the {0 1 1} face of α-lactose 
monohydrate crystals can be prepared by temperature controlled micro-crystallization.[10] 
The pure amorphous lactose can be produced by spray drying under the condition 
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described by Lloyd et al.[11] The physical characteristics of α-lactose monohydrate such 
as morphology, size, and β-lactose content could also vary if the nucleation and 
crystallization condition such as supersaturation, temperature, and impurity content 
change.[6] Other properties such as Young’s modulus vary greatly for α-lactose 
monohydrate (24.1 GPa), β-lactose (17.9 GPa), and spray dried lactose (11.4 GPa).[12] 
Furthermore, the manufacturing (e.g. flash drying) and pharmaceutical processing may 
mechanically induce various degrees of molecular disorders on the surface of the 
crystalline α-lactose monohydrate. These molecular disorders can also influence 
processing, storage, and delivery characteristics because they are usually 
thermodynamically unstable. At elevated moisture (water as plasticizer to lower glass 
transition temperature) or heat exposure, the activation energy barrier towards 
recrystallization could be significantly lowered with serious implications with regards to 
long-term stability and batch-to-batch variations.[13] The amount of surface amorphous 
contents could be small and undetectable by standard analytical techniques, but it could 
profoundly change the surface energy distribution, interparticulate interactions, and 
eventually the aerosolization performance.[14-17] Staniforth [18] reviewed the influence 
of different forms of lactose to the aerosolization properties of the formulation. The 
results showed the β-lactose was easily entrained, but bound the drug particles most 
strongly. The anhydrous α-lactose showed the opposite behavior and the α-lactose 
monohydrate showed intermediate behavior. However, anhydrous α-lactose is highly 
hygroscopic. Because the vast difference of these physicochemical properties, the 
production of inhalation grade lactose should be carefully selected and controlled because 
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it could eventually lead to significant therapeutic and biological effects. Lactose 
monohydrate may function in interactive physical mixtures or in a particle matrix that 
contain homogenously dispersed active drug at molecular or particle level. This 
dissertation will focus on the former, the interactive physical mixtures. The objective of 
this Chapter is to characterize the physicochemical properties of lactose monohydrate 
batches and their interactive physical mixtures with micronized model drug albuterol 
sulfate. 
 
2.1.2 Techniques for DPI Formulation Characterization 
2.1.2.1 Static powder characterization 
The physicochemical characterization of DPI formulation components (drug or 
carrier powder and the corresponding blends at rest) has been reviewed previously.[19] 
The classical physicochemical properties characterization of solid state material include 
scanning electron microscopy, differential scanning calorimetry, X-ray powder diffraction, 
atomic force microscopy, inverse gas chromatography, and laser diffraction. 
Scanning electron microscopy (SEM) scans the sample surface with high-energy 
beams of electrons in a raster scanning mode. The electrons interact with surface atoms to 
produce high-resolution images of the sample surface topography, composition and other 
properties such as electrical conductivity. It is routinely used for particle size, 
morphology, and surface feature analysis of dry powder formulations. 
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Differential scanning calorimetry (DSC) evolved from differential thermal 
analysis and share similar thermal analytical principles.[20] The basis of DSC 
measurement is depending on the specific heat (enthalpy: ΔH), the amount of sample 
(heat capacity: ΔCp), and the baseline deviation from that recorded with an empty sample 
holder. DSC can be applied to detect and quantify thermotropic phase transitions, phase 
behavior, and molecular interactions of powder formulation.[21] Either kinetic (fast) scan 
or thermodynamic (slow) scan is used to measure a number of physicochemical features 
including exothermic crystallization, recrystallization, decomposition, etc; or endothermic 
melting, desolvation, dehydration, glass transition, etc. Melting or crystallization 
undergoes first order transitions. The integration of the curve gives the energy involved in 
the transitions; whereas glass transition attributes to the second order transition, and the 
signal gives changes of the specific heat (shift of baselines).[22] Other applications of 
DSC include the analysis of amorphous solid state,[23] polymorphism,[24] isothermal 
analysis of oxidative reactions, and liquid crystals which belong to a state between 
anisotropic (solid) and isotropic (liquid) called meso-morphous state (e.g. some 
phospholipids).[25] Besides, DSC is also used as a quality control instrument for impurity 
detection and stability issues. 
X-ray powder diffraction (XRPD) is widely used to determine the degree of long- 
range order and crystallinity of pharmaceutical powders. The theoretical basis of XRPD 
was developed by Hermans and Weidinger.[26] Briefly, the crystalline intensity and 
amorphous intensity should be able to distinguish from the powder pattern. Usually, both 
peak intensity and area intensity are measured. The diffraction patterns are then compared 
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with a collection of single-phase X-ray powder patterns known as powder diffraction files 
(PDF) to determine the quality of the data. The PDF files are provided by several sources 
such as the University of Cambridge Database and the international center for diffraction 
data (ICDD, Newtown Square, PA).[27] The determination of amorphous content is 
based on the assumption that the proportionality exists between the experimentally 
measured amorphous intensity and the amorphous fraction in the standard sample.[28] 
 Atomic force microscopy (AFM) can be used to examine surface structures of a 
variety of materials with mesoscopic scale resolution (10-6-10-9 m) and quantify the 
individual particle pull-off forces by direct force measurement.[19] Basically, there are 
two primary operation modes: the contact mode and non-contact (tapping) mode. The 
contact mode uses the tip deflection as a feedback signal, whereas the non-contact mode 
detects the oscillation change due to cantilever tip-sample interaction when the cantilever 
is oscillated close to its resonance frequency. The oscillation change provides information 
about the sample surface characteristics (topography and phase). There are several factors 
that link the seemingly straightforward AFM surface topography and force measurement. 
They include: the cantilever tip consistency, the physical and chemical properties of 
colloid probe and the substrate surfaces, the environmental issues, and the contact area 
determination or normalization.[19] The surface roughness can be characterized by the 
root mean square deviation (Rrms) in a given area. The adhesion relies on the true contact 
area of interactions which are influenced by the surface roughness. The adhesion forces 
distributed more widely when a rough surface was used because the asperity radius or the 
effective contact area is more scattered.[29-31] 
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Laser diffraction (LD) is a commonly used light scattering methods of particle 
sizing based on either Frauhofer or Mie interpretation.[32] A laser source is applied (e.g. 
Helium-Neon laser, 682.3 nm, 5 mW) to the scattered powder sample to create a 
diffraction pattern. A large fraction of the power scattered by small particles is scattered 
into large angles, while a large fraction of the powder scattered by large particles is 
scattered into the near forward-direction. A set of concentric annular rings perpendicular 
to the axis of the laser beam forms the detector array to detect the light scattering of the 
sample and intensity of the light collected on each rings will determine the number of 
particles in the defined size range. Statistical analysis results in a combination of 
frequency and cumulative distribution curves from which the volume diameters (D10, D50, 
and D90) and span (span = (D90- D10)/D50) of the scattered particles can be obtained. The 
advantage of this technique is rapid measurement of particle volume size distribution. 
However, it is not possible to differentiate between drug and carrier particle.[33] 
2.1.2.2 Aerodynamic characterization (powder resuspension) 
The aerodynamic properties of powders including flow properties (characterized by ED) 
and deaggregation (characterized by FPF or FPM) may be evaluated in vitro by a variety 
of techniques generally described as inertial sampling techniques.[33] The inertial 
sampling theory is based on the Stokes’s terminal settling velocity and curvilinear particle 
motion. Two devices, the twin-stage liquid impinger and Andersen cascade impactor, and 
their deposition efficiency are depicted in Figure 2-1 [33]. 
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Twin-stage liquid impinger (TSLI) was introduced in the late 1980s [34] and 
included in British Pharmacopoeial standard in 1998 (Figure 2-1A).[35] It uses two 
stages to collect dispersed particles, with the cutoff diameter of 6.4 μm at 60 L/min 
airflow rate. The impaction surface is formed by the perpendicular between the airflow 
and the surface of the collection solution. Volumes of 7 and 30 mL are placed in stages 1 
and 2, respectively. The collection efficiency curve for TSLI is broad (Figure 2-1C), but 
it resembles the oropharyngeal deposition curve that allows quick characterization of 
aerodynamic properties of aerosols.  
Based on the inertial sampling principle, particles whose inertia exceeds a certain 
value are unable to follow the streamline, and impacted (deposited) on the impaction plate. 
Andersen non-viable cascade impactor (ACI) operates several impactor stages (up to 10 
stages are often used) with decreasing aerodynamic cutoff diameter, d50, in series (Figure 
2-1B). The sequential separation divides the particle distribution into a series of 
contiguous groups according to their aerodynamic diameters. Therefore, the 
aerosolization performance (ED, FPF, FPM, and MMAD) indicated by the aerodynamic 
size distribution can be obtained by statistically calculating the deposited fractions. ACI is 
more discriminating and precise than the TSLI. The collection efficiencies (Figure 2-1D) 
of each stage can be calibrated using monodispersed aerosols at defined airflow rate 
(typically at 28.3, 60, and 90 L/min.[36] It should be noted that in vitro ACI performance 
study does not truly represent lung deposition. Unlike the lungs that have rapid expanding 
surface area with descending generations, the surface areas of each ACI stages are similar. 
Unlike the upper airway such as oropharyngeal and trachea that have turbulent airflow, 
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the airflows in the acinar airways (respiratory bronchioles, alveolar ducts, and alveolar 
sac) are slow and laminar (Re < 2000). However, the sampling velocity and Reynolds 
number of ACI increases for successive stages (so that successively smaller particles 
could be collected).[37] 
 
2.2 Material and Methods 
2.2.1 Material 
Lactose monohydrate (RespitoseTM) batches were obtained from DMV-Fonterra 
Excipients. These batches consisted of six sieved batches (SV-A to SV-F) and two milled 
batches (ML-A and ML-B). These batches were selected from initially 35 batches lactose 
monohydrate based on two principal components analyses and cluster analyses performed 
independently. These analyses were used to assess the diversity of batches with respect to 
characteristic such as particle size, bulk and tap density, water activity, etc. The physical 
properties of these lactose monohydrates were supplied by the manufacturer and 
published previously (Table 2-1).[38] Micronized albuetrol sulfate (AS) was supplied by 
Pfizer Global R&D (Kent, UK). It was used immediately after sieving to reduce 
agglomeration due to storage. 
 
2.2.2 Blend preparation 
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AS is used as the drug probe for physicochemical and performance evaluation of the 
lactose monohydrate-based formulation. Micronized AS was allowed to pass through a 
125 μm sieve to reduce the degree of agglomeration. Two drug concentrations (0.5 and 2 
%w/w) of micronized AS in lactose monohydrate interactive physical mixtures were 
prepared. A preblend of AS (10 or 40 mg) with lactose monohydrate batches (1990 or 
1960 mg) was prepared by geometrical addition in an aluminum foil container using a 
spatula. The preblends were further processed in a Turbula® mixer (Model T2C, 
GlenMills, Inc., Clifton, NJ) for 20 min. Blend uniformity was evaluated by analyzing 
five samples of each mixture taken from different regions of the blends. The amounts of 
AS in the blends were quantified by UV absorption spectroscopy measured at a 
wavelength of λ = 225 (Shimadzu UV-1700 UV/Vis spectrometer, Shimadzu Corporation, 
Columbia, MD) in deionized water (Barnstead Nanopure, 18.0 MΩ). In all cases, a 
coefficient of variation (%CV) < 5.0% was considered homogeneous. The prepared 
interactive physical mixtures were placed in tightly sealed glass jars (Wheaton Science 
Products, Millville, NJ) which were then stored in glass desiccators (Drierite®/Indicating 
Drierite®) under ambient temperature and pressure prior to further characterization and 
aerosolization performance study. 
 
2.2.3 Analytical Approaches for Lactose Batches and Blends 
2.2.3.1 Size distribution, morphology, and surface features (SEM) 
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The volume size, morphology, surface features and blend uniformity of drugs, lactose 
monohydrate batches and corresponding blends were examined by SEM. The samples 
were sputter-coated with Au-Pd in Argon for 90 s before the experiment (Polaron 5200 
sputter coater, West Chester, PA). About 150-250 Å of Au-Pd thin films could be coated 
on the sample surface. Scanning electron micrographs (Jeol JSM 6300V SEM, Peabody, 
NY) at a number of magnifications (×150, ×600, ×1.5k, ×3k, ×6k, ×10k and ×20k) were 
examined for micronized albuterol sulfate, and at magnifications (×60, ×150, ×600, ×1.5k) 
for all lactose monohydrate batches and drug/lactose monohydrate blends. 
2.2.3.2 Thermal properties (DSC) 
The molecular and thermotropic phase transitions of each individual component including 
micronized AS, lactose monohydrate batches, and interactive physical mixtures were 
examined by DSC (Perkin Elmer DSC 6 Workstation, Norwalk, CT). Non-hermetically 
sealed aluminum pans containing 1.5-6.0 mg of accurately weighed samples were used. 
Nitrogen purge gas (N2 prepurified, Airgas National Welders Supply, Charlotte, NC) was 
set at 20 mL/min. The temperature and heat flow were calibrated using high purity 
Indium (m.p. = 156.60 oC, ΔHf = 28.45 J/g) and Zinc (m.p. = 419.47 oC, ΔHf = 108.37 
J/g). Various heating rates, including 2.0 oC/min, 5.0 oC/min, and 10.0 oC/min, were 
applied to examine the thermotropic phase behavior (ΔH, Tm) and kinetic/metastable 
phase transitions such as glass transitions (Cp, Tg). Thermograms were processed and 
analyzed using the accompanying software (Pyris Thermal Analysis Instrument Control 
and Data Analysis Software, v.3.01). 
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2.2.3.3 Crystallinity (XRPD) 
The degree of crystallinity and non-crystallinity of the drugs before and after milling, 
lactose monohydrate batches and interactive mixtures was examined by slit detector 
XRPD. (Regaku Multiflex, Tokyo, Japan). The powder was packed onto an etched square 
area of XRPD glass slide that was placed horizontally in the sample holder. 
Diffractograms were obtained to evaluate the crystallinity of the samples (1-2g).  The 
scanning was at 1 2θ degree/min and from 3-60 2θ degree at room temperature (23 oC) to 
cover angles and nanometer distances where peaks occur for pharmaceutical material. 
The intensity of the peaks and the area under the curves were compared with the 
University of Cambridge XRPD database to estimate the long-range and short-range 
order of the material. 
2.2.3.4 Particle volume size distribution (LD) 
The volume size distribution of drugs was characterized by Fraunhofer laser diffraction 
(Malvern Instruments 2600 Series, Worcs, UK) using micronized solid drug particles 
suspended in an organic dispersant. The focal length of the lens is 63 mm, giving a 
nominal size range of 0.5-118 μm. The organic dispersant was chloroform, which is 
commonly used as a dispersing liquid in surface chemical and interfacial experiments due 
to its favorable combination of hydrophobicity and low viscosity. The solid-liquid 
dispersion was sonicated briefly (20 s) to eliminate any small aggregates while not 
physically breaking the primary particles (ie. particle fracture) and modifying the primary 
particle size. 
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2.2.3.5 Surface Topography (AFM) 
Nanotopographic images of individual lactose monohydrate surfaces (SV and ML) were 
acquired using the Topometrix Explorer AFM (ThermoMicroscopes, Sunnyvale, CA) 
under ambient conditions (23-25 oC; 35-40% RH). Steel stubs (Ted Pella, Inc.) were used 
for mounting samples. Cantilever was mounted using superglue. Samples were mounted 
using MikroStikTM (Ted Pella, Inc.). Silicon nitride cantilever tips (non-contact tips 
without coating) were PPP-NCL (NanosensorsTM, Neuchatel, Switzerland) with the 
following specifications: Thickness: 7 μm (range: 6-8 μm); Length: 225 μm (range: 
215-235 μm); Force constant: 48 N/m (range: 21-98 N/m); Average resonance frequency: 
190 kHz. Scan rates were applied at 5 and 10 μm/s in non-contact acquisition mode. Scan 
ranges were 50 μm × 50 μm, 10 μm × 10 μm and 5 μm × 5 μm, respectively. Images with 
resolution set at 100, 300, 400, and 500 were obtained. Best images were obtained by 
using a combination of a slower scanning rate and higher resolution. The entire AFM was 
place onto a bungee suspension to reduce the low frequency vibration noise. 
ThermoMicroscopes SPM lab analysis software (ThermoMicroscopes) and Gwyddion 
software were used in analyzing the AFM images (some topography images and data 
processing were generated using Asylum Reseach MFP3D AFM). Sample preparation 
was carried out by mounting to steel discs at or near their plane of maximum stability by 
the following procedure: A small amount of powder was dropped from a height (0.5 m) 
onto clean overhead projector transparencies; then powder sample discs were painted 
with MikroStikTM adhesive until excess solvent had visibly evaporated; after that the disc 
was inverted (adhesive side down) on a position on the transparency that contained a 
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dilute region of powder; finally the un-adhered particles were removed by tapping of disc 
on bench. This method achieves good particle dilution, and a good probability for 
particles to adhere with large surfaces facing up. 
2.2.4 In Vitro Performance Assessment (TSLI) 
2.2.4.1 Standardized Entrainment Tubes (SETs) 
Four SETs (denoted as SET-A, B, C, and D) with airflow parameters encompassing those 
of commercial DPI devices were selected. The possible mechanisms of particle separation 
in the SETs include 1) particle entrainment in a laminar or turbulent shear fluidization; 2) 
particle entrainment in a laminar or turbulent wall boundary layer; 3) turbulent 
deaggregation of agglomerates by aerodynamic forces or turbulent transient acceleration 
(relative motion) and; 4) particle detachment by momentum transfer (e.g. impaction and 
vibration). Although all of these mechanisms could occur to a different extent during the 
powder resuspension, the aerodynamic contribution can be represented by four airflow 
parameters (Reynolds number, pressure drop, power, and shear stress) at defined airflow 
rate. (Table 1-1 [39]). The pressure drop, ΔP, is directly related to specific resistance (RD) 
(Eq. 2-1):[40] 
QRP D ⋅=Δ  (Eq. 2-1) 
where Q is the volumetric flow rate. The RD is dependent on the geometry and dimension 
of the airflow path, which is an intrinsic parameter of the SETs. Higher RD values are 
expected to correspond to greater turbulence and deaggregation, but too high RD values 
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will cause difficulty in inhalation maneuver. The Reynolds number (Re) of the SETs 
represents the ratio of inertial forces to the viscous forces (Eq. 2-2):[41] 
μ
ρ Vd
F
F
friction
inertial ⋅⋅==Re  (Eq. 2-2) 
where ρ is the density of air (1.20 kg/m3 at 20 oC); V is the linear velocity; d is the inner 
diameter of the SET; and μ is the dynamic viscosity of air (1.81 × 10-5 kg/(m s)). 
Reynolds number is a dimensionless number used to predict the transition from laminar to 
turbulent flow. The laminar flow is present at Re values smaller than 2100, whereas the 
turbulent flow is present at Re values greater than 4000.[41] Re also represents a measure 
of shear forces experienced with the SETs. Higher Re values correspond to higher shear 
forces.[39] The power is the rate of work done by the airflow through the entrainment 
tube (Eq. 2-3):[42] 
QPPower ⋅Δ=  (Eq. 2-3) 
The shear stress τs (Eq. 2-4, where μ is the dynamic viscosity of air; V is the velocity, y is 
the distance to the wall) is probably the most important parameter that acts on the particle 
deaggregation in the turbulent air stream. Shear stress represents the force required for 
one layer of fluid to slide over another layer. The viscous shear stress for turbulent 
airflow can be calculated from a nozzle flow applied from Kolmogorov turbulence theory 
(Eq. 2-5), where μ and v are the dynamic and kinematic viscosity of air, respectively; ε is 
the mean turbulent energy dissipation rate; and d the nozzle diameter.[43] 
y
V
s ∂
∂= μτ  (Eq. 2-4) 
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V
d
V
wheres
332/1 )2.0(22 ≈≅⎟⎠
⎞⎜⎝
⎛= εν
εμτ  (Eq. 2-5) 
The powder formulation (25 mg/actuation) was transferred onto the loading area, 
which was at the proximal end of the inlet section, prior to acturation. The loading area of 
SET-A and B refers to the peripheral wall, whereas a centrally located platform is 
employed for SET-C and D. Such designs maximize airflow velocity and turbulent shear 
stress. When the inlet and outlet sections were connected, the SET was held horizontally 
and checked using a bubble-level, and placed into the mouthpiece of commonly used 
inertial impaction apparatus such as TSLI or ACI. In order to evaluate the multiplicity of 
factors that influenced the aerosol formulation performance, the aerosolization was 
experimentally designed, the number of each experiment was randomly assigned (Design 
Expert 5.0.9 software, Stat-Ease Corp., MN), and performed at fixed airflow rate (Q = 60 
L/min). In vitro aerosolization was evaluated under ambient condition. (RH%: 23-44, 
temp: 23-24 oC) 
2.2.4.2 Twin-stage liquid impinger (TSLI) 
The SETs were connected directly at the inlet port of the TSLI. Both with and without 
solenoid switch actuation were assessed. For the performance studies with solenoid 
switch, the switch was placed between the TSLI and the vacuum pump to achieve instant 
actuation. After each actuation (25 mg formulation, 10 sec), deposited AS fractions were 
collected by washing the SET and each portion of the TSLI with deionized water, and 
analyzed by UV-spectrometer (λ = 225). The aerodynamic behavior of selected 
formulations was evaluated by emitted dose (ED: percentage of drug emitted from total 
 
68
dose), fine particle fraction (or absolute mass) from total dose (FPFTD: percentage of 
mass (or absolute mass, FPMTD) of drug below 6.4 μm cut-off size from total dose), and 
fine particle fraction (or absolute mass) from emitted dose (FPFED: percentage of mass 
(or absolute mass, FPMED) of drug below 6.4 μm cut-off size from emitted dose). Three 
SETs (denoted as SET-A, C, and D) with airflow parameters encompassing those of 
commercial DPI devices were selected. Their airflow parameters (Re, ΔP, power, and τs) 
at airflow Q = 60 L/min were shown in Table 1-1.[39] Moreover, in order to evaluate the 
multiplicity of factors including drugs, lactose monohydrate, and airflow conditions that 
influenced the formulation performance, full factorial (23) experimental analysis was 
designed, performed, and interpreted statistically (Design Expert 5.0.9 software, Stat-Ease 
Corp., MN) 
2.2.4.3 Andersen non-viable cascade impactor (ACI) 
Similar to TSLI studies, the aerosolization performance of selected formulations was also 
evaluated using eight-stage ACI (25 mg/actuation × 2 actuation) at 60 L/min airflow rate. 
The ACI cut-off diameters were calibrated previsouly (Table 2-2). Both with and without 
solenoid switch were evaluated (10 s per actuation). Before sampling, each stage of ACI 
was immersed into 0.1% silicone oil in hexanes and dried in ambient condition to avoid 
particle bouncing and reentrainment. A USP throat and preseparator were used. The 
quantification of the deposited AS was achieved by UV (λ = 225). The ED, FPF (or FPM), 
and MMAD were obtained by measuring and analyzing the quantity of AS deposited on 
each stage of ACI. The impactor wall loss was evaluated (< 5%) during method 
validation, but was not included in the designed experiment and calculation. 
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 2.3 Results and Discussion 
2.3.1 Aerosol Characterization 
2.3.1.1 Particle size and morphology (SEM) 
Representative SEM images of eight batches of lactose monohydrate (SV-A to F and 
ML-A to B), the micronized drug AS, and their corresponding interactive physical 
mixtures are shown in Figure 2-2 and 2-3. The SV lactose monohydrates had more 
uniform particle shape, smoother surface, and had much fewer intrinsic fine particles 
(designated as particle diameter less than 10 μm) than ML lactose monohydrates, 
although the major particle size of both SV and ML batches were comparable. This was 
consistent with the LD analyses shown below. For ML batches, there were significantly 
more fine particle agglomerates and nanocrevices than SV batches. The micronized AS 
was in the respirable size range and narrow size distribution. The particles had relatively 
smooth surface textures with rectangular-shaped non-spherical particles. Particle 
agglomeration was observed at all magnification before blending (some agglomerates as 
large as ~ 40 μm), indicating strong cohesive forces at the particle-particle interface. 
Image processing by modifying the threshold value indicated that more fine particle 
agglomerates in ML lactose monohydrates were observed to spread between the void 
instead of adhering on the surface of major particles.[19] It was hard to distinguish the 
fine lactose particles with the drug particles simply from the shape and morphology, 
especially ML lactose monohydrate containing many lactose fines. But there appeared to 
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be an increase in particles in range of 1-10 μm. The increase in fine particles appeared to 
adhere more onto the major carrier particle surfaces, with more roughness or crevices, 
indicating “high surface energy” in these sites (Figure 2-2). The particle size, size 
distribution, morphology, and surface features were comparable between the six SV 
batches, and between the two ML batches. The SEM result was consistent with LD data. 
The significant difference between SV and ML lactose monohydrate batches 
could change the aerosolization performance of the blends. The surface fines observed in 
ML could serve at an intrinsic ternary component to modify the interactions between the 
primary carrier particles and micronized drug particles. Either of the two ternary 
formulation hypotheses, “active” site mechanism or agglomeration mechanism (see 
Chapter 6), could contribute to improve the deaggregation during inhalation. 
2.3.1.2 Thermal Properties (DSC) 
Representative DSC thermograms are shown in Figure 2-4. Both SV and ML batches had 
an endothermic dehydration peak ~ 144 oC and a melting peak ~ 213 oC, indicative of 
predominant α-lactose monohydrate. The calculated ΔH of these two endothermic peaks 
were smaller for ML than SV. In both ML batches, there was a distinctive exothermic 
peak ~ 173 oC (ΔH of ML-A: ~ -9.4 J/g; ML-B: ~ -8.4 J/g) when 5 oC/min scanning rate 
was applied. This observation is consistent with the phase transition from molecular 
disordered to ordered state (amorphous content in ML). Scanning rate dependence was 
observed. In SV batches, this characteristic exothermic peak was much smaller (SV-A) or 
undetectable (SV-B). The glass transition temperature (Tg) was not observed for all 
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lactose monohydrate batches. Neither was the b-lactose anomer (typically Tm ~ 235 oC [5]) 
detected because of decomposition when using non-hermetically sealed pans. The heating 
rate at 5 oC/min gave more accurate fusing temperature than higher heating rate (such as 
10 oC/min) when micronized AS was measured (Figure 2-4C and 4D). The micronized 
AS exhibited an endothermic peak (Tm = 192 oC, ΔH ~ 184.9 J/g) at 5 oC/min. The 
decomposition occurred over 210 oC, which was in agreement with previous reports.[44, 
45]  
  Upon blending with AS, both endothermic peaks of all lactose monohydrate 
batches were broadened (indicated by the smaller onset and larger end temperature), 
particularly for the second endothermic peak. The exothermic peak intensity was 
increased and became noticeable for both SV batches, indicating an increased molecular 
disorder due to physical blending. The change in physical properties indicated by the 
thermograms of lactose monohydrates following interactive physical blending could 
affect the macroscopic aerosol performance. 
2.3.1.3 Crystallinity (XRPD) 
Representative XRPD data (courtesy of Dr. Heidi Mansour) of selected SV and ML 
batches were re-plotted using Match!® software, Crystal Impact, Inc., Germany [46]) 
(Figure 2-5A and 5B). The comparison of SV and ML diffractograms indicated that a 
higher degree of molecular disorder of the ML batches than SV batches, as was indicated 
by the reduced intensity of peaks observed in ML batches. No detectable β-lactose was 
observed for all lactose batches when compared with the XRPD from the University of 
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Cambridge database (Figure 2-5C and 5D) and previous reports.[19, 47] The mechanical 
process such as blending led to a varying degree of disorder due to the formation of 
defects or amorphous regions. These regions were believed to be more sensitive to 
moisture or chemical changes. The XRPD of AS is shown in the next Chapter, when a 
total of four different drugs were characterized (see Figure 3-6).  
2.3.1.4 Particle size distribution (LD) 
The particle size distributions of all 6 SV and 2 ML lactose monohydrate batches are 
shown in Table 2-1 (data supplied by the manufacturer). SV lactose monohydrate batches 
exhibited more uniform particle size distributions than ML batches, as were indicated by 
the smaller span values (span for SV: 1.10~1.23; ML: 3.13-3.14). But the volume median 
diameters (~52-61 μm, typical for DPI carriers) for all batches were in a comparable size 
range. The particle size distribution results were in good agreement with SEM images. 
The particle size distribution of AS was unimodal with very narrow span (D50 = 3.59 ± 
0.13 μm; span = 0.26 ± 0.09). 
2.3.1.5 Surface roughness (AFM) 
In order to gain a greater understanding of the surface feature of the lactose monohydrate 
batches, selected SV and ML batches were studied using AFM. The images were 
obtained using tapping mode AFM. Representative 3D images of SV and ML primary 
particle surfaces are shown in Figure 2-6. It appeared that the surface roughness of SV 
was mainly resulted in the fine particle attachment, whereas the surface roughness of ML 
could either due to the crevices or protrude of the primary particle surface, or due to the 
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scanning across the attached fine particles. Both microroughess (Figure 2-6C) and 
macroroughness (Figure 2-6D) were observed in SV and ML lactose batches. The two 
types of roughness could lead to vast difference in particle adhesion. The surface 
roughnesses could be formed during mechanical sieving and milling process. In order to 
account for the surface heterogeneity due to geometric contribution, the topography data 
was processed to produce root mean square roughness ( ∑
=
=
n
i
iRMS yn
R
1
21 ) values, where 
n is the number of points in topography profile and yi the distance of asperities (i) from 
the center line. The result showed that the surface roughness among the three SV batches 
(SV-B, SV-C, and SV-F) in a 10 μm × 10 μm scanning area were 507 ± 269 nm, 803 ± 
187 nm, 704 ± 148 nm, respectively (n = 3); and ML batch (ML-B) in a 20 μm × 20 μm 
scanning area as 1.38 ± 0.74 μm. From the images and analysis collected so far, it 
appeared that the ML batches (e.g. ML-B) had more irregular surface morphology and 
surface defects than SV batches. This is in good agreement with the SEM result. The 
scanning over the ML particle surface was sometimes more problematic, resulting in tip 
contamination by contact when the cantilever reaches the scanning capacity (Figure 
2-6D), or tip-fine particle contamination when scanning across the region with loosely 
attached surface fines. Scanning at lower amplitudes with higher set-points may reduce 
the chance of tip-fine contamination, but it also decreased image resolution. In the 
literature, efforts to reduce the tip-fine contamination were made by removing surface 
fines (e.g. decanting, air-jet sieving, etc), but such treatment may alter the surface 
structure and adhesion forces prior to AFM experiment. 
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 2.3.2 In Vitro Aerosol Performance Assessment 
2.3.2.1 TSLI 
Four interactive physical mixtures of AS (two lactose monohydrate (SV131 and ML058) 
at two concentrations of AS (0.5%w/w and 2%w/w)) were used in the initial performance 
studies with solenoid switch. Three SETs (SET-A, C, and D) were employed. The 
performance data are shown in Appendix 2-A. The performance results (ED and FPFTD) 
were plotted against SET parameters (pressure drop, Reynolds number, and shear stress) 
(Figure 2-7).[48] It indicated that there was a general trend that at lower values of SET 
parameters, the ED values were higher, but the FPF values were lower. The difference of 
ED across different formulations was larger at higher values of SET parameters. At 
higher values of SET parameters, there seem to be a level-off of FPF for ML formulations. 
SV formulations gave higher value of ED but lower value of FPF than ML formulations. 
For SV formulations, the FPF values were higher across the entire SET parameters at 
higher concentration. But this trend was not observed in ML formulations. 
  The results indicated that there was a trade-off between ED and FPF when SETs 
were used as the dispersion device. Higher ED values corresponded to lower FPF values. 
This could be explained by the capability of SETs to differentiate two portions of 
entrained powders: the portion undergoing deaggregation and the portion without 
undergoing deaggregation. This point would be discussed the next chapter, when 
comprehensive performance studies were discussed. When the performance data were 
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plotted against different SET parameters (i.e. pressure drop, Reynolds number, and shear 
stress), the trend were similar. This implied that the characterization of SETs using these 
parameters reflected the turbulent shear forces which were the major forces for powder 
deaggregation. At higher range of SET parameters, the ML formulation performance had 
less variability as the parameters changed. This indicated the reproducibility of 
performance efficiency at different inhalation maneuver, which is a desirable feature for 
formulation development. Physicochemical characterization results showed that SV 
lactose monohydrate batches were more uniform in size and shape than ML batches. This 
difference may lead to improved flow properties of SV formulations than ML 
formulations. Thus, superior ED of SV formulations observed in performance studies 
across all SET airflow parameters. ML batches had more intrinsic fine particles and much 
larger span. ML also had more surface irregularity, roughness, and surface molecular 
disorder than SV. Yet, ML formulations had superior FPF to SV formulations. The 
improved aerosolization performance could be explained as the effect of ternary blending 
mechanisms (see Chapter 6). The intrinsic fine particles in ML batches could possibly 
acted as ternary components, either masked the “active” sites or contributed to drug-fine 
agglomerates formation, both of which were ternary blending mechanisms that improved 
performance. It also showed that higher FPF were observed when higher concentration of 
SV formulation was used. It could be that the small amount of fines observed in SV 
batches was not enough to saturate all the “active” sites. When AS was bound to these 
sites, its removal from these sites became difficult. But, when higher concentration of AS 
was used, the AS particle adhere to sites with decreasing adhesive forces, and resulted in 
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increased FPF when the same removing forces were applied. However, the effect of drug 
concentration did not affect the performance in the ML formulation. 
The effects of carrier (2 SV and 2 ML lactose monohydrate batches), drug 
concentration (0.5%w/w and 2%w/w), and SET (D for low shear, A for high shear) were 
further analyzed using DesignExpert analysis (Appendix 2B and 2C). The notable 
contributing variables for the FPFTD and FPFED were lactoses and applied shears (SETs), 
while the drug concentration was not statistically significant contributor. The contributing 
variables for the ED were also not significant. In order to focus only the significant 
parameters, the drug concentration, from then on, would be fixed at 2%w/w for the 
studies in the next few chapters. 
2.3.2.2 ACI 
The aerosolization performance using ACI yielded similar results as the TSLI experiment 
(Figure 2-8).[48] ED values were higher for SV-0.5%AS formulation, whereas the FPF 
values were higher for ML-2%AS formulation. The FPF values are more important for 
the performance efficiency evaluation. It should be noted that when evaluating the 
particle size distribution of the aerodynamic deposition, the performance with solenoid 
switch vs. without solenoid switch gave totally different result. The performance with 
solenoid switch indicated that as shear stress increased, the MMAD decreased 
exponentially. Conversely, the performances without solenoid switch showed an initial 
increase at lower shear range, while decrease at the highest shear. It is known that 
MMAD is a fundamental aerodynamic parameter that represents the degree of 
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deaggregation. Smaller MMAD values represented greater deaggregations. This indicated 
that the inclusion of solenoid switch was necessary for reproducible and meaningful 
performance studies. Instantaneous actuation (with solenoid switch) was necessary for 
consistent drug aerosolization performance studies across different shear stress. Only 
instantaneous actuation data gave consistently increased FPF and decreased MMAD 
across the increasing shear stress if they were correlated. From then on, the solenoid 
switch would be used for all the further aerosolization performance studies. 
 
2.4 Summary 
A comprehensive set of experimental techniques were applied to characterize bulk and surface 
properties of different batches of SV and ML lactose monohydrate. This included 
physicochemical characterizations and in vitro aerosolization performance using SETs and a 
probe drug AS. Both individual component (one-component systems) and the interactive mixtures 
(two-component systems) were examined. Some sub-studies including the selection of 
appropriate lactose monohydrate batches, the influence of using solenoid switch vs. without using 
it, the concentration influence of the drugs in the interactive physical mixtures, the dosing in the 
SETs for performance reproducibility, and the ACI wall loss estimation (reasonable omission) 
were all considered. All of these sub-studies have been pulled together and served for the further 
studies that would be covered in the next few chapters. The general conclusions for the studies of 
lactose monohydrate carriers are that SV lactose monohydrate batches are more uniform in size 
and morphology. ML lactose monohydrate batches had much more surface fine particles and 
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molecular disorders (surface defects and amorphous content). The aerosolization performance 
studies using AS-ML formulations gave superior performance efficiency (higher FPF) to AS-SV 
formulations. The lactose carrier and SET parameters were significant contributors that influence 
aerosolization performance, whereas AS concentration was not always a significant contributor 
for performance. Solenoid switch was necessary for the performance reproducibility and 
interpretation. 
  In Chapter 3, the drugs in the formulation development will be focused on, and the 
effects of drugs, lactose monohydrate carriers, and SET shear stresses, respectively, will be 
discussed. Two ways forward for the formulation carrier development, either searching for 
alternative sugar carriers, or modifying current existing lactose monohydrate, will be discussed in 
Chapter 4 and Chapter 6, respectively.  
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Table 2-1. Selected physicochemical properties of eight batches of lactose as supplied by 
the manufacturer.[38] 
Batch SV-A SV-B SV-C SV-D SV-E SV-F ML-A ML-B
D10 29.9 29.1 29.0 30.9 29.6 31.5 4.20 4.13 
D50 61.1 59.7 61.4 60.9 59.1 59.7 54.6 52.0 
D90 101.9 97.6 104.7 99.4 98.5 97.3 174.9 167.5 
Pa
rti
cl
e 
si
ze
 
di
st
rib
. (
μm
) 
Span 1.18  1.15 1.23 1.12 1.17 1.10  3.13  3.14 
Specific surface area  
(m2/g) 
0.34 0.43 0.44 0.46 0.41 0.30 0.89 0.87 
Poured density 663 610 647 648 634 655 596 590 
Tapped density 802 786 771 778 774 817 875 874 
Hausner ratio 1.21 1.29 1.19 1.20 1.22 1.25 1.47 1.48 
Carr Index 17.3 22.4 16.1 16.7 18.1 19.8 31.9 32.5 
Static angle of repose 26.6 30.0 30.6 29.1 29.7 28.9 46.6 44.9 
Water (Karl Fischer) 5.16 4.52 5.00 4.50 4.87 4.82 4.58 5.06 
Protein (ion selective) 272 188 93 136 199 225 124 79 
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Table 2-2. The eight-staged ACI Aerodynamic Cut-off Diameter φ (μm) at Airflow Rate 
Q = 60 L/min for DPI Experiment After Calibration. 
 
Stage -1 -0 1 2 3 4 5 6 7 
Cutoff φ 8.6 6.5 4.5 3.2 1.9 1.1 0.5 0.2 Filter 
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Figure 2-1. The specification of the two inertial sampling devices used for aerosolization 
performance studies: (A) Twin stage liquid impinger (TSLI); (B) Andersen cascade 
impactor (ACI); (C) TSLI collection efficiency and semi-empirical oropharyngeal 
deposition curves (Model); (D) ACI collection efficiency curves (Adapted from Dunbar 
et al [33]) 
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Figure 2-2. Representative scanning electron microscopy images of lactose monohydrate 
batches (A) SV-A; (B) SV-B; (C) SV-C; (D) SV-D; (E) SV-E; (F) SV-F; (G) ML-A; and 
(H) ML-B at 600× magnification. 
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Figure 2-3. Representative scanning electron microscopy images of micronized albuterol 
sulfate (AS) (A) AS at 5,000× magnification and (B) AS at 20,000× magnification; 
lactose monohydrate-based blends (C) SV-B+0.5%w/w AS; (D) ML-A+2%w/w AS; (E) 
SV-B+ 2%w/w AS; (F) SV-C+2%w/w AS at 1,500× magnification. 
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Figure 2-4. Representative differential scanning calorimetry thermograms of (A) SV-A 
and SV-B; (B) ML-A and ML-B; (C) and (D) micronized albuterol sulfate; (E) blends of 
AS (2%w/w) with SV-A and SV-B, respectively; (F) blends of AS (2%w/w) with ML-A 
and ML-B, respectively. 
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Figure 2-5. Representative X-ray powder height intensity diffractograms of lactose 
monohydrate (A) SV; (B) ML (Raw data: Courtesy of Dr. Mansour. The data were 
re-plotted using Match® software, Crystal Impact, Inc.); (C) the University of Cambridge 
database of pure α-lactose monohydrate; (D) the University of Cambridge database of 
pure β-lactose. 
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Figure 2-6. Representative atomic force microscopy topographic images of lactose 
monohydrate by tapping mode: (A) SV-B (10μm × 10μm); (B) SV-C (10μm × 10μm); (C) 
ML-B (10μm × 10μm); (D) ML-B (50μm × 50μm); and (E-F) SV-F (5μm × 5μm) 
(A)  
 
(B)   
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Figure 2-7. The results of TSLI performance study of intereactive physical mixtures: 
albuterol sulfate (AS) and lactose monohydrate (SV131 and ML058). Two concentrations 
of AS were prepared at 0.5%w/w and 2%w/w. The performance results (ED and FPFTD) 
were plotted against SET parameters (pressure drop, Reynolds number, and shear stress).  
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Figure 2-8. The results of ACI performance study of intereactive physical mixtures: 
albuterol sulfate (AS) and lactose monohydrate (SV131 and ML058): (A) ED of 
0.5%w/w AS-SV131; (B) ED of 2%w/w AS-ML058; (C) FPFTD of 0.5%w/w AS-SV131; 
(D) FPFTD of 2%w/w AS0-ML058; (E) MMAD when solenoid switch was operated off; 
(F) MMAD when solenoid switch on. 
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CHAPTER 3 DRUG PERFORMANCE STUDY 
3.1 Introduction 
The therapeutic implication of respiratory drug delivery for the treatment of asthma has 
been discussed in Chapter 1.2. The drugs involved for disease therapy, based on their 
pharmacological mechanism of action, are mainly classified into five types: 1) 
β-adrenergic agonists; 2) antichlolnergics; 3) corticosteroids; 4) cromone derivatives; and 
5) xanthine derivatives. Among them, 1), 2), and 5) are called bronchodilators, but their 
bronchodilation mechanisms are different. The corticosteroids reduce or control 
inflammatory mediators. The cromone derivatives are a special class of drugs that prevent 
mast cell degranulation. In this chapter, the focus is on the physicochemical 
characterization of four model drugs and their interactive physical mixtures with four 
selected lactose monohydrate batches. The dry powder aerosols would be generated by 
standardized entrainment tubes (SETs) from drug blends with different batches of lactose 
monohydrate. The aerosolization performance was assessed by twin-stage liquid impinger 
(TSLI) and Andersen cascade impactor (ACI).  
The objectives of this study were: discriminatory assessment of dry powder 
aerosol performance using SETs and lactose monohydrate-based formulations and 
development of a novel analytical tool for aerosolization performance evaluation and 
prediction: the powder aerosol deaggregation equation (PADE). A fold-over experimental 
design and statistical analyses were also included in parallel with the PADE method. 
3.1.1 Drugs for the Treatment of Asthma and COPD 
Four model drugs: albuterol sulfate (AS), disodium cromoglycate (DSCG), ipratropium 
bromide monohydrate (IPB), and fluticasone propionate (FP) that represent four different 
classes of asthma and COPD treatment were selected (Figure 3-1).  
The first drug, AS, is a short-acting β2-adrenergic agonist with a long history of 
use for the relief of bronchospasm in asthma and COPD.[1, 2] The second drug, DSCG, 
having resulted in the first marketed dry powder inhalation aerosol product, is a mast cell 
stabilizer for the treatment of asthma whose origins are in anecdotal reports of natural 
product remedies. Its exact mechanism of action has yet to be elucidated.[3] The third 
drug, IPB induces bronchodilation and inhibits mucus secretion by competitive inhibition 
of muscarinic cholinergic receptors, causing blockade of acetylcholine-induced 
stimulation of guanyl cyclase, which, in turn, reduces the formation of cyclic guanosine 
monophosphate (cGMP), a mediator of bronchoconstriction.[4] It is a non-selective, 
short-acting bronchodilator (as the approved proprietary aerosol drug product, AtroventTM, 
Boehringer Ingelheim) for the treatment of bronchial spasms associated with chronic 
obstructive pulmonary disease, including chronic bronchitis and emphysema. It has also 
been co-administered (CombiventTM, Boehringer Ingelheim) with β2 adrenergic agonist 
albuterol sulfate through both anticholinergic and sympathomimetic mechanisms, which 
can achieve additive bronchodilator effect and prevent β2 agonist induced bronchospasm 
(asthma paradox).[5] The fourth drug, FP, is a synthetic steroid of glucocorticoid family 
used as an anti-inflammatory agent. The anti-inflammatory actions of FP in asthma are 
believed to result from direct inhibition of multiple cell types involved in airway 
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inflammation and inflammatory mediators produced by these cells.[6] On molecular level, 
FP not only suppresses immune response, but also inhibits prostaglandins and 
leukotrienes, as well as cyclooxygenases (both COX-1 and COX-2) expression, providing 
long-term control of persistent asthma (FloventTM, GlaxoSmithKline) and allergic rhinitis 
(FlonaseTM, GlaxoSmithKline) symptons.[7] 
 
3.1.2 Physicochemical Properties of Drugs 
AS is an ionic salt with electropositive properties, and perhaps the most extensively 
studied drug in therapeutic aerosol formulation.[2] The solid-state properties of DSCG is 
unique in that it quickly and reversibly sorbs and liberates water to form 
nonstoichiometric hydrates with the change of crystal lattice parameters.[8] When 
crystalline DSCG hydrate molecule collapses at high relative humidity, it demonstrates 
liquid crystalline properties by forming lyotropic mesophases at 20 oC.[9] IPB is a 
synthetic quaternary N-methyl isopropyl derivative of noratropine. As a hydrated salt 
crystalline powder, it is freely soluble in water and lower alcohol, but insoluble in 
lipophilic solvents such as ether, chloroform, and fluorocarbons.[10] It is a highly 
hydrophilic drug (LogP = -2.21).[11] A 1% aqueous solution of IPB has a pH of 5-7.5.[4] 
FP, a fluorinated corticosteroid ester, is insoluble in aqueous buffer with a pH of 7.4.[12] 
It is a lipophilic drug (LogP = 3.46) passing readily through the cell membrane and 
binding with the corticosteroid receptor.[6] The true densities of IPB and FP are 1.33 and 
1.37 g/cm3, respectively. 
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  Micronized AS (Pfizer Global R&D, Kent, UK) was used as supplied. DSCG 
(Sigma-Aldrich Inc., St. Louis, MO), IPB (Sigma-Aldrich Inc., St. Louis, MO), and FP 
(APAC Pharmaceuticals, Columbia, MD) were purchased in unmilled form and 
micronized using a Trost Impact Pulverizer (Gem T Research Model Jet Mill, Garlock 
Inc., Plastomer Products, Newton, PA). Lactose monohydrate (RespitoseTM) batches of 
two milled (designated as ML-A and ML-B) and two sieved batches (designated as SV-A 
and SV-B) were provided by DMV-Fonterra Excipients. (These four batches of lactose 
monohydrates were selected from initially 35 batches, then 8 batches (six sieved and two 
milled) of lactose monohydrates based on two principal components analyses,[13] and 
cluster analyses performed independently. These analyses were used to assess the 
diversity of batches with respect to characteristics such as particle size, bulk and tap 
density, water activity, etc. (see Table 2-1). The initial results showed drug concentration 
(0.5 and 2%w/w) was the least significant factor compared with lactose carrier and SET 
shear stress (see Chapter 2). The rigorous aerosol performance evaluation required 
preliminary identification of parameters of interest. Consequently, as the least significant 
factor, drug concentration, was excluded (fixed at 2%w/w), to allow greater focus on the 
drug, lactose monohydrate, and shear effects. However, concentration remains an 
important factor for future assessment. 
 
3.2 Methods 
3.2.1 Analytical Approaches 
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3.2.1.1 Aerosol Formulation Preparation 
The Jet-milling of DSCG, IPB, and FP (2 g/each) was conducted at opposing inlet/outlet 
pressure of 60/40, 75/55, 75/55 psig, respectively, using dry N2 gas (prepurified, Airgas 
National Welders Supply, Charlotte, NC) to achieve appropriate size and distribution. The 
yield of micronized particles collected was ~50-70 %. The particle size distribution and 
morphology were examined by laser diffraction (LD) and scanning electron microscopy 
(SEM). The powder obtained was re-milled if the volume median diameter was larger 
than 5 μm and re-characterized by LD and SEM. 
  The interactive physical mixtures (2 g each, 2 %w/w, 4 drugs × 4 carriers = 16 
blends) were prepared as follows: The micronized drugs were allowed to pass through a 
125 μm sieve to reduce the degree of agglomeration. A pre-blend of drugs (40 mg each) 
with lactose monohydrate batches (1960 mg each) was prepared by geometrical addition 
in an aluminum foil container using a spatula. The pre-blends were further processed in a 
Turbula® mixer (Model T2C, GlenMills Inc., Clifton, NJ) for 20 min. Blend uniformity 
was evaluated by analyzing 5 samples of each mixture taken from different regions of the 
blends. The amounts of AS, DSCG, IPB, and FP in the blends were quantified by UV 
absorption spectroscopy measured at a wavelength of λ = 225, 223, 211, and 238 nm 
(Shimadzu UV-1700 UV/Vis spectrometer, Shimadzu Corporation, Columbia, Maryland), 
respectively, in deionized water (Barnstead Nanopure, 18.0 mega-ohm) except FP blends, 
which was dissolved in EtOH/H2O mixture (ratio = 60 : 40). In all cases, a coefficient of 
variation (%CV) < 5.0% was considered homogeneous. The prepared interactive physical 
mixtures were placed in tightly sealed glass jars (Wheaton Science Products, Millville, NJ) 
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which were then stored in glass desiccators (Drierite®/Indicating Drierite®) under 
ambient temperature and pressure prior to further characterization and aerosolization 
performance study. 
3.2.1.2 Scanning Electron Microscopy (SEM) 
The volume size, morphology, surface features and blend uniformity of drugs, lactose 
monohydrate batches and corresponding blends were examined by SEM. The samples 
were sputter-coated with Au-Pd in Argon for 90 s before the experiment (Polaron 5200 
sputter coater, West Chester, PA). Scanning electron micrographs (Jeol JSM 6300V SEM, 
Peabody, NY) at a number of magnifications (x150, x600, x1.5k, x3k, x6k, x10k and 
x20k) were examined for both drugs before and after micronization, and at magnifications 
(x60, x150, x600, x1.5k) for all lactose monohydrate batches and drug/lactose 
monohydrate blends. 
3.2.1.3 Differential Scanning Calorimetry (DSC) 
The molecular and thermotropic phase transitions of each individual component including 
unmilled (original) drugs, milled drugs, lactose monohydrate batches, and interactive 
physical mixtures were examined by DSC (Perkin Elmer DSC 6 Workstation, Norwalk, 
CT). Non-hermetically sealed aluminum pans containing 1.5-6.0 mg of samples were 
used. Nitrogen purge gas (N2 prepurified, Airgas National Welders Supply, Charlotte, NC) 
was set at 20 mL/min. The temperature and heat flow were calibrated using high purity 
Indium (m.p. = 156.60 oC, ΔHf = 28.45 J/g) and Zinc (m.p. = 419.47 oC, ΔHf = 108.37 J/g) 
standards. Various scanning rates, including 2.0 oC/min, 5.0 oC/min, and 10.0 oC/min, 
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were applied to examine the thermodynamic phase behavior (Tm) and kinetic/metastable 
phase transitions such as glass transitions (Tg). For each sample, two separate scans were 
taken. The scanning range covered 20-300 oC. Thermograms were processed and 
analyzed using the accompanying software (Pyris Thermal Analysis Instrument Control 
and Data Analysis Software, v.3.01). 
3.2.1.4 X-ray Powder Diffraction (XRPD) 
The degree of crystallinity and non-crystallinity of the drugs before and after milling, 
lactose monohydrate batches and interactive mixtures was examined by slit detector 
XRPD. (Regaku Multiflex, Tokyo, Japan). The powder was packed onto an etched square 
area of XRPD glass slide that was placed horizontally in the sample holder. 
Diffractograms were obtained to evaluate the crystallinity of the samples (1-2 g).  The 
scanning was at 1 2θ degree/min and from 3-60 2θ degree at room temperature (23 oC) to 
cover angles and nanometer distances where peaks occur for pharmaceutical material. 
The intensity of the peaks and the area under the curves were compared with the 
University of Cambridge XRPD database to estimate the long-range and short-range 
order of the material. 
3.2.1.5 Laser Diffraction (LD) 
The volume size distribution of drugs was characterized by Fraunhofer laser diffraction 
(Malvern Instruments 2600 Series, Worcs, UK) using micronized solid drug particles 
suspended in an organic dispersant (dispersant for fluticasone propionate was deionized 
water). The focal length of the lens is 63 mm, giving a nominal size range of 0.5-118 μm. 
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The organic dispersant for the pulmonary drugs was chloroform, which is commonly used 
as a dispersing liquid in surface chemical and interfacial experiments due to its favorable 
combination of hydrophobicity and low viscosity. The solid-liquid dispersion was 
sonicated briefly (20 s) to eliminate any small aggregates while not physically breaking 
the primary particles (ie. particle fracture) and modifying the primary particle size. The 
LD data for lactose monohydrate batches were reported previously. 
 
3.2.2 In Vitro Aerosol Performance Characterization 
3.2.2.1 Standardized Entrainment Tubes (SETs) 
Four SETs (denoted as SET-A, B, C, and D) with airflow parameters encompassing those 
of commercial DPI devices were selected. Their airflow parameters (Re, ΔP, power and τs) 
at defined airflow rate were presented previously by Louey et al.[14] (see Table 1-1). The 
powder formulation (25 mg/actuation) was transferred onto the loading area, which was 
at the proximal end of the inlet section, prior to actuation. The loading and SET setup was 
the same as described in Chapter 2. In order to evaluate the multiplicity of factors that 
influenced the aerosol formulation performance, the aerosolization was separated into two 
blocks. The first block of studies focused on two drugs: AS and DSCG; and the second 
block of studies focused on the other two: IPB and FP. The studies in each block were 
experimentally designed, the number of each experiment was randomly assigned (Design 
Expert 5.0.9 software, Stat-Ease Corp., MN), and performed at fixed airflow rate (Q = 60 
L/min). In vitro aerosolization was evaluated in triplicate under ambient condition.  
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3.2.2.2 Twin-staged Liquid Impinger (TSLI) 
The SETs were connected directly at the inlet port of the TSLI. A solenoid switch was 
placed between the TSLI and the aspirator to achieve instant actuation. A total of sixteen 
formulations (4 drugs × 4 carriers) were assessed. After actuation (25 mg 
formulation/actuation, 10 sec), deposited drug (AS, DSCG, and IPB) fractions were 
collected by washing the SET and each portion of the TSLI with deionized water, then 
analyzed by UV-spectrometer (λ = 225, 223, and 211 nm for AS, DSCG, and IPB, 
respectively). For FP formulation, the solvent used for collecting deposited drug was 
EtOH/H2O mixture (ratio = 60/40), and analyzed by UV-spectrometer at λ = 238. The 
aerodynamic behavior of these aerosol formulations was evaluated by emitted dose (ED: 
percentage of drug emitted from total dose), fine particle fraction (or absolute mass) from 
total dose (FPFTD: percentage of mass (or absolute mass, FPMTD) of drug below 6.4 μm 
cut-off size from total dose), and fine particle fraction (or absolute mass) from emitted 
dose (FPFED: percentage of mass (or absolute mass, FPMED) of drug below 6.4 μm 
cut-off size from emitted dose). In order to evaluate the multiplicity of factors including 
drugs, lactose monohydrate, and airflow conditions that influenced the formulation 
performance, full factorial (23) experimental analysis was designed, performed, and 
interpreted statistically (Design Expert 5.0.9 software, Stat-Ease Corp., MN). The 
pair-wise comparison (paired t-test) was performed using SigmaPlot 9.01. The 
performance data were also correlated with SET shear stress (τs) for further analysis. 
3.2.2.3 Andersen Cascade Impactor (ACI) 
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The 8-stage ACI is an inertial impaction sizing device based on Stokes’ terminal settling 
velocity and curvilinear particle motion, but is more discriminating and precise than the 
TSLI, offering several cut-off sizes for measuring aerosol particle dispersion and 
deposition.[15] The calibrated ACI aerodynamic cut-off diameters at an airflow-rate of 60 
L/min are listed in Table 2-2. The formulation performance was evaluated using the ACI 
(25 mg formulation/actuation × 2 actuation, 10s). The mass median aerodynamic 
diameter (MMAD) for ACI was calculated as the 50th percentile of the aerodynamic 
particle size distribution by mass, in addition to ED, FPF and FPM. The FPF6.5 (or 
FPM6.5) and FPF4.5 (or FPM4.5) are fine particle fractions (or fine particle mass) below 
6.5 μm (stage 1 and under) and 4.5 μm (stage 2 and under) cutoff diameter, respectively. 
Similar experimental analyses (but reduced sample number) were performed as those 
applied in TSLI study. 
 
3.3 Results 
3.3.1 Aerosol Characterization 
3.3.1.1 Particle size and morphology (SEM) 
Representative SEM images of micronized DSCG, IPB, and FP are shown in Figure 3-2. 
The micronized AS, lactose monohydrate batches of ML and SV were shown in Figure 
2-2 and 2-3, respectively. The interactive physical mixtures are shown in Figure 3-3. As 
expected, the images are consistent with the particle size analysis. All four drugs were in 
the respirable size range and similar narrow size distribution (Figure 2-3A and B, 3-2B, 
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2G, and 2H) after air jet-milling. AS had relatively smooth surface textures with 
rectangular-shaped non-spherical particles. DSCG were more irregularly shaped and 
surface defects were observed at high magnifications. IPB particles exhibited regular 
morphology with relatively smooth surface after micronization, presumably because of 
the rigid crystalline monohydrate structure of its ionic salt. FP particles were more 
irregularly shaped with many superfine particles (<1 μm) observed on the surface of the 
primary particles and independently by SEM. This result was not reflected in the particle 
size analysis, probably due to the lower detection limit of approximately 0.5 μm of LD 
when using 63 mm focal lens. Particle agglomeration of these drugs was observed at all 
magnifications before blending, due to the high specific surface area of micronized 
particles and strong cohesive forces at the solid-solid interface. The SV lactose 
monohydrates were uniform particle shape, smooth, and had much fewer intrinsic fine 
particles (designated as particle size less than 10 μm) than ML lactose monohydrates, 
although the major particle size of both SV and ML batches were comparable (see 
Chapter 2). This was also consistent with the LD analyses. More fine particle 
agglomerates in ML lactose monohydrates were observed to spread between the void 
instead of adhering on the surface of major particles. It is hard to distinguish the fine 
lactose particles with the drug particles simply from the shape and morphology, 
especially milled lactose monohydrate containing many lactose fines. But there appeared 
to be an increase in particles in size range of 1-10 μm.  
In AS blends, the increase in fine particles appeared to adhere more onto the 
major carrier particle surfaces, with more roughness or crevices, indicating “high surface 
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energy” in these sites (Figure 2-3D, E, F). However, in DSCG blends, the increase in 
fine particles was observed to somehow detach from the major particle surfaces, and was 
more obvious in DSCG-ML systems which had more intrinsic fines (Figure 3-3A and B). 
Similarly, at 2%(w/w) concentration, fine particles (both lactose monohydrate fines and 
drugs) were discretely distributed on the primary particles for IPB-SV and FP-SV blends, 
and more fine particles were observed on the rough surface regions of the primary lactose 
monohydrate particles. For the IPB-ML and FP-ML systems, more agglomerates of fines 
were observed to spread in the voids among the primary particles.  
3.3.1.2 Thermal properties (DSC) 
Representative DSC thermograms of DSCG, IPB and FP are shown in Figure 3-4. The 
thermograms of AS was shown in Figure 2-4. The thermograms of unmilled and 
micronized DSCG (Figure 3-4A) exhibited a pre-transition peak at about 90 oC and loss 
of water molecules occurred at about 100 oC, which has often been observed in 
self-assembling surfactant system as a broad peak. It was reported that DSCG can 
accommodate 9 H2O molecules in its crystal structure before collapsing into a liquid 
crystal.[8, 9] A slow scanning rate (≤ 5 oC/min) was required to obtain meaningful 
thermotropic phase information and accurate Tm measurements. Both unmilled and 
micronized DSCG had Tm about 258 oC, indicating highly distorted and stressed crystal 
forms.[9] However, the Tm became undetectable when the scanning rate was reduced to 2 
oC/min, possibly because of decomposition just above Tm. Unmilled DSCG had higher 
ΔH for both endothermic peaks (ΔH1 = 93.3 J/g, ΔH2 = 70.7 J/g) than micronized sample 
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(ΔH1 = 75.1 J/g, ΔH2 = 31.1 J/g) in the same heating rate, indicative of partially loss of 
bound water and greater molecular disorder of the micronized sample due to milling. The 
thermograms of unmilled and micronized IPB and FP are shown in Figure 3-4B and C. 
The unmilled IPB plot has two endothermic peaks at T1 = 113 oC and T2 = 231 oC 
indicating the bound water removal (ΔH1 = 129.8 J/g) from the crystalline lattice and the 
melting of the crystalline anhydrate (ΔH2 = 290.6 J/g) at higher temperature. The 
micronized IPB exhibited endothermic peaks but reduced enthalpy (T1 = 109 oC, ΔH1 = 
100.3 J/g; and T2 = 235 oC, ΔH2 = 191.0 J/g) indicating partial loss of bound water from 
the monohydrate crystalline and increased molecular disorder from rigid crystalline 
during micronization. Some anhydrous IPB may be generated during milling. No 
crystalline polymorphic form was detected, before or after micronization. The 
thermograms of untreated and micronized FP were similar and did not show any 
distinctive peaks in the range of 20-270 oC at scanning rates of 2, 5, and 10 oC/min. 
However, peaks attributed to decomposition were observed in the range of 270-300 oC. 
No DSC phase transition signal other than decomposition was observed. This is 
consistent with previous reports of both micronized and spray dried FP.[16, 17]  
The thermotropic behavior of lactose monohydrate and DSCG, IPB, and FP 
blends are shown in Figure 3-5. AS blends was discussed previously in Chapter 2. For 
the DSCG and lactose monohydrate blends, the drug transitions were observed with 
broadening of the first endothermic peak of lactose monohydrates (indicated by the earlier 
onset temperature). Liquid crystalline effect of DSCG affected the transition of both SV 
and ML lactose monohydrate. The enhancement of the exothermic peak was distinct for 
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both DSCG/ML blends (ΔH of ML-A: -10.8 J/g; ML-B: -11.6 J/g) at 5 oC/min scanning 
rate, while the exothermic peak was unnoticeable for both DSCG/SV blends. When SV or 
ML lactose monohydrate was blended with micronized IPB, appreciable peak broadening 
occurred, particularly for the second endothermic peak. A trace of the IPB melting peak 
was visible for some blends (ML-A) due to the large enthalpy. The exothermic peak 
intensity from lactose monohydrate did not increase after blending, and was observable 
only in ML lactose monohydrate blends. When SV or ML lactose monohydrate was 
blended with micronized FP, there was a slightly lower onset temperature of both 
endothermic peaks. An exothermic peak was observed for ML blends but not SV blends.  
3.3.1.3 Crystallinity (XRPD) 
XRPD graphs of micronized drugs (AS, DSCG, IPB, and FP) are shown in Figure 3-6. 
The XRPD %Intensity diffractogram of micronized AS showed almost identical peak 
intensity when it was compared with the XRPD from the University of Cambridge 
database. It indicated that non-crystallinity mechanically induced by micronization was 
below the detection limit of XRPD diffractogram for AS. The XRPD %Intensity 
diffractogram of DSCG indicated the presence of partially ordered and disordered liquid 
crystalline mesophase, which was characteristic of liquid crystalline hydrate materials. 
The degree of molecular order and self-assembly depended on the amount of bound water 
and temperature, which could also affect the solid state stability and macroscopic 
properties of aerosol performance. However, no crystalline polymorph of DSCG was 
observable, consistent with previous reports.[8, 9] The %Intensity of diffractogram of 
micronized IPB, when compared with published resources,[18] indicated a majority of 
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crystalline material. The diffractogram of micronized FP was comparable to the previous 
reports of crystalline FP.[16, 19] Only polymorph I of FP was observed, whereas the 
metastable polymorph II, which could be formed in the supercritical fluid condition, was 
not detected in the entire scanning range. The diffractograms of SV and ML lactose 
monohydrate were shown previously in Figure 2-5. 
3.3.1.4 Particle size distribution (LD) 
The particle volume size distribution of jet-milled AS, DSCG, IPB, and FP before and 
after air jet-milling is shown in Table 3-1. AS and DSCG exhibited similar volume 
median diameters in the fine particle range (D50 = 3.59 and 3.68 μm, respectively) with 
narrow unimodal distribution (span = 0.26 and 0.32, respectively). IPB after first milling 
process did not yield ideal volume median diameter (D50 = 4.53 μm) comparable to AS 
and DSCG, but the value of span was excellent (span = 0.23). After the second milling, 
the particle size distribution was D50 = 3.29 μm, span = 0.34. The FP was also subjected 
to milling twice because the poor D50 for the first milling process. The particle size 
distribution was D50 = 4.47 μm, span = 0.36, which was comparable to the other three 
micronized drugs. The aerodynamic diameters (calculated from D50) of IPB and FP were 
3.79 and 5.23, respectively. 
  The particle size and size distribution, morphology, thermal properties, and 
crystallinity of drug and carrier particles were characterized for consideration with respect 
to their influence on drug aerosolization performance. The influences of these 
physicochemical properties of both drugs and lactose monohydrates following interactive 
 
107
physical blending reflected the molecular properties of drugs and their effect on the drugs 
and carriers. These changes could also affect the macroscopic aerosol performance. The 
focus of the present work is on the influence of three major factors: drug, carrier lactose 
monohydrate, and SET shear stress to the aerosolization performance efficiency. Other 
factors including size, size distribution of both drug and lactose monohydrate particles, 
drug concentration, dose, interactive physical blending, and environment factors were, to 
a large extent, kept constant or comparable.  
 
3.3.2 In Vitro Aerosol Performance Assessment 
3.3.2.1 TSLI 
The drug aerosolization performance of lactose monohydrate-based dry powder 
formulation is influenced by a variety of factors including physicochemical properties and 
surface features of given drugs and carrier particles, the parameters of airflow 
entrainment, and others.[20] Performance data obtained from TSLI studies are shown in 
Appendix 3-A1 and A2. For clarity, the influence of three factors: drug, lactose 
monohydrate, and SET shear stress on the aerosol performance will be discussed in 
categorical manner, then the overall effect will be summarized. The comparison of AS vs. 
DSCG will be discussed first, followed by IPB vs. FP. The unique assessment of aerosol 
performance using PADE will be applied to interpret the TSLI aerosol performance data. 
Drug Effect. The DSCG formulations resulted in similar ED delivery to AS formulations, 
but superior FPF (p < 0.001). This trend of higher FPF was more remarkable at higher 
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shear stress (p < 0.001). The FPF of AS formulations was more susceptible to carrier 
change than that of DSCG formulations.  
The IPB and FP formulations gave similar ED at highest shear stress (p > 0.05). 
However, IPB formulations gave superior ED values across all shear stress to FP 
formulations (p < 0.05). Compared with FP formulations, all IPB formulations gave 
superior FPF values across all shear stress (p < 0.001). The FPF of IPB formulations was 
less susceptible to shear stress change than FP formulations and reached a plateau at 
relatively lower shear stress (see FPF and shear stress correlation below for more 
explanation). 
Carrier Effect (SV vs. ML). In AS formulations, the ED was significantly lower (p < 
0.001), but FPF (p < 0.001) was significantly higher for ML blends than SV blends. SV-B 
had slightly higher ED than SV-A (p > 0.05), but FPF was similar (p > 0.05). The ED for 
both ML blends was insignificant (p > 0.05), but FPF of ML-A was significantly higher 
than that of ML-B (p < 0.05). In DSCG formulations, the ED was significantly higher for 
SV blends than ML blends (p < 0.001), except at highest shear, where ED was less 
dependent on formulation effect. The FPF for SV-A was significantly lower than that of 
SV-B (p < 0.01); and ML-A was significantly lower than that of ML-B (p < 0.01). In all 
DSCG formulations, the ML lactose monohydrate batches gave superior aerosolization 
performance efficiency (higher FPF, p < 0.05) to SV batches.  
In both IPB and FP formulations, SV blends gave higher ED values than ML 
blends across all shear stress range (p < 0.001). However, at the highest shear (τs = 13.143 
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N/m2), ED exhibited the greatest independence of the formulation effect (p > 0.05). ML 
blends reached lowest ED value at shear stress produced by SET-B (τs = 4.342 N/m2), 
then increased at the highest shear stress for both IPB and FP formulations. This could be 
explained by the effect of the SET design. SET-C and D have gradual enlargement and 
centrally located dose platform for maximizing flow, whereas SET-A and B have sudden 
enlargement and direct dose near the wall for maximizing shear.[14] However, SV blends 
showed a decreasing trend as shear stress was increased until ED values became 
relatively stable at high shear. SV-A gave superior ED values to that of SV-B (p < 0.05), 
whereas ML-A and B gave similar ED values (p > 0.05), but ML-A blend gave lower ED 
values than ML-B in FP formulation (p < 0.05). The FP with ML-A formulation showed 
an exceptional low ED value (51.5%, mean value, n = 3) at shear produced by SET-B. In 
both IPB and FP formulations, the ML blends gave superior performance efficiency 
(higher FPF values) to SV blends (p < 0.05). The FPF values in IPB blends showed less 
carrier type (ML or SV) influence (p < 0.05) than those in FP formulations (p < 0.001), 
especially at high shear stress range (4.342-13.143 N/m2). In IPB formulations, the FPF 
value of SV-A was significantly higher than that of SV-B (p < 0.05), but the FPF values 
of ML formulations were similar (p < 0.05). In FP formulations, the FPF value of ML-B 
was significantly higher than that of ML-A (p < 0.001), but the FPF values of SV 
formulations were similar (p > 0.05). 
SET Effect (Higher τs vs. Low τs). When SET shear stress (τs) was correlated with 
aerosol performance (ED, FPFTD, and FPFED), there was a general trend that the lowest 
shear stress SET (τs = 0.624 N/m2) gave higher ED (ED for AS: 83.4-93.1%; ED for 
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DSCG: 84.1-91.2%; ED for IPB: 84.7-90.6%; ED for FP: 84.0-90.5%, mean value, n = 3), 
but lower FPF (FPFTD for AS: 6.8-21.4%; FPFTD for DSCG: 20.9-25.4%; FPFTD for IPB: 
22.5-30.6%; FPFTD for FP: 10.8-22.0%, mean value, n = 3) for all studied systems. In 
contrast, the highest shear stress SET (τs = 13.143 N/m2) gave a relatively lower ED (ED 
for AS: 79.8-85.9%; ED for DSCG: 74.8-81.0%; ED for IPB: 67.7-71.2%; ED for FP: 
65.7-70.2%, mean value, n=3) but a dramatic higher FPF (FPFTD for AS: 14.7-42.9%; 
FPFTD for DSCG: 33.6-43.3%; FPFTD for IPB: 28.9-36.3%; FPFTD for FP: 15.1-24.2%, 
mean value, n = 3). The difference of ED at highest shear for different blends was smaller 
than that at lower shear (τs = 4.342, 2.199 and 0.624 N/m2), indicating less formulation 
dependency at the highest shear. A hyperbolic relationship was observed between 
FPF-shear stress correlations. 
Overall Effect. In order to elucidate the complete set of factorial effects and interactions 
(drugs, lactose monohydrates, and SET shear stress) with respect to the aerosol 
performance (ED, FPFTD, FPFED), full factorial analysis (23) was applied (Appendix 3-B). 
The half-normal plots indicated that data fell on a straight line where random variation 
around a mean (normal distribution) was observed. The points that did not fit on the 
straight line indicated effects that could not be explained as chance occurrences, and were, 
therefore, considered significant. Cube plots were also included to compare the predicted 
(or actual) effects from coded levels of three factors.  
The AS vs. DSCG formulations (blended with 2 SV and 2 ML, respectively) were 
compared first. The result showed that the greatest contributing factor, SET shear stress, 
was significant in all comparisons. When SV lactose monohydrate were compared with 
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ML lactose monohydrate, all three factors (drugs, carriers, and shear stress) were 
contributing variables and there were drug/carrier interaction and carrier/shear stress 
interaction. No carrier effect was observed when SV-A and SV-B were compared. 
Neither was ML-A and ML-B were compared. Cube plots indicated that ML lactose 
monohydrate, and DSCG combination gave the best performance (highest FPF) at high 
shear (SET-A); while SV lactose monohydrate and AS combination gave the worst 
performance at low shear (SET-D). Although an inverse relationship exists between ED 
and FPF in most cases, FPF is considered to be more important for evaluating formulation 
performance.  
The IPB vs. FP formulations were also compared. The half-normal plots of ED 
values indicated that the largest contributing factor, SET τs, was significant for all ED 
comparisons. This suggested the large influence of τs on the flow properties. However, 
the largest contributing factor to FPF values was the drug factor (IPB and FP), which was 
significant in all formulations. When SV were compared with ML, there was significant 
difference between SV-A and ML-B, and between SV-B and ML-B. There were drug and 
τs, drug/carrier interactions. No carrier effect was significant when batch-to-batch 
comparison was carried out between two SV or between two ML formulations. Cube 
plots of FPF indicated that ML-B and IPB combination gave the best performance 
(highest FPF) at highest τs, while SV-A and FP combination gave the worst performance 
at lowest τs. 
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3.3.2.2 Assessment of Aerosol Performance Using PADE 
It can be seen that the categorical comparison of aerosolization performance of different 
formulations using conventional method or DesignExpert analysis are quite inefficient 
and tedious. Here, a novel interpretation of drug aerosolization performance efficiency, 
the PADE, was developed by correlating performance with airflow parameter employed 
using SETs.[21] The utilize of this mathematical expression is based on: 1) The 
hypothesis that the model of molecular surface association described by surface 
adsorption expressions can be adapted to fit shear displacement observations; 2) The 
notion that drug particle removal from the surface of lactose carriers by shear force is 
analogous to surface site occupancy described in Langmuir adsorption isotherm, while the 
mechanism is analogous to molecular desorption. (see Chapter 5 for details of the 
analogy and difference between relevant physical phenomena such as surface adsorption, 
protein binding with similar algebraic equivalent expression). In this chapter, the 
mathematical expression defined below will be referred to as PADE: 
sd
sd
k
k
FPF
FPF
τ
τ
+= 1max
 (Eq. 3-1) 
)(
1
maxmax FPFkFPFFPF d
ss += ττ  (Eq. 3-2) 
where FPFmax is defined as the characteristic FPF at shear stress τs approaches maxima 
and further increasing of FPF would require comminution of the drug/carrier particles; kd 
is defined as the deaggregation constant, analogous to the Langmuir adsorption constant. 
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The PADE parameters (FPFmax and kd), and regression goodness of fit (R2 and adjusted 
R2) were determined. 
The correlation of FPFTD or FPFED with SET τs by PADE non-linear regression 
(Eq. 3-1) and PADE linear regression (Eq. 3-2) analyses are shown in Figure 3-7 and 3-8 
for AS and DSCG formulations, and in Figure 3-9 and 3-10 for IPB and FP formulations, 
respectively. For PADE non-linear regression analyses, the coefficients FPFmax and kd for 
each formulation combination, as well as the goodness of fit (R2 and adjusted R2) are 
shown in Table 3-2. An excellent goodness of fit was observed for all sixteen 
formulations based on the R2, adjusted R2 (adjusted R2: 0.8991-0.9993 for AS and DSCG 
formulations, and 0.9140-0.9990 for IPB and FP formulation, with the exception of 
FP_ML-A formulation, adjusted R2 = 0.7269). Higher FPF represented greater drug 
deaggregation and performance efficiency. A correlation analogous to Langmuir surface 
adsorption was observed. Greater initial increase of FPF was observed at low shear stress 
followed by smaller increases in FPF at higher shear stress until FPF approached to a 
plateau region at FPFmax. Here, the FPFmax represented the maximum FPF that could be 
achieved if the detachment shear stress reached maxima and in excess of the critical shear 
stress value. Further deaggregation of drug particles from carrier particles would not be 
possible because it would result in comminution of the drug/carrier particles. So FPFmax 
should be an important parameter for evaluating the performance efficiency of the aerosol 
formulations. The data interpreted by the foregoing mathematical approach showed that 
the rank order of performance efficiency based on FPFmax of the sixteen blends was:  
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1) ML-B/DSCG > ML-A/DSCG > ML-A/AS > ML-B/AS > SV-B/DSCG > SV-A/DSCG > 
SV-B/AS > SV-A/AS; 
2) ML-B/IPB > ML-A/IPB > SV-A/IPB > SV-B/IPB > ML-B/FP > ML-A/FP > SV-B/FP > 
SV-A/FP. 
Both FPFTD and FPFED give the same rank order. This rank order can be perceived more 
directly from the slopes (1/FPFmax) of the PADE linear regression plots (Figure 3-9 and 
3-10, Eq. 3-2). Excellent correlation was observed (R2: 0.9804-0.9998 for AS and DSCG 
formulations, and 0.9905-0.9999 for IPB and FP formulations, respectively). The steeper 
the slope, the poorer the performance efficiency is. In DSCG formulations, there exists a 
convergence point at τs ≈ 1.9 N/m2. In IPB formulations, the convergent point was at τs ≈ 
3.0 N/m2 between SV-A, ML-A, and ML-B, and about 1.6 N/m2 between SV-B and 
ML-B. In FP formulations, the convergent point also existed between SV-A, SV-B, and 
ML-A at τs ≈ 1.8 N/m2. The convergent points indicated that formulations with less 
performance efficiency had higher FPF than more efficiently dispersed formulation 
below the critical τs, whereas above this point, FPF rank order reverses. In AS 
formulations, this convergence point is only observed in two SV blends at a higher shear 
(τs ≈ 3.6 N/m2). It also implied that formulation heterogeneity may play a role, though the 
data fit and tolerate the PADE interpretation well. More data points are required to 
address this phenomenon. The interpretation of deaggregation constant kd is also related 
to the critical τs. A more rigorous discussion of this novel and approach to particle 
dispersion data is presented in Chapter 5.[22] 
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3.3.2.3 ACI 
The fold over selection of blends for ACI studies was AS_SV-A, AS_SV-B, 
DSCG_ML-A, DSCG_ML-B; IPB_SV-A, IPB_SV-B, FP_ML-A, and FP_ML-B. The 
deposition pattern of these selected blends actuated at highest (SET-A) and lowest 
(SET-D) shear stress are shown in Figure 3-11. The aerosol dispersion efficiency was 
evaluated by ED, FPF and MMAD. (Table 3-3) The AS-SV formulation gave 
significantly lower FPF than DSCG-ML formulation, as was exemplified by the trend in 
deposition shifting to the lower stages (smaller particle sizes). SV formulations gave 
smaller MMAD than ML formulations. When the worst, SV-AS, formulation was 
actuated at lowest shear stress, the FPF4.5 was 9.4-12.0%. While the best, ML-DSCG, 
formulation was actuated at highest shear stress, a significant increase of FPF4.5 was 
obtained (33.9-35.2%). This can be considered as “matched” formulation and shear stress. 
However, a “mismatched” formulation and shear stress resulted in a lower but 
comparable FPF4.5. (15.7-21.6% for AS/SV/high shear and 13.9-15.1% for 
DSCG/ML/low shear).  
For IPB and FP formulations, the ED was influenced greatly by τs. SET-D gave 
significantly higher ED values (87.0-91.6%) than SET-A (56.0-77.2%). Carrier effect was 
confounded by τs effect. IPB-SV formulation gave significantly higher FPF values than 
FP-ML formulation in both high shear (FPF4.5 for IPB-SV: 20.9-23.2%; FPF4.5 for 
FP-ML: 11.9-14.9%) and low shear (FPF4.5 for IPB-SV: 15.3-17.3%; FPF4.5 for FP-ML: 
6.0-8.2%), as exemplified by the deposition shifting to the lower stages. Higher τs and 
ML formulation resulted in the deposition to the lower stages than lower shear and SV 
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formulation, but the main influence of FPF was the drug effect. The highest τs gave 
smaller MMAD values than those at the lowest τs (p < 0.05). Both IPB-SV and FP-ML 
formulation gave similar MMAD values at the highest τs, but FP-ML formulation gave 
significantly smaller MMAD values than IPB-SV formulation at low τs.(p < 0.05). 
Similar statistical analyses were performed and the findings are consistent with the TSLI 
data analysis. 
Similarly, PADE applied to inhalation aerosol dispersion can be assessed. PADE linear 
regression can conventionally be simplified. (similar to the specific surface area 
determination of a solid from N2 adsorption isotherms, which could conventionally be 
analyzed by a single point method.[23]) For the present interpretation, a dual-point 
analysis (high shear and low shear) was conducted (Figure 3-12). The rank order from 
the slope of the lines indicated:  
ML-B/DSCG ≥ ML-A/DSCG >> SV-B/AS > SV-A/AS, 
and  SV-A/IPB > SV-B/IPB > ML-B/FP > ML-A/FP. 
which is in good agreement with the above TSLI analysis. This simple method can be 
used to quickly estimate the formulation performance within the desired shear stress 
range. 
 
3.4 Discussion 
3.4.1 Influence of Drugs
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3.4.1.1 AS vs. DSCG 
The physicochemical nature of drugs is important to the formulation performance 
efficiency. AS particle surfaces are relatively smooth and non-spherical. DSCG particles 
are more irregularly shaped and surface defects (potentially “high surface energy” sites) 
was observed at high magnifications in SEM. The interparticulate adhesion forces were 
previously reported to be stronger for pure carrier-free DSCG than AS, which could be 
attributed to spontaneous self-assembly behavior of pure DSCG and liquid crystalline 
formation.[24] DSCG is an amphoteric chemical posssessing both hydrophobic and 
hydrophilic moieties. This surface-active drug is known to possess liquid-crystalline 
self-assembling properties and demonstrate liquid crystalline phase behavior.[25, 26] 
Bulk characterizations using DSC demonstrated characteristic liquid crystalline 
thermogram which indicated molecular long-range vs. short range order for micronized 
DSCG in the solid-state. Bulk characterization using XRPD confirmed the existence of 
partially ordered and disordered liquid crystalline mesophase in the micronized DSCG. 
DSC thermograms also indicated that the micronization of DSCG by jet-milling 
introduced molecular disorder. However, DSCG/lactose monohydrate blends gave 
superior aerosol performance leading to greater drug aerosolization performance than 
AS/lactose monohydrate blends.[27] The superior aerosol performance may be attributed 
to the strong interfacial energy-reducing properties of DSCG at polar lactose 
monohydrate interface. It is generally recognized that liquid crystalline materials 
inherently possess surface activity and surface tension reducing properties of high-energy 
surface such as water (γ = 72 mN/m) and form stable soluble monolayers at air-water 
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interface.[8, 9, 25] These interfacial thermodynamic fact of DSCG appeared to reduce the 
high interfacial interactions occurring at the drug-carrier interface and resulted in better 
aerosol performance compared with AS. Besides, the electrostatic compatabiltiy between 
AS (positively charged) and lactose monohydrate (negatively charged) may also be a 
factor for poorer performance of AS formulation.[2] Furthermore, AS formulations were 
more susceptible to carrier change (SV vs. ML) than DSCG formulations, indicating 
stronger influence of ternary inclusion (intrinsic fines of ML) to the performance of AS 
formulations. It also suggested that AS formulations be more suitable for aerosolization 
performance mechanism studies of ternary-inclusion formulation. It is well-known that 
the inclusion of fines (typically less than 10 μm) improves formulation performance, 
though the performance mechanism following ternary blending is still debatable.[28] A 
balance of drug detachement from the carrier and deagglomeration of drug-drug or 
drug-fine lactose has been suggested recently.[29] It suggested that the micronized AS 
adhered to a greater extent to the major carrier particle surfaces than the micronized 
DSCG, which somehow detached from the major carrier surfaces, as was suggested by 
the increased fine particles after blending. It was further suggested that the balance of 
drug detachment from the carrier and deagglomeration could be different between AS and 
DSCG formulations. The balance could also be affected to a different extent if AS or 
DSCG concentration was changed. Because the available surface sites on the lactose 
monohydrate and the work of cohesion/adhesion for the drug and lactose mixture could 
result in different mixture structures. 
3.4.1.2 IPB vs. FP 
 
119
The physicochemical nature of drugs may strongly influence the formulation performance 
efficiency. The drug effect was the primary effect influencing the FPF values for IPB and 
FP formulations. After milling, the morphology of FP was greatly changed from smooth 
and elongated particles to rough and irregular-shaped particles, as was indicated by SEM. 
Aggregation was observed in both milled IPB and FP. The particle size distribution was 
narrow and median particle diameter of IPB and FP were similar, by LD. The 
thermoanalysis using DSC indicated a substantial influence of jet-milling and blending on 
the powder formulation. A partial loss of bound water from rigid crystalline IPB was 
observed, which indicated the generation of some anhydrous ipratropium bromide, and 
creation of crystalline defects and increased molecular disorder during milling. The 
change of FP by milling was not reflected in DSC thermograms. The DSC thermograms 
showed peak broadening in all IPB, FP/lactose monohydrate blends, indicating the 
influence of blending to the powder formulation. The surface roughness of both IPB and 
FP blends introduced by milling and blending may also contribute to the differences in 
drug deaggregation. The superfine particles adhered to the primary FP following milling 
may also be an important factor. Jet-milling may not only induce surface defects but also 
possibly introduce electrostatic charge. Through molecular modeling of surface charge 
density on IPB, it was reported that IPB has a predominantly neutral surface (with some 
small regions of positive and negative charge).[30] Consequently, weak long range 
electrostatic interaction was observed between IPB and negatively charged lactose 
monohydrate.[30] The charge of micronized dry powder FP has not been fully elucidated, 
but it has been reported that the cohesive-adhesive balance ratio between FP-FP and 
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FP-lactose monohydrate using micronized FP was quite small by AFM colloidal approach, 
indicating significant adhesion between micronized FP particle and lactose 
monohydrate.[31] This may explain the poor aerosolization performance exhibited by FP 
formulations. FP is a fluorinated corticosteroid that has a conjugated propionate moiety 
(Figure 1B). It is quite different from the ionic salt monohydrate IPB (Figure 1A) which 
has rigid crystalline monohydrate structure. The hydrophobic effect of FP due to the 
corticosteroid rings, the fluorine atoms, and the propionate moiety may strongly influence 
the interfacial properties and the subsequent aerosolization. The increased adhesion force 
may be explained by the increased contact area between FP and lactose monohydrate 
particles. Higher density of FP particle may also reduce the deaggregation due to inertia. 
3.4.2 Influence of Carriers
3.4.2.1 Carriers that blended with AS vs. with DSCG 
Lactose monohydrate batches are also important factors that influenced formulation 
performance. The differences between lactose monohydrate batches includes particle size 
distribution, surface roughness, amorphous content, crystallinity, and intrinsic fine 
particles. The SEM images demonstrated that ML lactose monohydrates had much more 
intrinsic fines (< 10 μm) which appeared to agglomerate between the interstices of major 
carrier particles instead on the particle surfaces. The distribution of intrinsic fines 
remained in the interstices after blending with 2% (w/w) drugs. The particles of SV 
lactose monohydrates were more regularly shaped and surfaces were smoother than those 
of ML lactose monohydrates, though their primary particle sizes were comparable.[13, 27] 
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DSC thermograms and XRPD diffractograms revealed higher amorphous content and 
lower crystallinity of the ML lactose monohydrate batches compared to SV samples. 
These properties influenced the interparticulate forces, resulting in improved flow 
properties of SV formulations than ML formulations. Thus, superior ED of SV 
formulations observed in performance studies across all SET airflow parameters. The 
intrinsic lactose monohydrate surface fines could serve as ternary components, 
responsible for the increase in FPF.[32] The statistical experimental data analyses 
indicated that SV-A and SV-B lactose monohydrate batches did not result in significant 
performance difference, nor did ML-B and ML-B lactose monohydrate batches. However, 
the performance efficiency between two SV or between two ML lactose monohydrates 
can be differentiated by using PADE. The TSLI and ACI were in good agreement to each 
other. 
3.4.2.1 Carriers that blended with IPB vs. with FP 
The lactose monohydrate batches had a great influence on powder fluidization and 
entrainment. This may be illustrated by the higher ED values observed for SV blends, and 
lower ED values for ML blends. Carrier demonstrated a smaller effect in drug 
deaggregation for IPB formulations than FP formulations. For example, although SV-A 
and ML-A are known to be different due to greater content of intrinsic fines, surface 
roughness, and amorphous content of the latter, the FPF values were similar at high shear 
stress for IPB formulations. However, the FP formulations exhibited much greater carrier 
effect than IPB formulations. The FPF values were significantly larger for ML blends 
than SV blends. This may be explained by the agglomeration mechanism for ternary 
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component. Micronized FP was known to strongly adhere to the lactose monohydrate, 
which was advantageous in forming larger agglomerates unlike the less adhesive 
micronized IPB, resulting in a large difference in performance between SV and ML 
formulations. Larger agglomerates were believed to be subject to greater deaggregation 
force.[28, 31] 
 
3.4.3 Influence of Shear Stress
Different devices may have distinct mechanism of deaggregation which cause aerosol 
particle separation by 1) aerodynamic ‘pull-off’ or tangential displacement;[33] 2) 
mechanical impaction;[34] 3) twisting ‘torque’ force that have been emphasized.[35] 
Conversely, the entrainment occurs in SETs by turbulence, collision, and to a large extent, 
shear force were not paid enough attention. The turbulent shear stress is believed to be the 
principal mechanism of deaggregation within the SETs overcoming interparticulate forces 
leading to formulation fluidization and deaggregation.[34, 36] Higher shear leads to 
higher degree of drug deaggregation and better aerosolization performance efficiency. 
The magnitude of shear stress is dependent on the specific resistance and patient’s 
inspiratory flow.[37] The specific resistance and the flow rate should be within a patient’s 
normal range of use. The specific resistance encompasses the values based on commercial 
inhalers.[14] The intent of the aerosolization performance studies was to challenge the 
formulation independently of the device, as a logical first step in product development. In 
order to do this it is desirable to employ as simple a method of particle stripping as 
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possible to challenge the association between drug and carrier. Undoubtedly, in the final 
product the impaction and momentum transfer are important, perhaps the most important, 
mechanisms for which a device is designed. However, it is reasonable to suggest that 
particles which can be stripped by shear forces may more readily be removed under the 
influence of impaction and momentum transfer, from which it can be inferred that these 
formulation performance studies may extrapolate qualitatively (as a rank order for 
example) to drug product (device and formulation) performance. 
The ED represents the degree of powder entrainment, where higher ED values 
indicate greater entrainment of the drug dose.[14] All SETs have an expansion region to 
allow for reduction in energy and to limit impaction in the inlet of the sampling device. 
The lower shear SET-C and D were designed to have gradual enlargment to facilitate 
gradual energy loss, and centrally located dosing platform to maximize airflow velocity, 
whereas SET-A and B were designed to have high shear which did not require 
consideration of reduction in energy loss as SET-C and D.[14] Other design features such 
as requirement for a much longer connection to the inlet of the sampling device or a 
larger angle for a diffuser for energy recovery contributed to the decision to not include a 
cone diffuser on SET-A and B. This resulted in higher ED in low shear SET-C and D and 
lower ED in higher shear SET-A and B, which is consistent with previous report.[14] 
This indicates that there are two portions of the entrained dry powders: a major portion 
that involves in particle deaggregation and a minor portion that remains in the SETs 
without undergoing deaggregation. The minor portion in SET-A and B was more 
pronounced than that in SET-C and D, due to the SET design and resulted in reduced ED. 
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It is important to note that ED described in this context is a portion of the emitted, or 
delivered, dose usually seen from inhalers. The portion that is deposited in the SET 
expansion outlet would deposit in the inlet of the sampling device (TSLI, ACI) if 
delivered from an inhaler. Such phenomena may explain that aerosol dry powder 
formulations having similar in vitro FPF values could exhibit quite different in vivo lung 
deposition.[38] The ability to discriminate between the portion of the delivered dose that 
is or is not deaggregated is a useful feature of the SETs since it points exclusively to 
formulation performance in the absence of specific inhaler design characteristics.  
The degree of deaggregation was represented by either FPFTD, FPFED, where 
larger FPF represented greater deaggregation. The correlation of FPF and SET airflow 
parameters indicated that increased FPF were obtained using higher shear SETs at given 
airflow, and hyperbola-shaped relationships were observed in all formulation blends. 
Greater initial increases in FPF were observed at low shear stress, and small increases in 
FPF at higher shear stress, until reaching a plateau. This suggests that aerosolization at 
higher shear stress will result in reduced actuation variability. According to the 
deaggregation mechanism, the shear stress applied overcomes the interparticulate forces 
that occur at the micronized pulmonary drug-sugar carrier interface i.e. solid-solid 
interface. It has been demonstrated systematically that the expression for surface 
interactions describing physical phenomena at an interface at the molecular level can also 
be applied to the aerosol particulate systems. The PADE appears to be a suitable and 
physically meaningful method facilitating interpretation of the aerosol performance data. 
This method, when adapted for pharmaceutical aerosolization performance, can be 
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directly related to the physical interactions occurring at the interface. Particles being 
removed with increasing difficulty because of the sites that they occupy is analogous to 
surface site occupancy described in Langmuir adsorption isotherm. The Langmuir 
adsorption isotherm is the cornerstone of almost all theories of surface interactions on a 
molecular scale. Many theoretical or semi-empirical surface adsorption models that take 
into account the surface heterogeneity and molecular lateral interaction could possibly be 
modified to describe aerosol performance.[39] More rigorous studies that consider 
particle heterogeneity and/or lateral interaction will be discussed in Chapter 5.[22] 
Furthermore, PADE linear regression can be further simplified to dual point analysis for 
quick comparison of aerosolization performance efficiency, which in the present studies 
also proved to be valid. 
 
3.5 Summary 
This chapter focuses on the physicochemical characterization and performance studies of 
well characterized aerosol formulations using a range of techniques, and using SETs that 
encompass a range of airflow parameters such as shear stress consistent with commercial 
device performance, to characterize and evaluate the aerosol formulation performance in 
a device independent manner. A fold-over statistical experimental design was employed 
that could later be used to compare and search for any other interactions that may exist. 
The formulation preparation involved micronization of drug particles, and interactive 
physical blending of micronized pulmonary drugs with coarser lactose monohydrate 
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carriers. SETs with well defined airflow parameters were employed and proved to be 
useful and device-independent screening tools for formulation performance study. Three 
important factors including: drug, carrier lactose monohydrate, and shear stress (SET) 
were compared and the performance efficiency was evaluated by statistical experimental 
design. The TSLI and ACI data demonstrated that the best performing blend in AS and 
DSCG systems (highest FPF, smallest and narrowest particle size distribution) was 
DSCG in ML lactose monohydrate batches at high shear stress, whereas the worst 
performing blend was AS in SV sample at low shear. The best performing blend in IPB 
and FP systems was IPB in ML lactose monohydrate batches at high shear, whereas the 
worst performing blend was FP in SV at low shear. There appeared to be an inverse 
relationship between ED and FPF, but FPF is a more important measure of the 
aerosolization performance efficiency since it is closely related to the actual pulmonary 
delivery of drugs. SET has the capability of differentiating the portion of blend that 
deaggregates from the portion that does not deaggregate when the blend is entrained in 
the SETs. A correlation of the SET shear stress with aerosol performance led to a new 
interpretation of particulate deaggregation, PADE, similar to molecular association such 
as surface adsorption exemplified here by Langmuir adsorption. Other interpretations 
such as protein binding equivalent or other more rigorous surface adsorption models that 
consider surface heterogeneity or lateral interaction may possibly be applied to the 
aerosol formulation depending on the specific systems and the performance evaluation 
results. Here, the PADE and its linear regression have been used as a meaningful method 
to rigorously and quickly select the formulation for prospects of good performance 
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efficiency while alleviating the necessity, in the first instance, to delve onto various 
individual forces acting on each individual particle or enter into device considerations. 
The PADE method using two-parameter Langmuir equivalent expression results in 
excellent goodness of fit and which facilitiates a physical interpretation, and may be used 
to evaluate dry powder formulations given similar deaggregation mechanisms applied by 
SETs. The dual-point analysis can greatly expedite the performance screening and 
prediction of aerosol formulations. 
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Table 3-1. Particle volume size distribution of albuterol sulfate (AS), disodium 
cromoglycate (DSCG), ipratropium bromide monohydrate (IPB), and fluticasone 
propionate (FP) before and after air jet-milling. (Mean ± SD). 
 
 Span D10 (μm) D50 (μm) D90 (μm) Dae (μm) 
Micronized AS 0.26 ± 0.09 3.20 ± 0.06 3.59 ± 0.13 4.13 ± 0.40 - 
Micronized DSCG 0.32 ± 0.01 3.24 ± 0.01 3.68 ± 0.02 4.40 ± 0.04 - 
IPB unmilled* 2.29 ± 0.02 3.64 ± 0.10 9.26 ± 0.19 24.87 ± 0.69 10.68 
IPB once-milled* 0.23 ± 0.04 4.12 ± 0.05 4.53 ± 0.16 5.16 ± 0.28 5.22 
IPB twice-milled* 0.34 ± 0.05 2.82 ± 0.21 3.29 ± 0.24 3.94 ± 0.20 3.79 
FP unmilled* 1.92 ± 0.09 11.39 ± 1.28 38.31 ± 5.40 85.01 ± 12.65 44.18 
FP twice milled* 0.36±0.22 3.87±0.20 4.47±0.09 5.47±0.83 5.16 
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Table 3-2. TSLI performance data analysis. The relationship between SET shear stress (τs) 
and FPFTD<6.4/FPF ED<6.4 for IPB/lactose monohydrate and FP/lactose monohydrate dry 
powder formulations using non-linear regression analysis. (n = 3). 
sd
sd
k
k
FPF
FPF
τ
τ
+= 1max
 (Eq. 3-1) 
 Drug Lactose FPFmax kd R2 Adj R2
SV-A 14.49 1.31 0.9739 0.9652 
SV-B 16.55 0.75 0.9362 0.9149 
ML-A 43.51 1.32 0.9893 0.9858 
AS 
ML-B 38.54 0.76 0.9691 0.9588 
SV-A 35.59 3.00 0.9896 0.9861 
SV-B 37.40 3.75 0.9927 0.9902 
ML-A 44.78 1.32 0.9978 0.9970 
DSCG 
ML-B 48.62 1.30 0.9987 0.9983 
SV-A 32.99 25.22 0.9954 0.9939 
SV-B 29.51 80.02 0.9438 0.9250 
ML-A 34.02 5.26 0.9967 0.9955 
IPB 
ML-B 37.56 2.11 0.9806 0.9741 
SV-A 14.95 14.84 0.9823 0.9764 
SV-B 16.04 3.37 0.9993 0.9990 
ML-A 18.57 5.19 0.9000 0.8667 
FPFTD
FP 
ML-B 24.20 14.33 0.9954 0.9939 
SV-A 18.03 0.93 0.9634 0.9513 
SV-B 21.45 0.45 0.9244 0.8991 
ML-A 54.05 1.21 0.9833 0.9778 
AS 
ML-B 50.44 0.68 0.9342 0.9123 
SV-A 46.34 1.76 0.9995 0.9993 
SV-B 47.51 2.23 0.9995 0.9993 
ML-A 61.15 1.00 0.9904 0.9872 
DSCG 
ML-B 64.13 1.10 0.9851 0.9801 
SV-A 45.63 4.25 0.9910 0.9879 
SV-B 42.06 4.91 0.9804 0.9738 
ML-A 50.04 2.27 0.9731 0.9641 
IPB 
ML-B 57.46 1.13 0.9456 0.9274 
SV-A 21.27 3.58 0.9946 0.9929 
SV-B 23.16 1.53 0.9939 0.9919 
ML-A 34.27 1.22 0.7951 0.7269 
FPFED
FP 
ML-B 37.91 2.88 0.9355 0.9140 
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Table 3-3. ACI drug aerosolization performance (ED, FPF, and MMAD) studies via 
SET-D (τs = 0.624 N/m2) and SET-A (τs = 13.143 N/m2) at airflow rate Q = 60 L/min. 
The formulations in comparison were SV-AS vs. ML-DSCG; and SV-IPB vs. ML-FP 
(mean values, n = 3 with standard deviation in parenthesis). 
 
SET Lactose-Drug 
ED 
(%) 
FPM6.5
(μm) 
FPM4.5
(μm) 
FPF6.5
(%) 
FPF4.5
(%) 
MMAD 
(μm) 
SV-A_AS 86.6 (2.6) 192.9 (6.8) 168.1 (6.2) 18.1 (0.2) 15.7 (0.2) 1.56 (0.04) 
SV-B_AS 92.1 (1.4) 225.5 (45.6) 204.6 (42.3) 23.8 (5.9) 21.6 (5.4) 1.45 (0.07) 
ML-A_DSCG 82.1 (0.7) 446.3 (43.8) 327.6 (28.5) 46.1 (0.3) 33.9 (0.8) 2.52 (0.12) 
SET 
A 
ML-B_DSCG 82.6 (2.0) 459.7 (34.3) 340.3 (26.2) 47.6 (2.5) 35.2 (2.0) 2.54 (0.14) 
SV-A_AS 87.8 (3.3) 130.5 (22.5) 104.2 (18.2) 11.8 (1.8) 9.4 (1.4) 1.73 (0.33) 
SV-B_AS 89.2 (4.2) 156.4 (49.2) 126.3 (39.1) 14.9 (4.4) 12.0 (3.5) 1.76 (0.14) 
ML-A_DSCG 81.8 (10.5) 205.9 (28.2) 134.3 (17.1) 21.3 (3.1) 13.9 (1.8) 2.88 (0.13) 
SET
D 
ML-B_DSCG 88.0 (3.0) 223.3 (18.3) 144.6 (15.0) 23.4 (1.9) 15.1 (1.5) 3.02 (0.19) 
 
SV-A_IPB 77.2 (1.9) 357.5 (12.7) 247.1 (11.2) 33.5 (2.4) 23.2 (1.5) 2.57 (0.34) 
SV-B_IPB 75.2 (4.4) 302.7 (57.0) 205.0 (47.6) 30.8 (3.0) 20.9 (3.1) 2.86 (0.45) 
ML-A_FP 56.0 (3.1) 142.5 (11.0) 102.8 (9.1) 16.4 (1.5) 11.9 (1.2) 2.62 (0.09) 
SET 
A 
ML-B_FP 64.3 (1.8) 180.3 (9.6) 128.6 (4.6) 20.9 (1.3) 14.9 (0.7) 2.54 (0.10) 
SV-A_IPB 91.6 (1.5) 276.2 (18.6) 166.0 (18.0) 25.3 (4.0) 15.3 (3.2) 3.26 (0.39) 
SV-B_IPB 91.3 (1.9) 275.2 (36.2) 168.7 (31.0) 28.2 (2.8) 17.3 (2.7) 3.21 (0.37) 
ML-A_FP 87.0 (1.7) 82.1 (10.8) 53.2 (7.7) 9.2 (1.1) 6.0 (0.7) 2.71 (0.09) 
SET
D 
ML-B_FP 87.5 (2.0) 112.3 (17.8) 75.0 (11.3) 12.3 (1.7) 8.2 (1.1) 2.84 (0.11) 
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Figure 3-1. Chemical Structures of (A) Albuterol sulfate; (B) Disodium cromoglycate; (C) 
Ipratropium bromide monohydrate; (D) Fluticasone propionate; (E) α-lactose 
monohydrate. 
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Figure 3-2. Representative scanning electron micrographs of disodium cromoglycate 
(DSCG), ipratropium bromide monohydrate (IPB), and fluticasone propionate (FP) before 
and after micronization by air jet milling: (A) raw DSCG (3k× magnification); (B) 
micronized DSCG (20k×); (C) raw IPB (3k×); (D) raw FP (150×); (E) IPB after 1st 
milling (3k×); (F) FP after 1st milling (3k×); (G) IPB after 2nd milling (10k×); and (H) FP 
after 2nd milling (10k×). 
(A) (B)
(C) (D)
(E) (F)
(G) (H)
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 Figure 3-3. Representative SEM images of drug (DSCG, IPB, FP) and lactose 
monohydrate (2 sieved batches (SV) and 2 milled batches (ML)) interactive physical 
mixtures at 2%w/w drug concentration: (A) DSCG-SV (1,500×); (B) DSCG-ML (1,500×); 
(C) IPB-SV (1,500×); (D) IPB-ML (1,500×); (E) FP-SV (600×); and (F) FP-ML (600×). 
(See Chapter 2 for AS-lactose monohydrate blends.) 
(A) (B)
(C) (D)
(E) (F)
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Figure 3-4. Representative Differential Scanning Calorimetry Thermograms of Raw 
Drugs and Drugs After Micronization by Jet-milling: (A) Unmilled and micronized 
DSCG; (B) Unmilled and micronized IPB; (C) Unmilled and micronized FP. Scanning 
rate is at 5 oC/min. 
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Figure 3-5. Representative DSC thermograms of drug-lactose monohydrate (SVs or MLs) 
interactive physical mixtures: (A) blends of DSCG (2%w/w) with SV-A and SV-B, 
respectively; (B) blends of DSCG (2%w/w) with ML-A and ML-B, respectively; (C) 
blends of IPB (2%w/w) with SV-A and SV-B, respectively; (D) blends of IPB (2%w/w) 
with ML-A and ML-B, respectively; (E) blends of FP (2%w/w) with SV-A and SV-B, 
respectively; and (F) blends of FP (2%w/w) with ML-A and ML-B, respectively. 
Scanning rate is at 5 oC/min. 
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Figure 3-6. X-ray powder %height intensity diffractograms of micronized drugs (A) 
albuterol sulfate; (B) disodium cromoglycate; (C) ipratropium bromide monohydrate; and 
(D) fluticasone propionate.  
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Figure 3-7. The relationship between SET airflow parameter (exemplified by shear stress 
τs) and TSLI formulation performance (ED, FPFTD, FPFED). Nonlinear regression 
analyses were applied using PADE for FPF-τs correlation (Eq.3-1). Left panels (A) to (C) 
are AS/lactose monohydrate systems (2%w/w): (A) ED-τs; (B) FPFTD-τs curve fitting; (C) 
FPFED-τs curve fitting. Right panels (D) to (F) are DSCG/lactose monohydrate systems 
(2%w/w): (D) ED-τs; (E) FPFTD-τs curve fitting; (F) FPFED-τs curve fitting. (Mean ± SD, 
n = 3). 
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Figure 3-8. The relationship between SET airflow parameter (exemplified by shear stress 
τs) and TSLI formulation performance (exemplified by FPFTD). Linear regression 
analyses were applied using Langmuir linear regression. (Eq. 3-2). (A) 2% (w/w) 
AS/lactose monohydrate systems; and (B) 2% (w/w) DSCG/lactose monohydrate systems. 
The R2 represents the goodness of fit of regression lines. (Mean ± SD, n = 3). 
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Figure 3-9. The relationship between SET shear stress (τs) and TSLI formulation 
performance (ED, FPFTD, FPFED). Nonlinear regression analyses were applied using 
PADE for FPF-τs correlation (Eq.3-1). Left panels (A) to (C) are IPB/lactose 
monohydrate systems (2%w/w): (A) ED-τs; (B) FPFTD-τs curve fitting; (C) FPFED-τs 
curve fitting. Right panels (D) to (F) are FP/lactose monohydrate systems (2%w/w): (D) 
ED-τs; (E) FPFTD-τs curve fitting; (F) FPFED-τs curve fitting. (Mean ± SD, n = 3). 
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Figure 3-10. The relationship between TSLI formulation performance (exemplified by 
FPFTD) and SET shear stress (τs). Linear regression analyses were applied using PADE 
linear regression (Eq. 3-2). (A) 2%w/w IPB/lactose monohydrate systems; and (B) 
2%w/w FP/lactose monohydrate systems. The R2 represents the goodness of fit of 
regression lines. (Mean ± SD, n =3). 
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Figure 3-11. The ACI deposition pattern of AS/SV, DSCG/ML, IPB/SV, and FP/ML 
formulations using SETs (Device, throat, and preseparator drug deposition were included 
in stage deposition calculation but not plotted). (A) 2% (w/w) AS/SV at lowest shear 
stress (SET-D, τs = 0.624 N/m2) vs. 2% (w/w) DSCG/ML at highest shear stress (SET-A, 
τs = 13.143 N/m2); (B) 2% (w/w) AS/SV at highest shear stress vs. 2% (w/w) DSCG/ML 
at lowest shear stress (SET-A, τs = 13.143 N/m2); (C) 2% (w/w) IPB/SV at lowest shear 
stress vs. 2% (w/w) FP/ML at highest shear stress; (D) 2% (w/w) IPB/SV at highest shear 
stress vs. 2% (w/w) FP/ML at lowest shear stress. (Mean ± SD, n = 3). 
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Figure 3-12. ACI Performance Evaluation (FPFTD<6.5) by Dual-point Performance 
Evaluation, FPF and shear stress (SET-D, τs = 0.624 N/m2 and SET-A, τs = 13.143 N/m2) 
correlation: (A) 2% (w/w) AS/SV vs. 2% (w/w) DSCG/ML; and (B) 2% (w/w) IPB/SV 
vs. 2% (w/w) FP/ML  (Mean ± SD, n = 3). 
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CHAPTER 4 ALTERNATIVE SUGARS AS CARRIER 
4.1 Introduction 
Although α-lactose monohydrate is most widely used DPI carrier, the selection of this 
sugar carrier was not based on any rigorous screening process. Historically, lactose 
monohydrate has been commonly employed as an excipient in many solid and liquid 
dosage forms; because it exhibits several ideal characteristics, such as its safety profile, 
availability, and cost. However, there are quite a few other pharmaceutical excipients, 
especially sugars (defined as low molecular weight carbohydrate including mono-, di-, 
oligo-saccharides) and sugar alcohols, which may also meet the criteria of a good carrier. 
Sugars are a group of complex small molecules with condensed functionalities (polyol, 
aldehyde, ketone) and chiral centers. There are six naturally occurring pentoses (four 
aldo- and two keto-) and twelve hexose (eight aldo- and four keto-). In solution, they exist 
in both open chain aldehyde/ketone and cyclic hemiacetals. Mutarotation further 
complicates the chemistry. The sugar alcohols are a group of polyols derived from 
corresponding sugars. It should also be noted that in majority pharmaceutical dosage 
forms, both sugars and sugar alcohols are presented in their thermodynamically most 
stable form, many of which are hydrate crystallines. 
A plethora of sugars and sugar alcohols exists but they were not sufficiently 
studied. The selection criteria were largely based on their availability and generally 
recognized as safe (GRAS) food additives. Their safety profiles for pulmonary delivery 
were not complete. The potential carrier sugar explored so far (Figure 4-1) include 
glucose [1-3], trehalose [4-6], maltose [2], raffinose [4, 5], and β-cyclodextrin [4, 5]. The 
sugar alcohols include erythritol [7, 8], xylitol [1, 4, 5], mannitol [1, 6, 9, 10] , sorbitol [2, 
9], and maltitol [1, 10]. Physicochemical investigations of these sugars relating with the 
formulation performance have only been attributed to a limited number of aspects. They 
include: differences in particle size or shape [9], surface roughness [8, 10], surface energy 
[6, 10], drug carrier adhesion [7, 10], and hygroscopicity [2, 11]. In fact, extra aspects 
should be considered carefully before switching to a new carrier system. The safety 
profiles of any alternative sugars should be under regulatory scrutiny. The long-term 
stability (physicochemical, pharmaceutical, and microbiological aspects) of final products 
containing the alternative sugars should be established at an early stage of product 
development. These concerns somehow delayed the development of alternative sugars 
into carriers. On the other hand, lactose as an inert carrier should come under some 
degree of scrutiny too. Lactose contains aldehyde functionality in its open chain form, its 
reducing characteristics may not be suitable for some active compounds such as peptides, 
proteins, or other amino-group containing compounds, non-enzymatic browning known 
as the Maillard reaction.[12] Reducing sugars also has the potential for microbes to use 
sugars as substrates for growth, adversely affect the anti-microbial drug therapy. Moreover, a 
proportion of people have a certain degree of lactose intolerance, which raises another 
issue for the lactose based formulations.[13] Lactose as a milk product, may introduce 
small amount of surface impurity during the manufacturing, which causes batch to batch 
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variation of the final product. Endotoxin content and bovine source of lactose are also 
minor concerns of using lactose.[1] 
The search for alternative sugar carriers based on all the above criteria is a 
daunting task. However, several simple rules that aim at limiting the scope of search may 
be enlightening. In chemistry, non-reducing sugars and sugar alcohols have the advantage 
of chemical stability and less likely being nutrient for bacterial growth. Some 
non-reducing sugar alcholos such as erythritol and xylitol cannot be metabolized and have 
the tendency to “starve” harmful bacteria.[14] In physics, an ideal sugar carrier should be 
non-hygroscopic (high critical relative humidity, RH0), stable during pharmaceutical 
processing and storage (e.g. high glass transition temperature), relative smooth surface 
crystalline without metastable structures and polymorphs. Molecules such as fructose and 
sorbitol (RH0 = 64% and 70%, respectively, at 25 oC [15]) are examples of hygroscopic 
sugar and sugar alcohol that may not be suitable carrier candidates. Based on these 
physicochemical criteria, a representative non-reducing sugar D-trehalose dihydrate, and 
sugar alcohol D-mannitol were chosen as potential carriers for the pulmonary drug 
delivery. The former is a disaccharide formed by 1,1-glucoside linkage, which makes the 
molecule resistant to acid hydrolysis and remains in closed-ring form (Acetal is 
non-reducing). Trehalose is accepted as a food ingredient under the GRAS terms in the 
U.S. It is manufactured by enzymatic hydrolysis of wheat or corn starch.[16] Because of 
its effect on stabilizing macromolecules such as vaccines, it is a potential excipient as a 
non-toxic cryoprotectant.[17] Anhydrous D-trehalose has relatively high a glass transition 
temperature at 115 oC.[17] The crystalline D-trehalose dihydrate has both a high 
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resistance to moisture (RH0 ~ 98 % at 23 oC [15]) and absorption and a characteristic of 
retaining high Young’s modulus (the force per unit area required to break or crack a 
substance) at high relative humidity.[18] The latter, D-mannitol is a six carbon sugar 
alcohol. It is often used as a stabilizing agent for proteins and peptides. It has been used 
as a therapeutic to treat head trauma and oliguric renal failure. The inhalation mannitol 
has been used as a treatment for cystic fibrosis (to osmotically thin the mucus) and 
bronchiectasis (BronchitolTM) and as a diagnostic test for airway hyperresponsiveness 
(AridolTM). Because mannitol is metabolized independently of insulin, it is applicable in 
diabetic patient. At present, mannitol is manufactured by chemical hydrogenation of 
fructose or glucose.[19] Other methods such as enzymatic hydrogenation and microbial 
production are also used but more costly. Crystalline D-mannitol is a relatively soft 
material (Young’s modulus: 12.2 GPa [20]). Crystalline D-mannitol (RH0 ~ 80% at 25 oC 
[15]) is more hygroscopic than D-trehalose dihydrate. 
As described in previous chapters and publications [21-26] using lactose-based 
formulations, various interparticulate and interfacial interactions may greatly affect drug 
aerosolization performance. The influencing factors including particle size, size 
distribution, morphology, surface roughness, degree of crystallinity vs. noncrystallinity, 
the presence of metastable surface phases by pharmaceutical processing, surface 
energetics, elasticity, electrostatic interactions surface heterogeneity of drugs and carriers 
should apply to the potential sugar carriers too. For example, it was reported previous that 
different qualities of mannitol batches (Sieved fractions: 32-125 μm) resulted in 
significantly different FPF of budesonide, varying from 15-50%.[1] Based on the earlier 
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studies using standardized entrainment tubes (SETs) and aerodynamic deposition studies 
for the evaluation of aerosolization performance, we have obtained valuable information 
about the physicochemical behavior of drugs, different batches of lactose monohydrate 
carriers, and their corresponding blend formulations. The discovery of the novel powder 
aerosol deaggregation equation (PADE) greatly broadened our horizon of knowledge for 
evaluating performance in a shear stress range. However, it is still unknown if the 
aerosolization performance using alternative sugars would furnish similar result that 
could apply PADE. The purpose of the studies in this chapter is to comprehensively 
characterize the physicochemical properties, to systematically generate performance data 
using SETs and inertial sampling, and to investigate the robustness and predictive 
behavior of PADE method in alternative carriers. 
 
4.2 Material and Methods 
4.2.1 Material 
The pulmonary drugs are the same as those described in Chapter 3. They include 
micronized albuterol sulfate (AS, C13H23NO7S; MW 337.39 g/mol; Pfizer Global R&D, 
Kent, UK); disodium cromoglycate (C23H14Na2O11; Molecular Weight: 512.33 g/mol; 
Sigma-Aldrich Inc, St. Louis, MO, US); ipratropium bromide monohydrate 
(C20H31Br2NO4; Molecular Weight: 509.27 g/mol; Sigma-Aldrich Inc., St. Louis, MO, 
US); and fluticasone propionate (C25H31F3O5S; Molecular Weight: 500.57 g/mol; API 
Inc., P.R. China). The micronization process was the same as that described in Chapter 3. 
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  Carriers used were D-mannitol (C6H14O6; Molecular Weight: 182.17 g/mol; ACS 
reagent, Batch No: 047K0064, Sigma-Aldrich Inc., St. Louis, MO, US) and 
D-(+)-trehalose dihydrate (C12H26O13; Molecular Weight: 378.33 g/mol; ≥98.5% purity, 
Batch No.: 047K3779, Sigma-Aldrich Inc., St. Louis, MO, US). Both carriers were sieved. 
The sieving was operated in a dry box with relative humidity controlled (~20 %RH, 23 ± 
0.5 oC). The sieve mesh sizes of 45, 75, 125, 180, and 300 μm were placed on a 3-inch 
sieve shaker (Model No. SS-5, Gilson Company Inc. Worthington, OH). The sieves were 
arranged in descending order of mesh size with the 300 μm sieve on top and the 45 μm 
sieve on the bottom. A mass of about 10 g of powder were placed on the top sieve and the 
sieve shaker was operated in the tap mode for two hours. Particles in the 0-45 μm, 45-75 
μm, and 75-125 μm size ranges were collected. The sieved fractions (2 sugars × 3 
fractions) were stored in sealed glass jars (Wheaton Science Products, Millville, NJ) 
which were then stored in glass desiccators under ambient temperature and pressure prior 
to further characterization and blending. 
  The carrier particle sizes in the range of 45-75 μm were used for preparation of 
physical interactive blends. The 4 drugs × 2 carriers were prepared by the same process as 
that described in Chapter 2 and 3. The prepared blends were stored in glass desiccators at 
ambient condition prior to further characterization and aerosolization performance study. 
4.2.2 Analytical Approaches 
The same physical characterization including scanning electron microscopy (SEM), 
thermal analysis using differential scanning calorimetry (DSC), crystallinity using X-ray 
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powder diffraction (XRPD), and particle sizing using laser diffraction (LD) (100 mm 
focal length for carrier particle size analysis) were employed. (see Chapter 3 for detailed 
operation). 
4.2.3 In Vitro Aerosol Performance Characterization 
Similar aerosolization using four SETs (SET-A, B, C, and D) and TSLI was employed. 
(see Chapter 3 for detailed method). The aerodynamic performance was evaluated by 
emitted dose (ED), fine particle fraction from total dose (FPFTD) and from emitted dose 
(FPFED). SigmaPlot 9.01 (Jandell Scientific, Systat software, San Jose, CA) was used for 
all data analysis and statistics. The PADE nonlinear (Eq. 4-1) and PADE linear (Eq. 4-2) 
regression analyses, as the algebraic equivalent expression of Langmuir surface 
adsorption theory, were applied. 
sd
sd
k
k
FPF
FPF
τ
τ
+= 1max
     (Eq. 4-1) 
)(
1
maxmax FPFkFPFFPF d
ss += ττ  (Eq. 4-2) 
 
4.3 Results 
4.3.1 Aerosol Characterization 
4.3.1.1 Particle size and morphology (SEM) 
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Representative SEM images are shown in Figure 4-2 and 4-3 for sieved D-mannitol 
(Mann), sieved D-trehalose dihydrate (Treh) (both 45-75 sieve range) and their interactive 
physical mixtures with four micronized pulmonary drugs. The SEM images of the drugs 
alone including albuterol sulfate (AS), disodium cromoglycate (DSCG), ipratropium 
bromide monohydrate (IPB), and fluticasone propionate (FP) were presented in Figure 
2-3 and 3-2. Treh (Figure 4-2A) exhibited columnar shape and very smooth crystalline 
surfaces with few surface fractures that were perpendicular to the length of the crystal. 
The surface fractures were possibly induced by mechanical sieving because the raw 
material SEM did not exhibit these fractures. Almost no intrinsic surface fine particles 
were observed. Conversely, Mann (Figure 4-2B) exhibited rough surface and long 
fractures along the length of the particle surface. The intrinsic fine particles with irregular 
shapes were resided in the grooves of primary particle surfaces (mechanical interlocking) 
where surface discontinuities exist even after sieving. The SEM of physical interactive 
mixtures demonstrated homogenous distribution of drug particles on the surface of the 
primary carrier particles for all the mixtures. Very few drug agglomerations were 
observed in the void of primary particles.  
4.3.1.2 Thermal properties (DSC) 
Representative DSC thermograms of Mann and Treh at a heating rate of 5 oC/min are 
shown in Figure 4-4. The DSC thermograms of drugs (unmilled and micronized) were 
shown in Figure 3-4 and discussed in Chapter 3. As seen in Figure 4-4A, Mann 
exhibited a single endothermic heat of fusing (Tm ~ 168 oC and ΔH ~ 264 J/g). In Figure 
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4-4B, Treh exhibited an endothermic dehydration peak (Tdeh ~ 93 oC and ΔH1 ~ 259 J/g) 
followed by a smaller endothermic heat of fusing (Tm ~ 212 oC and ΔH2 ~ 112 J/g) in the 
first scan. A small exothermic peak (Trec ~ 155 oC and ΔH3 ~ -15 J/g) was observed 
between the two endothermic peaks, indicating the molecular disorder to ordered state 
transition (recrystallization). Treh also exhibited scanning rate dependency. At scanning 
rate of 10 oC/min, the single dehydration peak split into doublet. Decomposition of Treh 
was observed when temperature was higher than 250 oC. No glass transition (Tg) was 
observed in the entire scanning range. However, by cooling the sample back to 20 oC, a 
second scanning of the same sample from 25 to 300 oC at a scanning rate of 20 oC/min 
exhibited an obvious Tg ~ 115 oC and ΔCp ~ 0.436 J/(g oC) (Figure 4-4B), indicating the 
glass transition of the amorphous D-trehalose caused by dehydration and cooling effect. 
  For AS/Treh formulation (Figure 4-5B), the dehydration endothermic peak of 
Treh (Tdeh ~ 99 oC and ΔH2 ~ 250 J/g) was comparable to that of Treh alone at a scanning 
rate of 5 oC/min. Two smaller endothermic peaks at ~210 and 220 oC were observed. The 
exothermic peak was shifted and partially overlapped with one of the small endothermic 
peak. For DSCG/Treh (Figure 4-5D), IPB/Treh (Figure 4-5F), FP/Treh (Figure 4-5H) 
formulations, the exothermic peak shifted to ~180 oC and became more appreciable 
(broader and larger peak area) in all formulations. These changes in thermal properties of 
sugar carriers, similar to lactose monohydrate based formulations, may affect the 
molecular properties of the drugs and carriers which consequently can affect macroscopic 
aerosolization performance. 
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4.3.1.3 Crystallinity (XRPD) 
The XRPD of Mann and Treh are shown in Figure 4-6A and B, respectively (Raw data: 
courtesy of Dr. Heidi Mansour. The data were re-plotted using Match!® software). Both 
diffractograms showed sharp intense peaks (with the absence of a noncrystalline “halo”) 
characteristic of highly crystalline materials.[27] These are in good agreement with 
diffractograms reported in the University of Cambridge database. 
4.3.1.4 Particle size analysis (LD) 
The particle volume size distribution of micronized pulmonary drugs was shown in 
Chapter 3. The particle size distributions of Mann and Treh are shown Table 4-1. Mann 
had a D50 of 52.95 ± 1.69 μm and span of 1.19 ± 0.02; and Treh had a D50 of 53.49 ± 0.79 
μm and span of 0.84 ± 0.04. It indicated that the particle size distributions of both sieved 
Mann and Treh at a range of 45-75 μm were comparable. A slightly larger span for Mann 
indicated that there were a few surface fines that could not be removed by mechanical 
sieving possibly due to mechanical interlocking. The LD data was in agreement with the 
SEM result. 
4.3.2 In Vitro Aeorsol Performance Assessment 
3.3.2.1 Twin Stage Liquid Impinger (TSLI) 
A total of eight formulations (4 drugs × 2 carriers) were subjected to aerosolization 
performance evaluation using four standardized entrainment tubes (SETs). The TSLI 
performance data are summarized in Appendix 4-A. In Chapter 3, a novel interpretation 
using powder aerosol deaggregation equation (PADE) was applied to describe and 
compare the particulate surface dissociation across a range of shear stress. Similar 
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statistical analytical process was applied to the performance data generated using 
alternative carrier systems.  
  As seen in Figure 4-7, when SET shear stress (τs) was correlated with 
aerosolization performance data (demonstrated using FPFTD<6.4), hyperbolic profiles were 
indicated. The non-linear regression analysis result (presented in FPFmax and kd, see 
Chapter 3 and 5 for detailed description of these two parameters) and the regression 
goodness of fit (presented in R2 and adjusted R2) using Langmuir type PADE (Eq. 4-1) 
are shown in Table 4-2. The non-linear regression using FPFTD data and FPFED data 
indicated good to excellent goodness of fit. The R2 and adjusted R2 values for all the 
evaluated formulations were in the ranges 0.8019-0.9845 and 0.7359-0.9793, respectively. 
(for FPFTD data). The rank order indicated by the value of FPFmax can be used to evaluate 
the performance efficiency and aid in formulation design. The evaluation of PADE linear 
regression indicated excellent correlation. The R2 values ranged from 0.9274 to 0.9968 
for the eight formulations investigated. 
Drug Effect (AS, DSCG, IPB, and FP). The AS and DSCG formulations gave 
significantly higher ED values than the other formulations, and FP formulation generally 
resulted in much lower ED values. According to the value of FPFmax, the performance 
efficiency (from FPFTD data) of Mann-based formulation gave a rank order of:  
DSCG/Mann > FP/Mann > IPB/Mann > AS/Mann 
The performance efficiency of Treh-based formulation gave a rank order of: 
DSCG/Treh > IPB/Treh > AS/Treh > FP/Treh 
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Carrier Effect (Mann vs. Treh). The performance evaluated from ED showed that 
carrier had limited influence on the ED. The ED of Treh/IPB was higher than Mann/IPB 
(Figure 4-9). All the other formulations showed that the carrier effect was not significant. 
However, the performance efficiency (from FPFTD data) of  
AS formulation gave a rank order of:   AS/Treh > AS/Mann 
DSCG formulation gave a rank order of: DSCG/Mann > DSCG/Treh 
IPB formulation gave a rank order of:   IPB/Treh > IPB/Mann 
FP formulation gave a rank order of:   FP/Mann > FP/Treh 
SET Effect (low shear vs. high shear). Similar to the performance studies using SETs in 
Chapter 2 and 3, there was a general trend that higher shear stress values corresponded to 
lower ED for all studied formulations. The explanation was that there existed two 
portions of entrained powder when using SETs. One portion involved particle 
deaggregation and the other did not (see Chapter 3 for detailed explanation).  
 
4.4 Discussion 
4.4.1 Influence of Drugs 
The physicochemical nature of drugs is important to the aerosolization performance 
efficiency. The SEM images showed that after blending, all drugs were distributed 
homogeneously on the surface of the carrier particles. The particle size analysis indicated 
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that the particle size distributions were comparable for all four drugs. Yet, DSCG 
formulations gave superior FPF values to the other formulations. The superior FPF values 
obtained of DSCG with both Treh and Mann formulations may be attributed to the strong 
interfacial energy-reducing properties. The unique physicochemical properties of DSCG 
[28] have been discussed in Chapter 3 when lactose monohydrate-based formulations 
were evaluated. This surface active drug was known to significantly lower the surface 
tension of high-energy surfaces such as water and form stable soluble monolayers at 
air-water interface.[29]  
4.4.2 Influence of Carriers 
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Both Treh and Mann had similar particle size distribution after they were sieved. 
Although Treh and Mann had very different surface roughness and morphology, their 
influence on the aerosolization performance was not remarkable. Treh as carrier gave 
higher performance efficiency (indicated by FPFmax) than Mann as carrier in AS and IPB 
systems, whereas Mann as carrier gave higher performance than Treh as carrier in the 
DSCG and FP systems. DSC thermogram of Treh indicated that it has a low dehydration 
temperature (~ 93 oC), caused by the loss of one or two bound water. At such a low 
dehydration temperature, the bound water loss could occur at low relative humidity and 
ambient temperature. Jones et al studied the dehydration of Treh and they showed that 
significant and irreversible changes in surface morphology occurred upon partial 
dehydration, in particular the formation of cracks.[30] This indicates that the surface 
properties of Treh may change during storage, which may occasionally favor but in most 
cases deteriorate the formulation performance efficiency, even though anhydrous Treh 
had a relatively high glass transition temperature. In this sense, the Treh formulations 
may be good candidate for the evaluation of formulation performance upon storage.  
4.4.3 Influence of SET shear stress 
For all the Treh and Mann-based aerosol systems presented in this study, the novel PADE 
method that allowed performance evaluation in the defined shear stress range was also 
applicable in the formulation using non-lactose sugar carriers. The PADE was developed 
based on the fundamental understanding that the forces acting at the particle interface are 
analogous to those at the molecular level, and that models of molecular surface 
association described by an adsorption expression can be adapted to fit shear 
displacement observations. As a shear force applies to the surface of a drug-coated carrier 
particle, no matter what the carrier is (the carrier could be lactose monohydrate, trehalose 
dihydrate or mannitol), the drug particles will be removed with increasing difficulty 
because of the sites that they occupy until a saturation is reached, when no drug particle 
can be removed at increasing shear force. The application of PADE using an algebraic 
equivalent expression to the Langmuir adsorption isotherm indicated that this novel 
method tolerated surface heterogeneity of different carriers and drugs. The heterogeneity 
refers to geometric features (such as surface roughness, morphology, polymorphism, and 
elasticity) and energetic features (surface energy distribution) and the drug-carrier 
interactions.  
  For all formulation systems studied so far (including lactose monohydrate based 
formulations, Chapter 3), there existed a variant (shear stress-dependent) region at 
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relatively low shear stress values and an invariant (shear stress-independent) region at 
higher shear stress range where the value of FPF was independent with increasing shear 
stress values.[27] From the invariant region of the aerosolization profile, the FPFmax 
could be obtained, which has important predictive implications for formulation screening 
and rational design of optimum formulation that can achieve high performance efficiency 
and interpatient therapeutic variability (i.e. the same FPF at different shear stress/patient’s 
maneuver). Furthermore, larger kd corresponds to a steeper rise in the variant region and 
FPF reaches maximum at lower shear stress. This is a desired feature because it reduces 
inter-patient variability when different inhalation maneuvers are implemented. However, 
formulations with larger kd often perform poorer than those with smaller kd at high shear 
when reaching FPFmax. This phenomenon will be addressed in Chapter 5. It should be 
noted that shear stress is a characteristic and fundamental parameter of interfaces. It was 
of interest to directly relate macroscopic phenomena of an aerosol performance with the 
interfacial properties of shear stress. (see Chapter 5). The shear stress-dependent region 
can provide a unique opportunity to study the mechanism of powder deaggregation. 
According to Kendall’s theory,[31] the separation of drug particles from the surfaces of 
carrier particles occurs when the energy consumption provided by shear force is 
proportional to the formation of new surfaces. In other word, the magnitude of shear 
stress (i.e. a linear motion that is exerted in two dimensions) must be sufficient to disrupt 
the favorable net interfacial forces at the drug/carrier solid-solid interface. Quantitatively, 
this is reflected in the unique PADE that directly related the performance result with shear 
stress. A hypothetically ideal deaggregation constant (kd = 1) could be introduced to the 
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PADE that accounted for the situation where aggregation and deaggregation are in 
equilibrium.[27] When kd =1, the PADE (Langmuir equivalent) equation reduced to Eq. 
4-3, when the performance efficiency (FPF) is dependent only on the applied shear stress: 
FPFFPF
FPF
s −= max
τ   (Eq. 4-3) 
By using formulation with kd close to 1, the magnitude of shear stress required to reach a 
certain FPF could be estimated. This feature could be used for device design when the 
turbulent shear stress is the principal mechanism of deaggregation. 
 
4.5 Summary 
Although lactose monohydrate dominates the carriers in the current marketed dry powder 
aerosol formulation, the formulation performance efficiency has been sub-optimal. Two 
trends are often used for carrier modifications and performance optimization. They 
include searching non-lactose sugars or sugar alcohols as alternative carriers, or surface 
modification of existing lactose monohydrate carriers. This chapter represents the first 
trend, while the second trend will be explored in Chapter 6. 
   The studies in this chapter were focused on: 1) rational evaluation of non-lactose 
based sugar (Treh) and sugar alcohol (Mann) and their potential as carriers for dry 
powder aerosol formulation; 2) performance studies of formulations using these 
alternative carriers (4 drugs × 2 carriers); 3) SETs were used and the predictive behavior 
and robustness of PADE method was challenged and result showed that PADE non-linear 
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regression and linear regression gave good to excellent correlation indicated by R2 and 
adjusted R2. Some mechanistic points of view regarding the physical meaning of the 
PADE interpretation were being formed. In the PADE non-linear regression analysis, the 
invariable (shear stress independent) region at high shear had important predictive 
implications for rationally designing or predicting formulation with high performance 
efficiency (represented by high FPFmax). Furthermore, the variable (shear stress 
dependent) region at low shear reflected in the specific interfacial and physicochemical 
properties of drugs and carriers. Given enough data points across the shear stress at this 
region, it has the potential to quantitatively determine the heterogeneity at the solid-solid 
interface. This point will be addressed in Chapter 5.  
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Figure 4-1. Schematic Representation of Potential Sugars and Sugar Alcohols Explored 
for Dry Powder Formulation Carriers. (A) D-glucose; (B) D-trehalose; (C) D-maltose; (D) 
D-raffinose; (E) erythritol; (F) D-xylitol; (G) D-mannitol; (H) D-sorbitol; (I) D-maltitol. 
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Figure 4-2. Representative Scanning Electron Micrographs (SEM) of Sugars (1,500× 
magnification) and Interactive Physical Mixtures (600×) of Micronized Pulmonary 
Drug/Sugar Carrier Systems in the Solid-state: (A) D-Trehalose dihydrate; (B) 
D-Mannitol; (C) Albuterol sulfate/D-Trehalose dihydrate; (D) Albuterol 
sulfate/D-Mannitol; 
(A) (B) 
(C) (D) 
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Figure 4-3. Representative Scanning Electron Micrographs (SEM) of Interactive Physical 
Mixtures (600×) of Micronized Pulmonary Drug/Sugar Carrier Systems in the Solid-state 
(cont’d): (A) disodium cromoglycate/D-trehalose dihydrate; (B) disodium 
cromoglycate/D-mannitol; (C) ipratropium bromide monohydrate/D-trehalose dihydrate; 
and (D) ipratropium bromide monohydrate /D-Mannitol. 
 
(A) (B) 
(C) (D) 
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Figure 4-4. Representative Differential Scanning Calorimetry (DSC) Thermograms at a 
Heating Rate of 5 oC/min for Carriers: D-mannitol (Mann) and D-trehalose dihydrate 
(Treh) in solid state: (A) Mann; (B) Treh (The 1st scan: 5 oC/min up to 220 oC; the 2nd 
scan: 20 oC/min). 
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Figure 4-5. Representative DSC Thermograms at a Heating Rate of 5 oC/min for Interactive 
Physical Mixtures. Drugs: albuterol sulfate (AS), disodium cromoglycate (DSCG), ipratropium 
bromide monohydrate (IPB), and fluticasone propionate (FP); Carriers: D-mannitol (Mann) and 
D-trehalose dihydrate (Treh) (sieved fraction: 45-75 μm): (A). AS/Mann; (B). AS/Treh; (C). 
DSCG/Mann; (D). DSCG/Treh; (E). IPB/Mann; (F). IPB/Treh; (G). FP/Mann; and (H) FP/Treh. 
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Figure 4-6. X-ray Powder (slit-detector) Height Intensity Diffractograms* of Alternative 
Sugar carriers (sieved fraction: 45-75 μm) at a scanning rate of 2θ degrees/minute: (A) 
D-mannitol; (B) D-trehalose dihydrate.  
(A) 
 
(B) 
 
 
* Raw data: courtesy of Dr. Heidi Mansour. The data were re-plotted using Match® 
software, (Crystal Impact, Inc.) 
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Figure 4-7. PADE Non-linear Regression Applied to TSLI Aerosolization (FPFTD<6.4: 
mean ± SD, n = 3) of dry powders for various interactive physical mixtures of micronized 
pulmonary drugs with trehalose dihydrate and D-mannitol sugar carrier systems: (A) 
albuterol sulfate; (B) ipratropium bromide monohydrate; (C) disodium cromoglycate; and 
(D) fluticasone propionate. 
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Figure 4-8. PADE Linear Regression Applied to TSLI Aerosolization FPFTD<6.4: mean 
value, n = 3) of dry powders for various interactive physical mixtures of micronized 
pulmonary drugs with trehalose dihydrate and D-mannitol sugar carrier systems: (A) 
albuterol sulfate; (B) ipratropium bromide monohydrate; (C) disodium cromoglycate; and 
(D) fluticasone propionate. The R2 of the linear regression is listed below: 
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AS/Treh: R2 = 0.9918;   AS/Mann: R2 = 0.9872; 
DSCG/Treh: R2 = 0.9968;   DSCG/Mann: R2 = 0.9955; 
IPB/Treh: R2 = 0.9909;   AS/Mann: R2 = 0.9710; 
FP/Treh: R2 = 0.9274;    FP/Mann: R2 = 0.9964. 
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Figure 4-9. The Relationship Between SET Shear Stress (τs) and TSLI Formulation 
Performance (ED). Various interactive physical mixtures of micronized pulmonary drugs 
with trehalose dihydrate and D-mannitol sugar carrier systems: (A) albuterol sulfate (AS); 
(B) ipratropium bromide monohydrate (IPB); (C) disodium cromoglycate (DSCG); and 
(D) fluticasone propionate (FP). 
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Table 4-1. Particle Volume Size Distribution of D-Mannitol (Mann) and D-Trehalose 
Dihydrate (Treh) (sieved fraction 45-75 μm). 
 Span D10 (μm) D50 (μm) D90 (μm) 
Mann 1.19 ± 0.02 13.49 ± 0.24 52.95 ± 1.69 76.98 ± 0.18 
Treh 0.84 ± 0.04 28.86 ± 1.35 53.49 ± 0.79 73.83 ± 0.12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  173
Table 4-2. TSLI Performance Data Analysis. The relationship between SET shear stress 
(τs) and FPFTD<6.4/FPFED<6.4 for Treh-based and Mann-based dry powder formulations 
using non-linear regression analysis. (n = 3). 
sd
sd
k
k
FPF
FPF
τ
τ
+= 1max
 (Eq. 4-1) 
 
 Carrier Drug FPFmax kd R2 Adj R2
AS 13.31 0.78 0.9728 0.9637 
DSCG 18.04 2.89 0.9845 0.9793 
IPB 17.62 0.79 0.9711 0.9614 
Treh 
FP 8.00 10.88 0.8019 0.7359 
AS 10.50 1.24 0.9646 0.9528 
DSCG 22.29 1.14 0.9812 0.975 
IPB 11.56 0.91 0.8985 0.8647 
FPFTD
Mann 
FP 14.44 4.31 0.9654 0.9538 
 
AS 14.98 0.66 0.9651 0.9535 
DSCG 20.67 2.18 0.9943 0.9924 
IPB 22.54 0.61 0.9700 0.9600 
Treh 
FP 12.00 2.39 0.8612 0.8149 
AS 11.57 1.13 0.9577 0.9437 
DSCG 25.93 0.97 0.9792 0.9722 
IPB 15.20 0.75 0.898 0.864 
FPFED
Mann 
FP 19.94 2.08 0.9886 0.9849 
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CHAPTER 5 THEORETICAL DATA INTERPRETATION 
5.1 Introduction 
Despite several decades of very active research in the field of dry powders prepared for 
inhalation, they remain complex and poorly understood systems. A direct correlation of 
particulate interaction with the aerosol performance is difficult because of the heterogeneous 
nature of both drug and carrier surfaces, and assumptions with respect to force measurement. 
The prediction and reproducibility of performance of pharmaceutical dry powder aerosols 
remains empirical. Under these circumstances, it is desirable to reassess the relationships 
between the fundamental intermolecular and surface forces, the deaggregation forces, and the 
aerodynamic behavior of the particulate systems. 
In Chapter 1 (Section 1.4), the fundamental forces for particle adhesion/cohesion 
and deaggregation in pharmaceutical dry powder aerosol formulations were discussed. 
Current trends for performance prediction and optimization of dry powder aerosol 
formulation have been reviewed (see Section 1.5). The previous two sections are the 
foundation of experimental work on which the theory of powder aerosol deaggregation 
equations (PADE) is based. A great deal of experimental evidence shown in Chapter 3 and 4 
indicated the robustness of the PADE in evaluating the aerosolization performance in the 
defined shear stress range. Based on the experimental data collected, for a total of twenty-
four formulations (i.e. both the lactose monohydrate-based and two alternative sugar-based 
formulations, and four different drugs.), all resulted in excellent correlations when PADE 
was applied. 
In this chapter, the theoretical foundation for the PADE will be developed in four 
sections. (I) Description of PADE as an analogy to Langmuir adsorption isotherm; (II) 
“Experimental” justification of PADE based on performance of carrier-based dry powder 
formulation and statistical analysis. (III) Discussion and mechanistic interpretation of PADE 
for heterogenous particle deaggregation. (IV) Conclusion. 
 
5.2 PADE – An Analogy to Langmuir Adsorption Isotherm 
5.2.1 Surface Adsorption Theory 
A potentially predictive and quantitative correlation of performance with aerosol formulation 
properties in response to a range of airflows has not previously been reported. To introduce a 
new method that describes the heterogeneous particle deaggregation across the entire shear 
stress range in detail, consideration of the fundamental theories applied for physical surface 
adsorption on solids that were developed in the late 19th and 20th century may be enlightening. 
In 1916, Langmuir [1] stated “cohesion, adsorption and surface tension are all 
manifestations of forces similar in their nature to those acting between the atoms of solid 
bodies…”. He presented a large amount of evidence in support of the nature of adsorption. 
Two years later, he proposed a monolayer adsorption theory of gas molecules onto a flat 
surface based on a kinetic principle that there is a continual process of adsorption of 
molecules onto the surface and a corresponding desorption (evaporation) of molecules, and at 
dynamic equilibrium the rate of adsorption is equal to the rate of desorption from the 
surface.[2] The forces acting between the adsorbate gas molecules and the solid adsorbent are 
mainly van der Waals forces, and this physical adsorption process is reversible (i.e. 
adsorption ↔ desorption).[3] Relating the dynamic equilibrium with surface fractional 
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coverage of gas molecule (θ) at constant temperature, he obtained the Langmuir adsorption 
isotherm (Eq. 5-1a or 5-1b): 
kP
kP
+= 1θ       (Eq. 5-1a) 
or        
kP
kP
+
Γ=Γ
1
max          (Eq. 5-1b) 
where Γ is the amount of gas adsorbed (g); Γmax is the maximum adsorption to a monolayer 
surface coverage (g); P is gaseous partial pressure (N/m2); and k is the Langmuir adsorption 
constant (m2/N), which is a measure of how strong an adsorbate molecule is attracted onto a 
surface. Later on, based on a large number of experimental data, the Langmuir theory was 
adapted to the solution adsorption isotherm (Eq. 5-2) 
kC
kC
+
Γ=Γ
1
max  (Eq. 5-2) 
where Γ is the amount of solute adsorbed (mg/g or mmol/g); Γmax is the monolayer surface 
coverage (mg/g or mmol/g); k is still the Langmuir adsorption constant (L/mg or L/mmol); 
and P is replace by C, the final equilibrium concentration (mg/L or mmol/L). Langmuir 
adsorption isotherm can also be derived from Gibbs thermodynamic approach when two-
dimensional solution expression is applied.[4] 
Langmuir theory [4] assumes: 1) Adsorption molecules are adsorbed at definite, 
localized sites, each having an area σ0. 2) Each site can accommodate only one molecule 
(monolayer coverage). 3) Adsorption energy is constant over all sites (homogeneity). 4) No 
lateral interaction exists between adsorbates. The Langmuir theory is generally accepted as 
the cornerstone of all theories of adsorption. It is the best known and most often used 
adsorption isotherms, accurately representing results. At low pressure or low concentration 
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(kP or kC << 1), the two-parameter Langmuir isotherm equation reduces to the Henry’s law 
isotherm. 
 
5.2.2 Powder Aerosol Deaggregation Equation (PADE) 
Returning to the performance studies of dry powder aerosol formulations, the fundamental 
forces that contribute to the adhesion and deaggregation have been described in Chapter 1 
(see Section 1.4). The forces acting at the particle interface are similar to those at the 
molecular level. So the Langmuir theory that describes molecular forces should, by analogy, 
be applicable to macroscopic particles, surfaces and even complex multicomponent 
systems.[5] The current techniques and methods for performance prediction have been 
reviewed (see Chapter 1, Section 1.5) and a promising trend for performance and airflow 
parameter correlation was observed. The pharmaceutical aerosol formulations involve 
hetereogeneous particles with different energy density regions. Similar to the heterogeneous 
adsorption phenomena, micronized drug particles prefer to adhere (or adsorb) onto sites 
having higher energy “active” sites. When these “active” sites are gradually occupied, the 
drug particles adhere onto progressively lower energy density sites, resulting in a decreased 
heat of adhesion (or from the guiding analogy, adsorption) with loading. When a certain 
shear stress is applied, those drug particles at lower energy density sites are preferentially 
deaggregated while those at higher energy density sites remain associated unless higher shear 
stress is applied. At a certain point, the shear stress is no longer able to remove more drug 
particles and reaches FPFmax. At the fundamental level, we propose, that the models of 
molecular surface association described by adsorption expressions can be adapted to fit shear 
displacement observations. The algebraic equivalent of Langmuir adsorption isotherm is 
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shown in Eq. 5-3, and is referred to as the Langmuir equivalent expression of powder aerosol 
deaggregation equation (PADE) (see below):  
sd
sd
k
kFPFFPF τ
τ
+= 1
max   (Eq. 5-3) 
where FPF is the fine particle fraction below a certain cutoff size (%). It has been shown in 
previous chapters that higher FPF represents greater drug deaggregation, and higher FPF 
was obtained with increasing turbulence whereas turbulence is not the sole mechanism of 
deaggregation;[6] The parameter FPFmax is the maximum achievable fine particle fraction 
(%). Further increasing of FPF with increasing shear stress is not possible without 
comminution of the primary particles. This represents the efficiency of formulation 
performance when sufficient shear stress is applied and can be used as a standard for 
formulation optimization. The parameter kd is the deaggregation constant (m2/N). This 
constant represents the ease of drug deaggregation from carrier particles or agglomerates; 
And τs is the viscous shear stress (N/m2) that is obtained for SETs using Kolmogorov 
turbulence theory (see Chapter 2, Section 2.2.4.1).[7] The shear stress considers both 
contributions of turbulent airflow at core and laminar shear force near the wall of SETs for 
drug deaggregation. The parameter, shear stress across the SETs has a contribution analogous 
to P (Eq. 5-1b) or C (Eq. 5-2) of Langmuir adsorption isotherm which can be derived from 
Gibbs thermodynamic approach using two-dimensional expression. (Both τs and P have the 
same unit N/m2, and this unit is also used for interfacial or surface tension). So shear stress 
should provide the best correlation with FPF when compared with the other airflow 
parameters (Re, ΔP, and power).  
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The correlation of FPF with τs using PADE (Langmuir equivalent expression) (Eq. 
5-3) can be achieved by non-linear regression analysis (curve fitting) of each set of 
experimental data with any of various computer programs such as SigmaPlot, Origin, 
MatLab, Winnolin, and Igor Pro software. Here, SigmaPlot 9.0.1 software will be used for 
this analysis. The goodness of fit is evaluated from the error analyses including coefficient of 
determination (R2), adjusted R2, the sum of squared errors (SE), coefficient of variation (%cv), 
and normality test.  
The Langmuir adsorption isotherm is linearly transformable, and the linear models 
include Scatchard, Eadie-Hofstee, Lineweaver-Burk, and Langmuir linear equation (Figure 
5-1). The choice of appropriate linear model depends on the R2, the linearization without 
altering the error structure and normality assumption, and the meaningful physical 
interpretation of the selected model. The Scatchard model is the linear form of the binding 
equilibrium, which is derived from protein binding that follows the adsorptive 
phenomenon.[3] The Scatchard regression gives good representation of data fit for dilute 
solutions, but is biased in the high concentration range. The Lineweaver-Burk (double-
reciprocal) and Eadie-Hofstee models are transformed from the Michaelis-Menten kinetics 
and often applied in the area of pharmacokinetics. They have bias to fit the data in the low 
concentration range. The Langmuir linear model was introduced by Langmuir himself to fit 
the data in surface adsorption phenomena. The Lineweaver-Burk model, which is sometimes 
referred to Langmuir linear model-II, is also applied as an alternative in surface adsorption 
fitting.[8] The Langmuir linear model is inherently biased toward fitting the data in the high 
concentration range. Furthermore, many surface adsorption models (which have been 
discussed below) such as Freundlich, Sips, and Fowler-Guggenheim expressions, are used as 
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complementary or more rigorous treatment for the data fitting that consider the factors of 
surface heterogeneity and/or lateral interaction.[9] 
For convenience and consistency with the previous chapters (Chapter 3 and 4) that 
described such a novel interpretation of drug aerosolization performance using Langmuir 
equivalent PADE and applied to shear displacement observations in pharmaceutical 
inhalation aerosols, additional fundamental surface adsorption theories such as Freundlich, 
Sips theories will be included to evaluate dry powder aerosol performance that are inherently 
heterogeneous. Likewise, these mathematical expression equivalents on the whole are 
referred to, for convenience, as PADE. 
 
5.3 “Experimental” Justification of PADE 
5.3.1 The Different Linear Regression Models 
Using TSLI, a summary of 24 formulation performance data (4 drugs × 6 excipients) at 4 
different shear stress (τs) values has been examined (see Chapter 3 and 4). Four model drugs 
were chosen with distinct physicochemical properties and pharmacological mechanism of 
actions for the treatment of respiratory diseases (asthma and chronic obstructive pulmonary 
disease). Four lactose monohydrate carriers (sieved {SV-A, SV-B}, milled {ML-A, and ML-
B}) and two alternative carriers (D-Trehalose dihydrate {Treh} and D-Mannitol {Mann}) 
were selected for the performance evaluation. The thorough physicochemical 
characterization of the drugs, carriers, and dry powder formulation using different techniques 
were described in previous chapters.[10-12] The particle size distribution of micronized 
drugs characterized by laser diffraction exhibited comparable volume median diameter (D50) 
in the respirable range (3.5~4.5 μm) with narrow unimodal distribution (Span < 0.5). The 
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values of D50 of carrier lactose monohydrate, mannitol, and trehalose dihydrate were 
comparable (52~61 μm). However, the span of milled lactose monohydrate (~3.1) was much 
larger than sieved lactose monohydrate (~1.2). The span of mannitol and trehalose dihydrate 
was ~1.2 and ~0.8, respectively. The performance data (exemplified as FPFTD<6.4 which is 
defined as the percentage of mass of drug below 6.4 μm cutoff from the total dose) using 
twin-stage liquid impinger (TSLI) was then correlated with shear stress τs of the SETs using 
PADE (Langmuir equivalent expression). The four different linear regression result including 
Langmuir, Scatchard, Eadie-Hofstee, and Lineweaver-Burk linear regressions is shown in 
Table 5-1. The differences between the linear forms of PADE significantly affected the 
regression result due to the influence of linearization process. The coefficients of 
determination (R2) ranges of these models are 0.9274-0.9999, 0-0.9911, 0-0.9911, and 
0.0007-0.9983, respectively. These data indicate that Langmuir, by virtue of variation in the 
linear regression analysis, is the most suitable and consistent model for all the data presented, 
followed by Lineweaver-Burk model. In contrast, Scatchard and Eadie-Hofstee linear 
regression did not result in good correlations for some of the IPB and FP formulations. The 
rank order based on the performance of (FPFTD) in Langmuir linear regression is shown 
below:  
a. Rank order (FPFmax) of AS formulation:  ML-A > ML-B > SV-B > SV-A > Treh > Mann 
b. Rank order (FPFmax) of DSCG formulation: ML-B > ML-A > SV-B > SV-A > Mann > Treh 
c. Rank order (FPFmax) of IPB formulation:  ML-B > ML-A > SV-A > SV-B > Treh > Mann 
d. Rank order (FPFmax) of FP formulation:  ML-B > ML-A > SV-B > SV-A > Mann > Treh 
It showed that the PADE (Langmuir equivalent expression) fitted the experimental data in all 
studied formulations. The parameter FPFmax is suitable for evaluating the efficiency of 
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formulation performance and the result is consistent across different carrier-based dry 
powder formulation evaluated. It has also been observed that the SV lactose monohydrate 
formulations generally yield higher deaggregation constant kd than ML formulations, 
represented in PADE non-linear regression graphs are the sharp increase of the deaggregation 
curve at low shear stress of SV formulations.[10-13] Whereas SV formulation reaches 
saturation at much lower shear stress than ML formulation which implies that higher 
deaggregation formulations have lower deaggregation capacity. This phenomenon can be 
explained as more agglomeration of drug and fine particles in the ML formulation increases 
the capacity and result in higher FPFmax. 
 
5.3.2 The Adaptation of Different PADE Models 
The adaptation of Langmuir adsorption isotherm to describe the deaggregation process is 
based on the assumption that there is neither surface heterogeneity nor lateral interaction, 
which is rarely true for relevant pharmaceutical aerosol formulations. Two specific aims 
were addressed in order to assess the mechanism of deaggregation accurately. The first aim 
was to adapt different surface adsorption models to fit the experimental dataset (PADE non-
linear regression). This is a method that is frequently applied for surface adsorption studied 
in many different systems, and a plethora theoretical and empirical adsorption isotherms have 
been developed or adapted to many complicated systems that consider surface heterogeneity, 
adsorbate mobility, lateral interaction, porous adsorbent, and multi-component adsorption. 
Due to the similarity (Table 5-2) of surface adsorption phenomena and the pharmaceutical 
aerosolization performance, and the good fit of aerosol performance data using algebraic 
equivalent Langmuir adsorption theory (Table 5-1), these adsorption isotherms or equations 
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are arguably good candidate for adaptation to the performance studies. A comparison of 
PADE non-linear regression using algebraic equivalent Langmuir isotherm and Freundlich 
equation is shown in Table 5-3. The second aim was to introduce additional SETs to increase 
the number of data points for more accurate correlation. The airflow parameters of three 
additional SETs are listed in Table 5-4. Their dimension and geometry were designed and 
calculated based on the existing four SETs. (see Appendix 5-A). Two carrier-based 
formulations including DSCG/ML-B and AS/Mann were selected for this study. The 
selection of these two formulations is somewhat arbitrary, but the former represents the best 
performance formulation among all studied formulations and the latter represents an 
alternative sugar formulation.[10-13] The performance data are shown in Appendix 5-B). In 
this study, a comparison of three different algebraic equivalent surface adsorption 
expressions including Langmuir isotherm, Freundlich expression, and Sips expression were 
applied to fit the experiment dataset. The reasons for selecting these three algebraic 
equivalent surface adsorption models have their theoretical justification and will be discussed 
in the next section. The PADE non-linear curve fitting is illustrated in Figure 5-3 and the 
statistics in Table 5-5. 
 
5.4 Discussion 
5.4.1  Similarities & Differences Between Surface Adsorption & Aerosol Deaggregation 
(Table 5-2) 
The Langmuir adsorption isotherm, protein binding equilibria, Michaelis-Menten kinetics, 
and the novel PADE share an algebraically equivalent formula. However, they are inherently 
different expressions to account for different physicochemical phenomena.  
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As is described above, Langmuir adsorption theory equates the rates of adsorption 
and desorption in term of fractional loading. It is time independent when a dynamic 
equilibrium is reached. Langmuir adsorption has fundamental theoretical basis. The isotherm 
equation reduces to the Henry law isotherm when the pressure is very low (kP << 1). At high 
pressure, the amount adsorbed reaches the saturation capacity to form a monolayer surface 
coverage. When the Langmuir adsorption constant is larger, the surface is covered more with 
adsorbate molecules due to stronger affinity of adsorbate molecules towards the surface, so 
that the adsorption curve will have a more rapid increase with increasing pressure. Increase 
in the temperature or decrease the heat of adsorption results in reduced adsorption due to 
increased mobility of adsorbate molecules or reduced energy barrier for evaporation.[9] It 
should be noted that the physical adsorption is reversible whereas the chemisorption is 
irreversible and quite different, although they are expressed by the same formula. The 
heterogeneity of surface adsorption is caused by adsorbent geometric and energetic features, 
the adsorbate size, shape, and conformation, and an interaction between adsorbate-adsorbent. 
The treatment of heterogeneous adsorption is achieved by grouping the similar surface 
energy site in a patchwise or random manner using statistical thermodynamics and applies 
appropriate isotherm to each local adsorption (Figure 5-4).[9] 
Similarly, the protein binding is also a time independent equilibrium process. The 
amount of adsorbed and monolayer surface coverage in Langmuir adsorption isotherm are 
now described as the percentage of drug bound in the total protein and the number of 
independent binding sites, respectively. The protein binding curve will have a more rapid 
increase when the association constant is large (affinity), whereas the number of binding sites 
determines the saturation capacity. The association constant is also temperature dependent. If 
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there’re multiple binding sites or binding sites are dependent one another (heterogeneity), the 
treatment is usually to group similar classes of binding sites, treat each class of protein 
binding separately and then add them up.[3] 
The enzyme kinetics that governed by the Michaelis-Menten equation is 
algebraically equivalent to the Langmuir adsorption isotherm. But the physical meaning is 
the relationship between reaction rate with substrate concentration, which is quite different 
from either the surface adsorption or protein binding. 
We can find some unifying concepts in dry powder aerosolization using SET, 
Langmuir adsorption, and protein binding. These physicochemical phenomena are governed 
by the same fundamental forces as we mentioned above. Besides the kinetic approach, the 
Langmuir adsorption equilibria can also be derived quite readily by statistical 
thermodynamic approach based on Gibbs law.[4, 14] The particle deaggregation process, 
despite its complexity, can possibly be explained by similar thermodynamic approach. The 
interfacial driving force in Langmuir adsorption isotherm is the gaseous partial pressure P 
(N/m2) or solute concentration C (mg/g), while the aerosol entrainment and deaggregation 
requires the shear stress τs (N/m2) to overcome particulate adhesion. In other words, the 
separation occurs when the energy consumption provided by shear stress is proportional to 
the formation of new surfaces.[15] Corresponding to the surface coverage in adsorption, and 
number of independent binding sites in protein binding, the parameter in deaggregation 
expression is defined as, FPFmax, the maximum achievable fine particle fraction. Furthermore, 
a striking analogy can be drawn to account for the heterogeneity and lateral interaction in 
surface adsorption, protein binding, and aerosol dry powder deaggregation. Among them, the 
heterogeneity in particle deaggregation is probably the most complicated because geometric, 
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energetic characteristics of both drug particle and carrier particle, and the interfacial 
interaction of both particles contribute to the heterogeneity. The treatment of the surface 
heterogeneity can follow either the classifying of different binding site and add up for protein 
binding, or the patchwise treatment of each local adsorption (i.e. sites having the same 
surface adhesion energy are grouped together into one patch). The lateral interaction in 
surface adsorption is analogous to drug-drug cohesion or surface agglomeration. 
Despite the unifying concepts between adsorption, protein binding, and aerosol 
deaggregation, there are fundamental differences between the powder deaggregation and the 
other two concepts. Both molecular adsorption/desorption (physical adsorption) and protein 
binding/disassociation are derived from time independent equilibria. They are reversible 
processes. However, the particulate adhesion/deaggregation is mainly a time dependent 
process. The particle entrainment and drug deaggregation, due to the particle size and system 
dimension, cannot be treated as a continuum for the continual process of drug particle 
adhesion and deaggregation from the carrier surface as equilibrium. There could be a small 
chance of drug/fine particles to adhere to other particles after deaggregation if there is 
sufficient settling time, but the chance of forming a dynamic equilibrium similar to interfacial 
adsorption or protein binding is remote. Furthermore, unlike surface adsorption and protein 
binding that have constant system volume and boundary condition, the particle deaggregation 
involves rapid system volume expansion and the corresponding net gain in entropy. It is not 
important that there is full coverage of the surface as is described for monolayer surface 
adsorption. 
However, the analogy between these three processes will still hold, and can be used 
for explaining the experimental results in the dry powder aerosol performance. Similar to the 
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Langmuir adsorption and protein binding, the deaggregation expression may serve as a link 
between macroscopic statistical thermodynamics and microscopic individual particle 
deaggregation. 
 
5.4.2 The Choice of Surface Adsorption Instead of Protein Binding 
The adaptation of Langmuir adsorption isotherm (both Langmuir adsorption and protein 
binding) for shear displacement (Eq. 5-3) has been tested by the aerosolization performance 
studies of a total of sixteen lactose monohydrate-based formulations, four D-trehalose 
dihydrate- and four D-mannitol-based formulations with four distinct drugs. In every case, 
the result has furnished striking confirmation of the correctness for such adaptation. Among 
the four studied linear regression analyses using PADE (Langmuir equivalent expression), 
Langmuir-type linear regression of performance and shear stress gave the most consistent 
and excellent correlation result (Table 5-1). Langmuir linear regression is widely used in gas 
or solution adsorption analyses. It indicates that this linear regression method tolerates the 
surface heterogeneity and lateral interaction, and still furnishes valuable deaggregation 
information from coefficient (FPFmax, kL). However, linear regression such as Scatchard 
regression did not yield consistent correlation result. This is possibly because the process of 
heterogeneous particle deaggregation is quite complex and cannot be explained by a single 
class of binding sites. The treatment using multiple binding sites and add-up method is need. 
Due to the limitation of measuring each class of binding (adhesion) site, the adaptation using 
protein binding method may not be applicable. Furthermore, the scatchard plot requires the 
regression from both X-axis (FPFTD) and Y-axis (FPFTD/τs), while the Langmuir linear 
regression regresses only on the Y-axis (τs/FPFTD). Besides, the surface adsorption studies 
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has a long history starting from late nineteenth century and a plethora of theoretical and 
semi-empirical adsorption models have been developed based on different studied systems.[9, 
16, 17] Many of those models have rigorous theoretical basis or theoretical reasoning. With 
the foregoing background, the adaptation of surface adsorption models was selected as the 
model for PADE. 
 
5.4.3 PADE Considering Surface Heterogeneity 
The Langmuir adsorption expression is the cornerstone of almost all the surface adsorption 
isotherms and has been most widely used. Subsequently developed theoretical and semi-
empirical isotherms were based on experimental data and statistical thermodynamic 
derivation considering various influences such as affinity constant change (e.g. Volmer 
isotherm [9]), surface heterogeneity (e.g. Freundlich,[18] Sips,[19] Toth,[20] Unilan equation 
[9]), and lateral interaction (e.g. Fowler-Guggenheim equation [9]).  
It is proposed that an expression that is algebraically equivalent to Langmuir 
adsorption theory is suitable to describe the deaggregation phenomenon. However, this 
treatment does not fully consider the surface heterogeneity between solid particles. The direct 
evidence of the surface heterogeneity is the convergent points among different regression 
lines/curves (Figure 5-2). In this case, several surface adsorptions equation equivalents that 
consider the surface heterogeneity were selected. The algebraic equivalent of these surface 
adsorptions could possibly be applied to the aerosolization performance as well. In this paper, 
the algebraic equivalents of Freundlich and Sips equation have been used as examples for 
alternative adaptation to the algebraic equivalent of Langmuir adsorption isotherm. 
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The Freundlich equation is the earliest known adsorption expression that was 
developed empirically to account for non-ideal sorption of solute or gas molecules onto 
heterogeneous surfaces.[18] The equation takes the following form (Eq. 5-4a):  
n
F PKC
/1=μ  (Eq. 5-4a) 
n
sFkFPF
/1τ=  (Eq. 5-4b) 
where Cμ is the concentration of the adsorbed species, and KF and n are two constants that 
relate to the heat of adsorption and heterogeneity factor. The corresponding algebraic 
equivalent of the Freundlich equation is shown in Eq. 5-4b. Because n is an empirical 
parameter, it does not reveal the source of the heterogeneity during drug deaggregation. But 
similar to the FPFmax in Langmuir adsorption isotherm, it can be used to fit the dataset for 
macroscopic evaluation. The more heterogeneous the system for the drug deaggregation is, 
the larger n will be. Unlike the Langmuir adsorption isotherm, the Freundlich equation does 
not have a fundamental thermodynamic basis since it does not have a proper Henry law 
behavior at low pressure, nor does it have a finite limit when pressure is sufficiently high (no 
saturation). Despite being an empirical equation, it has a theoretical basis for heterogeneous 
surface having patchwise local Langmuir adsorption mechanism and an exponential decay 
energy distribution.[9] Two assumptions are involved: 1) No interaction between patches and; 
2) Adsorbate molecule occupies only one adsorption site. 
A comparison of the PADE non-linear regression results using algebraic equivalent 
Langmuir and Freundlich equations is shown in Table 5-3. Interestingly, the non-linear curve 
fitting using Freundlich model also gave excellent correlation (adjusted R2: 0.7159-1.0000) 
comparable to Langmuir model correlation (adjusted R2: 0.8655-0.9983). The application of 
alternative surface adsorption isotherm for shear displacement observation adds strong 
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evidence that the methodology of surface adsorption theory can be used to adapt the shear 
displacement of the aerosol formulation. It should be noted, however, that the parameter n for 
empirical heterogeneity evaluation of our current data did not furnish useful result, although 
it is known that ML carriers are more heterogeneous than SV carriers from the 
physicochemical surface analyses. It indicates that the heterogeneity factor that influences 
drug deaggregation may not be a simple scenario. The extent of the heterogeneity may not 
only be determined by the geometric and energetic heterogeneity feature on both carrier and 
drug particles, but also account for the capacity for surface adhesion (e.g larger surface area), 
agglomerate formation or the ratio of cohesion-adhesion balance.  
The initial attempt to increase the surface adsorption parameter from 2-parameter to 
3-parameter PADE model was unsuccessful, though a higher coefficient of determination 
was obtained in many formulations. The results showed high dependency due to over-
parameterized model selection. In order to obtain more accurate data fitting, three additional 
SETs were prepared and two formulations were selected for further study. The correlation 
using three different algebraic equivalent surface adsorption models including Langmuir 
adsorption isotherm, Freundlich equation, and Sips equation (Eq. 5-5) were evaluated. 
(Figure 5-3 and Table 5-5). Sips equation (Eq. 5-5) is an extension of Freundlich equation 
having both a heterogeneity parameter (n’) and a finite saturation limit at high pressure or 
concentration. A slight increase in the R2 was observed when a 3-parameter Sips adsorption 
model was applied compared with the other two adsorption models, but 
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the adjusted R2 are comparable. It implied that the 3-parameter Sips model may not give 
more informative result than the Langmuir adsorption model. In order to obtain a more 
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accurate PADE non-linear curve fitting, more data points are needed. In the assessments 
performed to support PADE theory, the algebraic equivalent of the Langmuir adsorption 
isotherm was the most robust method for formulation screening and prediction.  
 
5.4.4 Application of the PADE 
Perhaps the most useful application of PADE is the formulation screening and prediction. It 
has been shown that the two parameters (FPFmax and kd) in Eq. 5-3 can be obtained by 
correlation of performance data with SET shear stress. It’ll be easy to find the optimum shear 
stress required for efficient deaggregation close to the plateau, yet within the specific 
resistance limit for patient’s inhalation. This new method for heterogeneous dry powder 
formulation evaluation is significant because it not only describes the formulation 
performance across the entire shear stress range, but more importantly it has the potential to 
reveal the mechanism of drug deaggregation considering the surface energy heterogeneity 
and lateral interaction forces. This can be achieved by increasing the dataset for PADE non-
linear curve fitting of different algebraic equivalent surface adsorption models, and use 
statistical thermodynamic approach to particle deaggregation studies analogous to those used 
in adsorption theory.  
The analogy of aerosol performance from dry powder formulations with molecular 
surface adsorption has important implications. Expressions describing surface adsorption 
were intended to allow elucidation of mechanisms including using the Brunauer 
classification for reference, lateral interactions, multilayers and capillary condensation.[21] 
The evolution of the Brunauer Emmett Teller (BET) equation encompassed the Langmuir 
expression as a special case with the assumptions identified above.[22, 23] Similar 
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approaches were described by Giles et al. for solute adsorption at solid surfaces from solution 
resulting in a range of isotherms equivalent to the Brunauer classification.[16, 17] By using a 
similar expression for aerosol performance which is limited only by the data available at 
various shear stresses, from which the hyperbolic curve is derived, it is conceivable that an 
analogous mechanistic approach to the evaluation of particle-particle (drug-drug, drug-
excipient fines), particle-surface (drug-excipient carrier, excipient fines-excipient carrier) 
interactions might be achieved. Such an approach would have the benefit of describing 
accurately the magnitude of the interaction and the likely underlying mechanism, based on 
inflections in FPF with respect to shear that could be probed, subsequently, by controlled 
experiments (highly engineering particles) or using surface analytical methods. To our 
knowledge this is the first time that such an approach has been suggested. It is a simple and 
descriptive method that can find its use in many more practical applications. This theory 
chapter is served to open a new window for the novel interpretation of aerosol formulations 
development.  
Two examples using PADE are illustrated below. The first example is aimed at 
comparing the aerosolization performance of SETs and commercial devices. Two 
commercial devices: Rotahaler® and Aerolizer® were chosen for this study. The second 
example is an evaluation of selected formulations upon storage. Both examples illustrate the 
robustness and flexibility of performance evaluation using PADE. 
 
5.4.4.1 Commercial devices vs. SETs  
Rotahaler® (GSK) and Aerolizer® (Novartis) are two first generation devices that have long 
been approved for use in the United States. (see Appendix 1-A). The powder supply for both 
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devices is single dose capsule. Their mechanisms of powder fluidization and deaggregation 
were well-studied using experimental [24, 25] and computational fluid dynamics [26, 27] 
methods. The Rotahaler® is classified as a low specific resistance device (RD = 0.036 
cmH2O1/2/(Lmin-1)).[24] Its shear stress value at 60 L/min was reported to be 2.026 N/m2.[7] 
The actuation of Rotahaler® is achieved by mechanically breaking the capsule in half. 
Carrier-based formulation (Ventolin Rotacaps®) fluidization from the open capsule is a 
combination of vibration, impaction and shear force. Particle deaggregation is mainly caused 
by turbulence promoted by the grid upstream of the mouthpiece. The Aerolizer® has a 
relatively high specific resistance (RD = 0.072 cmH2O1/2/(Lmin-1)).[26] Its shear stress value 
at 60 L/min airflow rate (8.248 N/m2) was derived from the pressure drop (see Appendix 5-
B). During actuation, the capsule in the Aerolizer® is pierced at both ends and the powder 
emptying occurs primarily by capillary fluidization due to pressure drop across the capsule. 
Deaggregation is mainly caused by shear force and relative motion. Based on the Poiseuille’s 
law, the airflow conditions in both devices are not fully-developed. 
The characteristics of SETs was introduced in Chapter 1, section 1.3.2.2. The 
SETs have fully developed and well-defined airflow parameters. The principal mechanism of 
fluidization and deaggregation is the aerodynamic turbulent shear force.[7] The SETs are 
designed such that the impact of particles due to inertia could be minimized. However, the 
range of specific resistances provided by SETs encompassed those of commercial DPIs. 
The aim of this study was to compare the aerosolization performance of DPIs and 
SETs using the same carrier-based formulations. Based on the predictive behavior of PADE 
method across the investigated shear stress range, we hypothesized that if the aerosolization 
performance of SETs was comparable to that of DPIs, the performance efficiency of DPIs 
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could be predicted from the performance data using SETs, i.e. the performance data using 
DPIs would land on the PADE non-linear regression or linear regression curves generated 
using SETs. 
Following the evaluation of PADE models, the same two formulations: AS_Mann 
and DSCG_ML-B at 2 %(w/w) drug concentration were selected. The performance data (ED, 
FPFTD, PFPED) using SETs were adopted from previous TSLI experiment. The performance 
of Rotahaler® and Aerolizer® was evaluated in similar conditions (with solenoid switch, 10 
s actuation at 60 L/min, TSLI). Two types of size #3 hard capsules: the gelatin capsule 
(Capsugel®, Greenwood, SC) and HPMC capsule (Vcaps® Plus, Greenwood, SC) were used 
for the performance studies. As usual, the number of each experiment was randomly assigned 
(Design Expert 5.09 software, Stat-Ease Corp., MN) and in vitro aerosolization was 
evaluated in triplicate under ambient condition. 
The performance data (ED, FPFTD, and FPFED) of Rotahaler® and Aerolizer® are 
shown in Appendix 5-D. The ED values obtained using SETs were generally higher than 
those obtained using the inhaler devices. The lower ED values using inhaler devices were 
attributed to the use of capsules and grids in DPIs. Extra energy was required to fluidize the 
powder by mechanical impaction (Rotahaler®) and shear fluidization (Aerolizer®). The ED 
values using Aerolizer® were superior to those of Rotahaler®. The influence of different 
capsules, gelatin or HPMC capsule, to the aerosolization performance was inconclusive 
because of the limited data obtained. But the data indicated a trend that HPMC capsules 
resulted in higher ED, whereas gelatin capsules gave higher FPF. When the FPFTD and shear 
stress (τs) of the devices (SETs and DPIs) were correlated, the PADE analysis is depicted in 
Figure 5-5. The FPF values obtained using DPIs were well-predicted using SETs. For 
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AS/Mann formulation, the performance (FPFTD) data using DPI devices were on the PADE 
regression curves predicted by SETs. For DSCG/ML-780 formulation, a slightly lower but 
quite comparable FPFTD values were obtained using DPI devices. This was reasonable 
because powder fluidization and entrainment from the SETs were not hindered by capsules 
or grids. The collision on the rigid stainless steel walls of SETs vs. softer and possibly 
electrostatic charged plastic walls of DPI devices could also explain the slight over-estimated 
performance efficiency using SETs. However, considering the apparent differences in 
geometry, dimension, and the mechanisms of particle separation, the prediction of 
aerosolization performance using SETs was remarkable. The performance using SETs was 
initially evaluated using Ventolin® (AS-lactose monohydrate) formulation vs. two DPI 
devices (Rotahaler® and Inhalator®).[7] Here, the predictive capability of SETs was further 
confirmed by variation in four different factors including drugs (AS and DSCG), carriers 
(lactose monohydrate and D-mannitol), DPI devices (Rotahaler® and Aerolizer®), and 
capsules (gelatin and HPMC).  
The intent of this performance study was to challenge the predictive capability of 
SETs as device independent screening tools. Undoubtedly, in the final product, the DPI 
devices with different principal mechanisms of particle separation would be employed. The 
exact mechanisms of particle separation of specific DPIs, due to their turbulent nature, were 
still unclear. Many literatures were focused on the impaction and momentum transfer 
mechanisms (mass or volume related contribution) for which many devices were designed. 
However, the important role of aerodynamic shear to the aerosolization performance was not 
emphasized or simply ignored. Nevertheless, it is reasonable to suggest that particles which 
can be stripped by aerodynamic shear may more readily be removed under the influence of 
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volume or mass related contribution. The SETs are excellent tools for the formulation 
optimization and prediction during the early stage of DPI development. 
 
5.4.4.2 Storage effect 
The pharmaceutical processing may inevitably induce surface imperfection and molecular 
disorder in the dry powder formulations. They are susceptible to change at elevated relative 
humidity (RH) or temperature because there is a tendency for the transformation of these 
formulations to the thermodynamically most favorable state. Many literatures have reported 
the influence of storage humidity on the aerosolization performance of dry powder 
formulations.[28, 29] The performance change, often deterioration, could result in 
insufficient dose and under-treatment. The influence by RH could be effectively minimized 
by using individually sealed blisters or capsules of each dose. However, in some 
formulations, particularly those containing steroids (e.g. Seretide Diskus: 
salmeterol/fluticasone propionate), the performance deterioration could occur even at well-
controlled storage condition. The exact cause of the change in performance is still unknown, 
presumably because of relaxation and phase change at molecular level.  
The intent of this study was to examine if the PADE method could still be used 
after formulation storage, and if the regression analysis would still furnish good data fit. Two 
formulations DSCG-ML780 and FP-Treh were chosen for this study. Since the earlier studies 
(Chapter 3 and 4), they have been stored in sealed glass jars which have in turn, been stored 
in desiccators (Drierite®/Indicating Drierite®) under ambient temperature and pressure for 
about a year. From the previous studies (Chapter 3), DSCG-ML780 was known to give the 
best performance efficiency (highest FPFTD) among all assessed formulations. DSCG is an 
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interesting molecule that can reversibly sorb and librate water to form nonstoichiometric 
hydrates.[30, 31] It was reported previously that elevated RH may greatly influence the 
aerosolization performance of a DSCG-Pharmatose (Lactose monohydrate) formulation.[28] 
However, the performance of this formulation at well-controlled storage conditions was not 
studied. The other formulation, FP-Treh was chosen for two reasons. FP is a steroid known to 
affect performance upon storage.[29] Treh is a dihydrate that may partially lose bound water 
and preferentially turn to its α-polymorph at low RH.[32] The thermal analysis using DSC 
also showed that Treh had a low dehydration temperature (onset ~ 86 oC and peak ~ 93 oC) 
(Figure 4-4). The morphology change and dehydration may lead to variations in formulation 
performance. 
The performance data before and after storage are shown in Appendix 3-A1, 5-B, 
and 5-E, respectively. (Some data were adopted from early studies). The PADE regression 
analyses are depicted in Figure 5-6. The result indicated that the performance of DSCG-
ML780 did not have appreciable change upon storage over a year range. However, the 
aerosolization of FP-Treh became less efficient. The value of FPFmax (plateau region in 
Figure 5-6D) decreased upon storage, and followed a new PADE curve. The shear stress 
dependent region increased (indicated as a slower rise in the graph) as well. This implied that 
the formulation reproducibility at different shear stress decreased after storage. Both PADE 
nonlinear and linear regression gave good correlation results. We assumed that the 
performance of other formulations after storage could also be predicted using PADE. Based 
on this assumption and the good correlation results obtained so far, we concluded a rule of 
thumb that the PADE linear regression divided the graph into two regions, any further 
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performance data that landed on the right-lower region had better performance efficiency, 
whereas any performance data that landed on the left-upper region had poorer performance. 
 
5.5 Conclusion 
In the current literature, attention was focused on inertial separation forces (volume or mass 
related: collision, rotation, vibration) and “torque” forces, while much less emphasis was put 
on the fundamental aerodynamic shear stress for particle separation. Using SETs in which 
particle separation occurs in response to shear stress, a novel method that correlates the 
pharmaceutical dry powder formulation performance with this airflow parameter for 
formulation screening and prediction in the entire shear stress range has been proposed. 
Particles which can be stripped by shear forces may more readily be removed under the 
influence of impaction and momentum transfer, from which it can be inferred that these 
formulation performance studies may extrapolate qualitatively (e.g. as a rank order) to drug 
product (device and formulation) performance. Two examples showed the robustness of 
PADE in formulation prediction across a defined shear stress range. PADE, as a theoretical 
method analogous to the Langmuir adsorption isotherm, also has the potential to allow a 
statistical thermodynamic approach to particle detachment utilizing a variety of expression 
used in a plethora surface adsorption theories, such as Freundlich, Sips, Toth, Volmer, 
Fowler-Guggenheim, Hill-deBoer, and many more. It may serve as a link between 
macroscopic statistical thermodynamics and microscopic individual particle deaggregation. 
This methodology gives an entirely new perspective for the rationale design of DPI 
formulation for pulmonary drug delivery. The current studies leading to PADE was based on 
carrier-based formulation systems. The dry powder aerosolization performance is a very 
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complex process. The heterogeneity of particulate systems, lateral interaction, the non-
ideality of the bulk, and the inconsistent airflow conditions in inhaler devices, all influence 
the macroscopic aerosol formulation performance. This complex deaggregation process can 
now simply be described by adapting surface adsorption theories and fitting the shear 
displacement using SETs. The effect of different formulation performance and the 
heterogeneity can be discussed in terms of theoretical or empirical surface adsorption models 
and measured experimentally to describe the aerosol performance across the entire shear 
stress range. It is suitable for accurate prediction of deaggregation mechanisms for real 
pharmaceutical formulations having surface energy heterogeneity and lateral interaction 
forces. It may also be applied for the studies such as the debatable ternary formulation 
deaggregation (“active” site vs deagglomeration), formulation stability and storage prediction, 
the influence of engineered particles such as porous carriers to the formulation performance.  
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Table 5-1. Results of PADE Linear-regression Using Four Different Linearization Methods 
of PADE (Langmuir isotherm equivalent) for Performance Studies* 
 
Langmuir linear regression Scatchard linear regression 
Eadie Hofstee 
linear regression 
Lineweaver-Burk 
linear regression
Formulation FPFmax 
(%) 
K 
(m2/N) R
2 R2 R2 R2
SV-A 15.9  0.81  0.9937 0.8203  0.8203  0.9137  
SV-B 16.9  0.59  0.9804 0.6888  0.6888  0.9172  
ML-A 45.7  1.01  0.9986 0.9228  0.9228  0.9747  
ML-B 36.6  0.85  0.9912 0.8224  0.8224  0.9442  
Treh 14.3  0.59  0.9918 0.8262  0.8262  0.9391  
A
Sa
Mann 11.6  0.73  0.9872 0.8070  0.8070  0.9100  
SV-A 33.6  5.77  0.9995 0.8693  0.8693  0.9400  
SV-B 35.3  7.81  0.9996 0.8823  0.8823  0.9249  
ML-A 45.8  1.13  0.9997 0.9854  0.9854  0.9983  
ML-B 48.8  1.22  0.9998 0.9911  0.9911  0.9976  
Treh 15.4  - 0.9968 0.8366  0.8366  0.8608  D
SC
G
b
Mann 23.3  0.84  0.9955 0.9027  0.9027  0.9832  
SV-A 31.4  - 0.9997 0.3453  0.3453  0.3881  
SV-B 28.7  42.74  0.9956 0.0000  0.0000  0.0007  
ML-A 32.2  18.65  0.9995 0.9226  0.9226  0.9560  
ML-B 37.7  2.00  0.9981 0.8211  0.8211  0.8985  
Treh 16.1  1.05  0.9909 0.8641  0.8641  0.9876  
IP
B
c
Mann 9.9  1.33  0.9710 0.4555  0.4555  0.9684  
SV-A 15.2  6.01  0.9978 0.2588  0.2588  0.4300  
SV-B 15.9  3.43  0.9999 0.9862  0.9862  0.9912  
ML-A 21.4  1.25  0.9906 0.1468  0.1468  0.1252  
ML-B 24.3  10.16  0.9995 0.6102  0.6102  0.4825  
Treh 9.1  1.04  0.9274 0.0106  0.1783  0.0066  
FP
d
Mann 12.5  - 0.9964 0.5756  0.5756  0.7440  
 
* The correlation of FPFTD (n = 3) and SET shear stress τs of twenty-four formulations using four 
different linear regression models. Based on the langmuir linear regression model: 
 
a. Rank order (FPFmax) of AS formulation:  ML-A > ML-B > SV-B > SV-A > Treh > Mann 
b. Rank order (FPFmax) of DSCG formulation: ML-B > ML-A > SV-B > SV-A > Mann > Treh 
c. Rank order (FPFmax) of IPB formulation: ML-B > ML-A > SV-A > SV-B > Treh > Mann 
d. Rank order (FPFmax) of FP formulation: ML-B > ML-A > SV-B > SV-A > Mann > Treh 
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Table 5-2. A Comparison of Surface Adsorption, Molecular/Colloidal Assembly, and Aerosol Dispersion (Analogy and Contrast) [10-13] 
 
 
+
ka
kd
Adsorbate
Adsorbent +
ka
kd
Drug
Protein
 
+
kd
Drug
Carrier
ka
 
Adsorption ?? Desorption Association (binding) ?? Dissociation Adhesion ?? Deaggregation 
PK
PK
L
L
+
Γ=Γ
1
max    (Langmuir isotherm) 
][1
][
f
f
DK
DvK
r +=   (Protein binding equilibria) sd
sd
k
kFPFFPF τ
τ
+= 1
max   (Deaggregation equation) 
Γ : Amount adsorbed r : amount of drug bound per amount of protein FPF: fine particle fraction below certain cutoff size 
Γmax: maximum adsorption to monolayer coverage v:  number of independent binding sites FPFmax: maximum achievable fine particle fraction 
KL: Langmuir adsorption constant K: association constant kd: deaggregation constant (overcome adhesion) 
P: gaseous partial pressure or solute concentration [Df]: concentration of free drug (ligand) τs: viscous shear stress 
SIMILARITY 
Phenomena governed by the same fundamental forces: van der Waals, electrostatic, capillary interactions, hydrogen bonding 
A result of surface energy, capable of being described as interfacial interaction, the same algebraic expression 
Interfacial phenomena. Interfacial driving force: gaseous partial pressure (N/m2), solute concentration (mg/g), shear stress (N/m2) 
Real systems require the consideration of surface heterogeneity, different binding affinity and sites, and lateral interaction 
DIFFERENCE 
Gas-Solid or Liquid-Solid Interface Liquid-Liquid or Liquid-Solid Interface Solid-Solid Interface 
Molecular adsorption/desorption;  Colloidal aggregation/deaggregation Particulate adhesion/deaggregation 
Statistical thermodynamics or kinetic approach Derived from binding equilibria Possibly the statistical thermodynamic approach 
Equilibrium (time independent) Equilibrium (time independent) Time dependent kinetic process 
System volume & boundary condition remain constant System volume & boundary condition remain constant Rapid system volume expansion, net gain in entropy 
Monolayer surface coverage Number of independent binding sites Maximum achievable fine particle fraction 
 HETEROGENEITY  
Adsorbent geometric and energetic feature Affinity distribution, binding site dependency Carrier geometric and energetic characteristics 
Adsorbate size, shape and conformation Different classes of binding sites Drug geometric and energetic characteristics 
Lateral interaction Drug-drug interaction, agglomeration Drug-drug cohesion, agglomeration 
EXAMPLE 
Chemosorption (irreversible), 
Physical adsorption (reversible) 
Protein binding (reversible),  
drug-drug interaction (reversible or irreversible) 
Enzyme kinetics (irreversible) 
Dry powder Aerosol dispersion (irreversible) 
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Table 5-3. A Schematic Comparison of Algebraic Equivalent Langmuir* and Freundlich 
Expression for TSLI Formulation Performance. (PADE non-linear regression analyses). 
 
PADE Langmuir* Freundlich PADE Langmuir* Freundlich
Expression 
sL
sL
k
kFPFFPF τ
τ
+= 1
max  n
sFkFPF
/1τ=  Expression
sL
sL
k
kFPFFPF τ
τ
+= 1
max  n
sFkFPF
/1τ=  
FPFmax = 14.49 n = 4.46 FPFmax = 32.99 n = 110.40 
kL  = 1.31 kF  = 8.27 kL  = 25.22 kF  = 31.93 
R2 = 0.9739 R2 = 1.0000 R2 = 0.9954 R2 = 0.9933 A
S SV-A 
Adj. R2 = 0.9652 Adj. R2 = 1.0000 
IP
B
 
SV-A 
Adj. R2 = 0.9939 Adj. R2 = 0.9911 
FPFmax = 16.55 n = 3.37 FPFmax = 29.51 n = - 
kL  = 0.75 kF  = 7.51 kL  = 80.02 kF  = 29.3 
R2 = 0.9362 R2 = 0.9882 R2 = 0.9438 R2 = 0.9435 A
S SV-B 
Adj. R2 = 0.9149 Adj. R2 = 0.9843 
IP
B
 
SV-B 
Adj. R2 = 0.9250 Adj. R2 = 0.9246 
FPFmax = 38.54 n = 4.62 FPFmax = 34.02 n = 14.29 
kL  = 0.76 kF  = 25.07 kL  = 5.26 kF  = 28.53 
R2 = 0.9691 R2 = 0.9957 R2 = 0.9967 R2 = 0.9840 A
S ML-A 
Adj. R2 = 0.9588 Adj. R2 = 0.9943 
IP
B
 
ML-A
Adj. R2 = 0.9955 Adj. R2 = 0.9786 
FPFmax = 43.51 n = 3.67 FPFmax = 37.56 n = 6.39 
kL  = 1.32 kF  = 18.08 kL  = 2.11 kF  = 25.45 
R2 = 0.9893 R2 = 0.9371 R2 = 0.9806 R2 = 0.9746 A
S ML-B 
Adj. R2 = 0.9858 Adj. R2 = 0.9161 
IP
B
 
ML-B
Adj. R2 = 0.9741 Adj. R2 = 0.9662 
FPFmax = 13.30 n = 3.53 FPFmax = 17.62 n = 3.77 
kL  = 0.78 kF  = 6.21 kL  = 0.79 kF  = 8.40 
R2 = 0.9740 R2 = 0.9996 R2 = 0.9716 R2 = 0.9038 A
S Treh 
Adj. R2 = 0.9654 Adj. R2 = 0.9995 
IP
B
 
Treh 
Adj. R2 = 0.9621 Adj. R2 = 0.8717 
FPFmax = 10.49 n = 4.30 FPFmax = 11.56 n = 4.28 
kL  = 1.25 kF  = 5.86 kL  = 0.91 kF  = 5.94 
R2 = 0.9653 R2 = 0.9928 R2 = 0.8991 R2 = 0.7870 A
S Mann 
Adj. R2 = 0.9537 Adj. R2 = 0.9905 
IP
B
 
Mann
Adj. R2 = 0.8655 Adj. R2 = 0.7159 
FPFmax = 35.59 n = 9.10 FPFmax = 14.95 n = 35.12 
kL  = 3.00 kF  = 26.83 kL  = 14.84 kF  = 13.95 
R2 = 0.9896 R2 = 0.9603 R2 = 0.9823 R2 = 0.9802 DS
C
G
 
SV-A 
Adj. R2 = 0.9861 Adj. R2 = 0.9471 
FP
 
SV-A 
Adj. R2 = 0.9764 Adj. R2 = 0.9736 
FPFmax = 37.40 n = 10.78 FPFmax = 16.04 n = 9.16 
kL  = 3.75 kF  = 29.55 kL  = 3.37 kF  = 12.28 
R2 = 0.9927 R2 = 0.9714 R2 = 0.9993 R2 = 0.9867 DS
C
G
 
SV-B 
Adj. R2 = 0.9902 Adj. R2 = 0.9618 
FP
 
SV-B 
Adj. R2 = 0.9990 Adj. R2 = 0.9822 
FPFmax = 44.78 n = 4.73 FPFmax = 18.57 n = 8.46 
kL  = 1.32 kF  = 25.98 kL  = 5.19 kF  = 14.68 
R2 = 0.9978 R2 = 0.9857 R2 = 0.9000 R2 = 0.9368 DS
C
G
 
ML-A 
Adj. R2 = 0.9970 Adj. R2 = 0.9809 
FP
 
ML-A
Adj. R2 = 0.8667 Adj. R2 = 0.9157 
FPFmax = 48.62 n = 4.75 FPFmax = 24.20 n = 27.39 
kL  = 1.30 kF  = 28.12 kL  = 14.33 kF  = 22.34 
R2 = 0.9987 R2 = 0.9739 R2 = 0.9954 R2 = 0.9962 DS
C
G
 
ML-B 
Adj. R2 = 0.9983 Adj. R2 = 0.9652 
FP
 
ML-B
Adj. R2 = 0.9939 Adj. R2 = 0.9950 
FPFmax = 18.06 n = 9.29 FPFmax = 7.99 n = 18.76 
kL  = 2.87 kF  = 13.58 kL  = 10.70 kF  = 7.15 
R2 = 0.9847 R2 = 0.9461 R2 = 0.7987 R2 = 0.8014 DS
C
G
 
Treh 
Adj. R2 = 0.9797 Adj. R2 = 0.9281 
FP
 
Treh 
Adj. R2 = 0.7316 Adj. R2 = 0.7352 
FPFmax = 22.30 n = 4.20 FPFmax = 14.43 n = 15.43 
kL  = 1.13 kF  = 12.08 kL  = 4.35 kF  = 11.96 
R2 = 0.9811 R2 = 0.9891 R2 = 0.9657 R2 = 0.9318 DS
C
G
 
Mann 
Adj. R2 = 0.9747 Adj. R2 = 0.9854 
FP
 
Mann
Adj. R2 = 0.9543 Adj. R2 = 0.9090 
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Table 5-4. Dimensions of the Additional SETs and Their Corresponding Airflow Parameters. 
 
Dimensions (mm) ** Airflow parameters 
SET External 
outlet length 
(a) 
Inlet 
length 
(b) 
Internal 
outlet length
(c) 
Inlet outer 
diameter 
(e) 
Inlet inner 
diameter 
(f) 
Reynold’s 
No., Re, 
Shear Stress 
τs (N/m2) 
A1* 144 300 134 7.0 5.2 16196 8.742 
B1* 133 300 123 8.5 7.0 12059 2.775 
C1# 121 600 111 10.1 8.3 10126 
 
1.412 
 
* The SET-A1 and SET-B1 use peripherally-located dosage table 
# The SET-C1 uses centrally-located dosage table.  
** The powder dosage length (d) is set at 10 mm. 
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Table 5-5. A Comparison of PADE Models Using Algebraic Equivalent Surface Adsorption 
Expressions for TSLI Formulation Performance (Using 7 SETs, Correlated by PADE non-
linear regression analyses including algebraic equivalent Langmuir isotherm, Freundlich, and 
Sips expressions.) 
 
PADE non-linear regression  
Langmuir Freundlich Sips 
'/1
'/1
'
max )(1
)(
n
sS
n
sS
k
kFPFFPF τ
τ
+=
PADE 
Expression sL
sL
k
kFPFFPF τ
τ
+= 1
max n
sFkFPF
/1τ=  
Parameters FPFmax, kL n, kF FPF’max, n’, kS
FPFmax = 46.51 - FPF’max = 53.72 
kL  = 1.19 kF  = 26.76 kS  = 0.89 
- n = 4.64 n' = 1.50 
R2 = 0.9651 R2 = 0.9610 R2 = 0.9698 D
SC
G
/ 
M
L-
B
 
Adj. R2 = 0.9593 Adj. R2 = 0.9545 Adj. R2 = 0.9578 
FPFmax = 10.95 - - 
kL  = 0.90 kF  = 5.58 - 
- n = 3.84 n' = 12.2 
R2 = 0.9197 R2 = 0.9682 R2 = 0.9701 
Fo
rm
ul
at
io
ns
 
A
S/
 
M
an
n 
Adj. R2 = 0.9064 Adj. R2 = 0.9629 Adj. R2 = 0.9581 
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Figure 5-1. PADE (Langmuir equivalent expression) and its linear transformation, where kd 
is the deaggregation constant (m2/N); τs is the viscous shear stress of SETs (N/m2); FPF is 
fine particle fraction at certain cutoff size (%); FPFmax is the maximum achievable fine 
particle fraction (%). 
 
FPF  = FPFmax kdτs
1 + kdτs
Langmuir equivalent
τ s = kdFPFmax − kdFPF
Scatchard
FPF = FPFmax -
FPF
kdτs
Eadie-Hofstee
FPFmax
1
kdτsFPFmax
11
= +
Lineweaver-Burk
FPFmax
τs
kdFPFmax
1τs
= +
Langmuir
 = kdτ s Henry's LawFPFmax
FPF
FPF
FPF
FPF
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Figure 5-2. The relationship between FPFTD and SET shear stress (τs) by TSLI experiment. 
PADE (Langmuir isotherm equivalent) linear regression analyses: (A) Albuterol sulfate 
formulations; (B) Disodium cromoglycate formulations; (C) Ipratropium bromide 
monohydrate formulations; (D) Fluticasone propionate formulations. All formulations were 
at 2 %w/w drug concentration. SV: Sieved lactose monohydrate; ML: Milled lactose 
monohydrate; Treh: D-Trehalose dihydrate; Mann: D-Mannitol. 
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Figure 5-3. TSLI experimental dataset of (A) DSCG/ML-B and (B) AS/Mann formulation 
using additional SETs, and correlation using PADE non-linear regression: algebraic 
equivalent of surface adsorption expressions including Langmuir isotherm, Freundlich, and 
Sips equivalent.  
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Figure 5-4. Schematic Illustration of The Different Models* of Heterogeneous Surfaces in 
Adsorption Theory (Adapted from [33]) 
 
 
 
 * (A) patchwise; (B) random; (C) medial; and (D) regular distributions of adsorption sites on 
surface 
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Figure 5-5. TSLI Performance (FPFTD) and Shear Stress (τs) Correlation:* (A) Performance 
Predicted by PADE Non-linear Regression; (B) Performance Predicted by PADE Linear 
Regression. 
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Figure 5-6. The Influence of Formulation Performance upon Storage: (A) DSCG-ML780, 
Nonlinear Regression; (B) DSCG-ML780, Linear Regression; (C) FP-Treh, Nonlinear 
Regression; (D) FP-Treh, Linear Regression. 
 
 
(A)
Shear stress (N/m2)
0 2 4 6 8 10 12 14
%
FP
F T
D
0
10
20
30
40
50
60
Before storage
After storage
Non-linear reg. (before storage)
 
(B)
Shear stress (N/m2)
0 2 4 6 8 10 12 14
τ s/
FP
F T
D
*1
00
0
5
10
15
20
25
30
35
Before storage
Linear reg. (before storage)
After storage
 
 
(C)
Shear stress (N/m2)
0 2 4 6 8 10 12 14
%
FP
F T
D
0
2
4
6
8
10
12
14
16
After storage
Before storage
Reg. before storage
Reg. after storage
 
(D)
Shear stress (N/m2)
0 2 4 6 8 10 12 14
τ s/
FP
F T
D
*1
00
0
50
100
150
200
250
300
Before Storage
After Storage
Reg. before storage
Reg. after storage
 
 
 
 
 
 
 213
References 
 
1. I. Langmuir, J Am Chem Soc, 38, 2221-2295 (1916). 
 
2. I. Langmuir, J Am Chem Soc, 40, 1361-1403 (1918). 
 
3. A. Martin, P. Bustamante and A.H.C. Chun, in: Physical pharmacy: physical 
chemical principles in the pharmaceutical sciences, pp. 379-392. Lea & Febiger, 
Malvern, PA, (1993). 
 
4. A.W. Adamson and A.P. Gast, Physical chemistry of Surfaces. John Wiley & Sons, 
Inc., NY (1997). 
 
5. J.N. Israelachvili, Intermolecular and Surface Forces. Academic Press, London, UK 
(1992). 
 
6. W.H. Finlay, The Mechanics of Inhaled Pharmaceutical Aerosols: An Introduction. 
Academic Press, London, UK (2001). 
 
7. M.D. Louey, M. VanOort and A.J. Hickey, J. Aerosol Sci., 37, 1520-1533 (2006). 
 
8. Y.S. Ho, Carbon, 42, 2113-2130 (2004). 
 
9. D.D. Do, Adsorption analysis: equilibria and kinetics. Imperial College Press, 
London, UK (1998). 
 
10. Z. Xu, H.M. Mansour, T. Mulder, R. McLean, J. Langridge and A.J. Hickey, J Pharm 
Sci, (2010 in press). 
 
11. Z. Xu, H.M. Mansour, T. Mulder, R. McLean, J. Langridge and A.J. Hickey, J Pharm 
Sci, (2010 in press). 
 
12. H.M. Mansour, Z. Xu and A.J. Hickey, J Pharm Sci, (2010 in press). 
 
13. Z. Xu, H.M. Mansour, T. Mulder, R. McLean, J. Langridge and A.J. Hickey, J Pharm 
Sci, (2010 in press). 
 
14. W. Rudzinski and D.H. Everett, Adsorption of gases on heterogeneous surfaces. 
Academic Press, San Diego (1992). 
 
15. J.R. Coury and M.L. Aguiar, Powder Tech., 85, 37-43 (1995). 
 
16. C.H. Giles, D. Smith and A. Huitson, J Colloid Interface Sci, 47, 755-765 (1974). 
 
17. C.H. Giles, D. Smith and A. Huitson, J Colloid Interface Sci, 47, 766-778 (1974). 
 
18. H.M.F. Freundlich, J Phys Chem, 57, 385-470 (1906). 
 214
19. R. Sips, J Chem Phys, 16, 490-495 (1948). 
 
20. J. Toth, Adv Colloid Interface Sci, 55, 1-239 (1995). 
 
21. A.W. Adamson and A.P. Gast, Physical chemistry of Surfaces. John Wiley & Sons, 
New York (1997). 
 
22. S. Brunauer, P.H. Emmett and E. Teller, J Am Chem Soc, 60, 309-319 (1938). 
 
23. T.L. Hill, J Chem Phys, 14, 263-267 (1946). 
 
24. A.R. Clark and A.M. Hollingsworth, J Aerosol Med, 6, 99-110 (1993). 
 
25. C.A. Dunbar, A.J. Hickey and H. P., Kona, 16, 7-45 (1998). 
 
26. M.S. Coates, H.K. Chan, D.F. Fletcher and J.A. Raper, Pharm Res, 22, 1445-53 
(2005). 
 
27. M.S. Coates, H.K. Chan, D.F. Fletcher and H. Chiou, Pharm Res, 24, 1450-6 (2007). 
 
28. M.A. Braun, R. Oschmann and P.C. Schmidt, Int J Pharm, 135, 53-62 (1996). 
 
29. L. Borgstrom, L. Asking and P. Lipniunas, J Aerosol Med, 18, 304-10 (2005). 
 
30. J.S. Cox, G.D. Woodard and W.C. McCrone, J Pharm Sci, 60, 1458-65 (1971). 
 
31. L.R. Chen, V.G. Young, Jr., D. Lechuga-Ballesteros and D.J. Grant, J Pharm Sci, 88, 
1191-200 (1999). 
 
32. M.D. Jones, J.C. Hooton, M.L. Dawson, A.R. Ferrie and R. Price, Int J Pharm, 313, 
87-98 (2006). 
 
33. M. Jaroniec and R. Madey, Physical Adsorption on Heterogeneous Solids. Elsevier 
Science Publishers, New York (1988). 
 
 
 215
  
CHAPTER 6 SURFACE MODIFICATION FOR LACTOSE 
6.1 Introduction 
Instead of searching for alternative carriers, surface modification (e.g. surface coating, 
etching, smoothing) is another strategy that manipulating the interparticulate forces and 
the corresponding performance optimization. The particle core is not critical to 
functionality other than its size and size distribution when the particle surfaces are applied 
with thin layer of coated material, often called force control agents. A controlled coating 
layer can effectively mask the particle surface heterogeneity and enable optimization of 
interfacial properties (adhesion and friction) of drug and carrier particles. The surface 
coating in dry powder formulation can change the physicochemical properties such as 
stability, hygroscopicity [1], flowability and dispersibility [2]. The coating of carrier 
particles with low surface energy material has been reported to increase the aerosolization 
efficiency of DPI formulations.[3-8] Before delving into the surface coating and 
performance studies, some background information including the proposed ternary 
blending mechanisms, the nature of particle surfaces, and coating techniques for dry 
powder aerosols, will be discussed first. 
 
6.1.1 Proposed Ternary Blending Mechanisms 
Jones et al [9] reviewed the influence of various ternary blending of lactose or other fines 
of carrier-based dry powder formulations. It is known that the addition of fines (typically 
volume median diameter of < 10 μm for lactose) of many different materials improves 
formulation performance, as shown by increased fine particle fraction (FPF), whereas the 
removal of intrinsic fines from a lactose carrier has been shown to decrease formulation 
performance. Furthermore, there exists an optimal concentration of fines for maximum 
FPF.[10] The influence of fines on the formulation performance is consistent even though 
different formulation and methodologies were used.[9, 11] However, the mechanism by 
which fines improve formulation performance differs. Two debatable mechanisms of 
ternary blend increasing FPF have been proposed regarding the nature of lactose-drug 
interactions influencing the efficiency of particle separation and, therefore, drug 
aerosolization. Each mechanism has its supporting empirical evidence. 
♦ Active sites: which give rise to greater binding of fine particles at carrier surfaces; 
♦ Agglomerates: of lactose fines and drug at the surface of carrier particles that are 
dispersed at low shear. 
 
6.1.1.1 Proposed “Active Site” Mechanism (Figure 6-1) 
It was proposed that high-energy active sites exist on the coarse carrier particles [12]. The 
addition of ternary fine particles preferentially binds to these highly adhesive sites, 
forcing the drug to the weaker binding site, thus drug particles are more easily liberated 
from the surface of the carrier particles after actuation. The surface area distribution 
function for heterogeneity in surface energy can be probed by N2 adsorption isotherm 
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using energy density function theory.[13] The presence of high energy sites on the carrier 
surface can also be detected by atomic force microscopy (AFM) spatial adhesion map and 
phase diagram.[14-17] If this hypothesis is true, the active sites should be saturable, and 
the order of mixing of drug, carrier, and fine will result in performance difference, 
according to ordered mixing of cohesive/adhesive interactive physical mixture.[84] 
Young et al [15] studied the influence of dose on the performance of dry powder 
formulation and found that no statistically significant difference in fine particle dose 
(FPD) at low dose range until the occupancy of “active sites” are saturated. Zeng et al [18] 
found that the blending of coarse lactose/fines before adding drug gave superior FPD to 
the blending of drug/coarse lactose first. The FPD of lactose produced gave opposite 
result. Furthermore, lactose fines enough for monolayer coverage gave good FPD, 
whereas too much fines resulted in poor FPD. These experimental evidences support the 
“active site” mechanism. However, the formulation performance was observed to be 
independent of the blending order in some other systems.[19, 20] The blending time 
could arguably be an influencing factor since the interactive physical mixing involves 
statistical and time-dependent particle redistribution. Zeng et al [18] suggested that the 
effect of blending order is also dependent on the particle size of the fines, the device and 
airflow rate applied. It was also found by AFM pull-off force measurement that active 
sites still existed and the adhesion forces on the carrier surface increased after addition of 
ternary component.[21] Moreover, Louey et al [20] found evidence that the addition of 
albuterol sulfate particles can in fact displace intrinsic fine lactose particles from carrier, 
thus casting doubt on the “active site” mechanism. It was speculated that competitive and 
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multilayer adhesion may produce equilibrium mixtures where drugs could interact with 
both carriers and surface fines. 
6.1.1.2 Proposed “Agglomerates” Mechanism (Figure 6-2) 
The inconsistencies in evidence for the previous mechanism led to the introduction of an 
alternative “agglomerates” mechanism. It was proposed that during interactive mixing, 
drug particles were distributed between the surface of carrier and fines, forming weak 
agglomerates of drug and fines that could be dispersed easily. The direct experimental 
observation [19, 20] of this mechanism was the drug and fine agglomerates by scanning 
electron microscopy.[22, 23] Louey et al [20] suggested that multilayer and multiplet 
“agglomerates” had greater detachment mass and was more easily librated from the 
carrier. Smaller drug-fine agglomerates could also contribute to the drug deposition 
without being separated. Islam et al [10] observed that an optimum drug and lactose count 
ratio of 1:1 exists when studying the salmeterol xinafoate blends. This can be explained in 
terms of agglomerates of drug and lactose fines weakening the cohesive interactions 
between drug particles. An investigation [24] of the mechanism by AFM 
cohesive-adhesive balance (CAB) approach suggested that increasing relative drug-fines 
adhesion gave rise to larger drug-fines agglomerates which would experience greater 
aerodynamic forces and kinetic energies for deaggregation, thus increase performance. 
However, this observation is limited to the drug being more adhesive than cohesive. The 
situation when the drug being more cohesive than adhesive is still unclear.[9] Similarly, 
Cline et al [25] examined the surface energy interaction of several drugs and carriers by 
inverse gas chromatography (IGC), and correlated it with formulation performance. These 
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researchers also found the increasing of surface energy between drug and carrier resulted 
in greater fine particle fraction of drug. No substantial difference was observed between 
surface free energy values of different lactose batches even though the amount of intrinsic 
fines was different. 
  Up to now, there’s no definitive conclusion regarding which of the proposed 
mechanisms prevail, owing to the myriad of formulation parameters (such as different 
drugs, carriers, different size, size distribution, morphology of drug and carrier particles) 
and diverse methodologies (such as different techniques for adhesive force measurement, 
different devices) employed by different research groups. The evidence in support of 
either mechanism is limited and sometimes contradictory. For example, Podczeck [26] 
used a centrifuge technique to assess the adhesion between salmeterol xinafoate and 
lactose carriers with or without lactose fines. The adhesion increased with the addition of 
fines. However, Lord and Staniforth [27] used a different centrifuge technique to evaluate 
the adhesion forces between an albuterol sulfate (0.8 %w/w) and lactose formulation. 
They found that inclusion of lactose fines (VMD = 12.6 μm) resulted in decreased 
adhesion between drug and carrier. These findings indicated that the ternary blending 
mechanisms could be formulation dependent. It also indicated that the phenomenology 
based on the surface analytical techniques may not directly account for the aerosolization 
performance. Moreover, to elucidate the mechanisms, it is necessary to develop a 
theoretical description of the powder deaggregation process including the fundamental 
forces of interaction that occur during the aerosolization of ternary inclusion formulation, 
as well as a standardized methodology to employ it. 
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6.1.2 The Nature of Particle Surfaces 
It is generally known that the surfaces of dry powder aerosol formulations are 
heterogeneous. However, describing the surface heterogeneity by dividing carrier surface 
into areas of strong and weak adhesion (active and non-active sites, shown in majority of 
literatures that support the “active” site mechanism) may be too simple. A few other 
studies proposed that the filling of fines in the carrier crevices or pores may prevent the 
drugs from being trapped by mechanical interlocking.[28, 29] More recently, studies 
using AFM colloid probe techniques may shed light on the nature of particle surfaces. A 
rule of thumb from these studies indicated that both heterogeneous asperity (geometric 
variations in the contact zone) and heterogeneous surface energy would cause logarithmic 
normal distribution of the adhesive forces.[30, 31]  
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In principle, the heterogeneity manifests on the particle surfaces should be similar 
as that described in the surface adsorption or surface chemistry since the fundamental 
forces and surface energies are described and characterized similarly.[32, 33] In surface 
adsorption theory, heterogeneity can be roughly classified from geometric and energetic 
perspectives (see Figure 5-4). The former includes particle size, size distribution 
(including the presence of a ternary component), morphology, surface asperities, 
meso-/micropores, and particle deformation, and the latter, the energy density difference 
caused by surface imperfection such as amorphous content, polymorphic state, or surface 
impurities. Even perfectly crystalline materials have different energy distributions due to 
their molecular orientation and crystal habit. The form of distribution varies with different 
dry powder material. They will influence the interparticulate forces, heat capacity, 
mechanical stress, etc. The practical approach to describing energy heterogeneity (such as 
that employs in adsorption theory or protein binding) is to average local thermodynamic 
quantities and treat them statistically (i.e. distribution function).[33] Several distribution 
functions have been used in the literature, such as uniform distribution, normal 
distribution, log-normal distribution, exponential distribution and Rayleigh distribution. 
In addition, the surface heterogeneity feature is a characteristic of mutual interaction 
between particles rather than an independent particle. 
 
6.1.3 Surface Coating Techniques 
Surface coating has been widely used in the pharmaceutical processing. An ideal surface 
coating layer will provide solely surface properties and the core material become less 
critical. Several different techniques have been employed for the preparation of surface 
modified or coated particles (either drug or carriers) for dry powder aerosol formulations. 
They were aimed at several purposes such as manipulation of interparticulate forces (or 
surface energy) to improve powder flowability and dispersibility, prevent moisture 
ingress and hygroscopic growth, and reduce batch to batch variability. They can be 
roughly divided into dry and wet coating methods. 
The dry methods is virtually a mixing process that relies on mechanical (shear, 
impact, etc) forces that bring smaller guest particles (nano- to micro-size range) into 
contact with larger host particles.[2] To meet the needs of different coating requirement, 
the mixing process can be further classified based on the energy input such as 
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conventional V-shape blending, intensive elliptical-rotor-type mixing [8, 34], and high 
energy machanofusion.[35]  
The wet methods are more flexible and they include conventional techniques and 
a few technological advances. The conventional techniques involve suspensions and 
emulsions where particles are coated and stabilized in a solution. There are some good 
examples such as adsorption coacervation [36-38], fluidized bed coating (Wurster 
processor) [39], and spray drying [40]. A good dispersion of particles prior to coating is 
needed for homogeneous distribution of coating layer. Particles suspended in 
nonpolarized and non-conducting media (e.g. liquid nitrogen) may disperse better than in 
air due to the reduced Hamaker constant.[41] Recently, A new technique was introduced 
by diffusion or deposition of sublimed gas vapor (e.g. L-leucine at ~145 oC) in a laminar 
aerosol flow reactor.[42, 43] This gas phase coating allows in situ formation and surface 
coating of micro- to nano-sized albuterol sulfate particles. 
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The selection of proper coating method depends on the host particle 
characteristics, the availability of coating equipment, and the desired coating layer. A 
discrete coating layer without disrupting the host particles is desired to provide expected 
surface properties. Thin layer coating is desired to reduce guest material mass and avoid 
appreciable particle size increase. Among various coating techniques, the adsorption 
coacervation and mechanofusion methods may be most suitable for current studies. The 
former is a method of adsorption of long chain fatty acids with different chain length 
from non-aqueous solution to the host particles. Host micronized particles such as 
disodium fluorescein [36, 38, 44] and disodium cromoglycate [37] were coated with 
lauric or capric acid to prevent hygroscopic growth and facilitate powder flow properties. 
The advantages of this method are precision coating of fatty acid in nanometer thickness, 
less energy input and heat generation, and easy operation. However, Non-aqueous solvent 
used in this method may change the properties of host particle discrete of the coating. The 
latter method relies on intensive energy input to mechanically fuse a nano-layer of force 
control agents (FCA) onto the host particles.[35] This method is aimed at modifying 
surface energy and particle shape of lactose carrier.[5, 35] Using this approach, several 
force control agents such as L-leucine, lecithin, and magnesium stearate were coated on 
the surfaces of lactose carrier [4, 45] or drug particles [35]. Due to the specific equipment 
required for mechanofusing, this method was considered as an alternative. Instead, the 
adsorption-coacervation method was chosen.  
  The purpose of this study was to apply a thin layer of fatty acid onto the 
hydrophilic surfaces of lactose monohydrate carrier particles. The introduction of 
minimum amount of fatty acid is proposed not to enter the lung. It is hypothesized that 
the carrier surface treatment by fatty acid surface coating can reduce the surface 
heterogeneity and improve the aerosolization efficiency of dry powder aerosol 
formulation. 
 
6.2 Material and Methods 
6.2.1 Material 
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Two lactose monohydrate (RespitoseTM) designated as sieved (SV) and milled (ML) were 
selected from previous studies. The physicochemical properties of these two lactose 
monohydrate batches were reported previously. Briefly, SV powder had more smooth 
surface textures and regular shape, lower molecular disorder and higher crystallinity, 
much less surface fines than ML powder. A broader span was observed in ML (~3.1) than 
SV (~1.1) particles, although the volume median diameters were comparable (55~60 μm). 
The specific surface area of ML (0.89 m2/g) was about three times that of SV (0.30 m2/g) 
particles. Two micronized drugs, albuterol sulfate (AS) and fluticasone propionate (FP) 
were prepared previously and used immediately after passing a 125 μm sieve. The 
interactive physical mixtures were prepared at 2%w/w concentration as was described 
previously. 
  The selection of fatty acids was based on: 1) Safety issue. FDA has stringent 
draft guidance for DPI formulation. The excipient/carrier and non-active ingredient are 
expected to be swallowed instead of inhaled. The introduction of minimum amount of 
fatty acid is proposed not to enter the lung. The naturally occurring fatty acids with even 
number of carbon atoms are often used in food science and human nutrition and generally 
regarded as safe. 2) Physicochemical consideration. As a starting point, only saturated 
fatty acids will be selected. Fatty acid as amphiphile is expected to adsorb onto the 
hydrophilic lactose monohydrate surface. Vertically orientated fatty acid occupies a 
surface area of ~20 Å2 per molecule.[36] Four naturally occurring fatty acids including 
stearic acid (C18H36O2, MW 284.5 g/mol), palmitic acid (C16H32O2, MW 256.4 g/mol), 
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myristic acid (C14H28O2, MW 228.4 g/mol), lauric acid (C12H24O2, MW 200.3 g/mol) 
were all purchased from Sigma-Aldrich Inc. (St Louis, MO).  
  Based on previous selected non-polar aprotic solvents that were used for 
adsorption studies, dichloromethane (anhydrous, CH2Cl2, Sigma-Aldrich Inc., St Louis, 
MO) and chloroform (anhydrous, CHCl3, Sigma-Aldrich Inc., St Louis, MO) were 
selected. The surface tensions of CH2Cl2 and CHCl3 at 20 oC were reported to be 28.1 and 
27.2 mN/m, respectively.[46] 
 
6.2.2 Preparation of Fatty Acid Coated Lactose Monohydrate 
Adsorption-coacervation: Surface coated particles were prepared by dissolving 0, 0.2, 
0.4, 0.8, 1.6, 2.4, 3.2, 4.8, 6.4, 8.0, and 10.0 mg/mL of fatty acid in 15 mL of 
dichloromethane. SV or ML (500 mg each) was placed in dried test tubes and the fatty 
acid solution was added. The test tubes were sealed by Teflon-wrapped stopcocks to 
avoid any leakage. SV or ML particles were suspended in the fatty acid solution by 
swirling at room temperature (23.5 ± 1 oC). After 6 h, 3 mL of chloroform was added to 
the suspension to promote coacervation. Seventy-two hours after initial preparation, the 
coated powders were flash dried using a Buchner flask and Whatman 50 hardened filter 
paper at ambient condition (23.5 ± 1 oC, RH%: 25~44). The collected powders were dried 
in a vacuum oven at room temperature overnight to remove trace amount of solvent. The 
powders were then stored in desiccator at ambient temperature. 
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Quantification of Coated Fatty Acid: The coated SV or ML samples (250 mg) were 
placed in 20 mL test tubes. Dichloromethane (5 mL) and deionized water (10 mL, 
Barnstead Nanopure, 18.0 mega-ohm) were added to each test tube. The mixtures were 
shaken vigorously and the bottom layer (CH2Cl2) was collected in scintillation vials and 
dried over anhydrous sodium sulfate (Aldrich-Sigma). An equal volume (4 mL) of 
collected dichloromethane, together with a standard fatty acid (palmitic acid for analyzing 
stearic acid, myristic acid for analyzing palmitic acid, lauric acid for analyzing palmitic 
acid, and palmitic acid for analyzing lauric acid) solution (5 mg/mL) in dichloromethane 
(1 mL). The solvent was evaporated. The resulting fatty acids (with internal fatty acid 
standard) were derivatized by adding 14% borotrifluoride in methanol (Sigma-Aldrich, 
Inc., St Louis, MO). The solutions were heated in boiling water for 2 min for complete 
derivatization. After cooling to room temperature, the methyl ester was extracted by 
adding petroleum ether (10 mL, 40-60 oC, Acro, NJ) and deionized water (15 mL). The 
top layer (petroleum ether) was extracted and dried once more over anhydrous sodium 
sulfate. The prepared methyl ester solution was added into cuvette for Gas 
Chromatography (GC) analysis. 
  The amount of fatty acid associated with lactose monohydrate was determined 
by GC analysis (Shimadzu GC-2014, Maryland, USA). The GC column used for fatty 
acid quantification was a capillary column 30×0.32 with 1 μm film thickness (Alltech 
Heliflex AT-1000, Deerfield, IL). The injection port temperature, the oven/column 
temperature, and the detection temperature were set at 200, 180, and 250 oC, respectively. 
The detection temperature for lauric acid was set to 160 oC. A flame ionization detector 
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was used with a mixture of hydrogen (IND 176 CF) and air (zero grade, 300CF). Helium 
(research grade 6.0) was used as the convey gas flowing at 27.8 mL/min. The retention 
time for derivatized fatty acid standard was obtained in Figure 6-2. The amount adsorbed 
and the equilibrium concentration was correlated to obtain the adsorption association 
isotherm. 
  According to the adsorption curve obtained, two equilibrium concentrations 
(designated as low and high) were chosen. The adsorption-coacervation was repeated at 
these two fatty acid equilibrium concentrations but at larger scale. SV or ML (10 g) was 
used and the fatty acid solution was drawn to scale. The original (+SVcontrol and 
+MLcontrol) and solvent treated (0 mg/mL fatty acid) (-SVcontrol and –Mlcontrol) 
lactose monohydrate were used as control. The prepared SV or ML was stored in 
desiccicator before blending.  
 
6.2.3 Blending 
The drugs were micronized albuterol sulfate (AS) and fluticasone propionate (FP) (see 
Chapter 3). Four interactive physical mixtures (2 drugs: AS and FP; 2 carriers: original 
SV and ML) were selected, twelve new interactive physical mixtures (2 drugs; 4 stearic 
acid coated carriers and 2 solvent treated control) were prepared using the same blending 
method described in previous chapters. The eight carriers included four batches each of 
sieved (SV) and milled (ML) lactose monohydrate. They were symbolized as original 
control (+SVcontrol and +MLcontrol), solvent treated control (-SVcontrol and 
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-MLcontrol), low equilibrium concentration stearic acid coating (SVlow and MLlow), 
and high equilibrium concentration stearic acid coating (SVhigh and MLhigh). The 
blending homogeneity for all the formulations were tested and a coefficient of variation 
smaller than 5.0% was considered homogeneous. 
 
6.2.4 Physicochemical Characterization 
6.2.4.1 Bulk/tapped density (powder flow) 
The bulk and tapped densities were determined using a modified method (reduced volume 
due to limited amount of powder) before and after fatty acid coating. Approximately 10 
mL of accurately weighed powder was employed to conduct each measurement by 
pouring into a glass syringe. The volume of powder was determined by measuring the 
cross-sectional area and the height using a caliper. The tapping was achieved by dropping 
the syringe vertically for > 200 times at a height of 0.5 m. The height of powder was 
determined when no further decrease of height was observed. The experiment was 
repeated (n = 3) and average bulk and tapped densities were calculated. The Carr’s 
compressibility index (CCI) was determined by using Eq. 6-1.[47] The CCI is a 
parameter for quantifying the powder flow. As powder flow improves, the bulk density 
approaches the tap density.[47] Smaller CCI corresponds to improved powder flow. 
%100×−=
densityTap
densityBulkdensityTapCCI   (Eq. 6-1) 
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6.2.4.2 Thermal properties (DSC) 
The thermotropic phase transitions of SV and ML before and after coating, and 
interactive physical mixtures were examined by DSC (Perkin Elmer DSC 6 Workstation, 
Norwalk, CT). Non-hermetically sealed aluminum pans were used. The heating rate was 
set at 5 oC/min from 20-250 oC. Thermograms were processed and analyzed using the 
accompanying software (Pyris Thermal Analysis Instrument Control and Data Analysis 
Software, v.3.01).  
 
6.2.5 In Vitro Aerosolization Performance Assessment 
The aerosolization performance of twelve new formulations after carrier coating with 
stearic acid and blending with AS or FP was assessed using twin-stage liquid impinger 
(TSLI). The setup and actuation for TSLI was described previously (25 mg, 10s at 60 
L/min for each actuation). The PADE non-linear and linear regression analyses were used 
to correlate the aerosol performance with shear stress. The statistical analysis was carried 
out using SigmaPlot software. (SigmaPlot 2004 for Windows Ver 9.01, Systat Software, 
Inc., CA). 
 
6.3 Result and Discussion 
6.3.1 The Theoretical Estimation for Monolayer Surface Coating 
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The lactose surface area of SV and ML powders were measured using N2 adsorption and 
Brunauer Emmett, and Teller equation to be 0.30 m2/g and 0.89 m2/g, respectively. 
Vertically orientated fatty acids occupy a surface area of ~20 Å2 regardless of chain 
length.[36] Based on the assumption that the each fatty acid would occupy the same 
vertical surface area for a monolayer surface coating, the mass of fatty acid associated 
with a unit mass of lactose monohydrate can be calculated according to the Eq. 6-2:[36] 
where SSA is the specific surface area of lactose; Sa is the surface area of standing fatty 
acid (m2/molecule); NA is Aveogadro’s constant; MW is the molecular weight of the fatty 
acid; Cads is the mass of fatty acid associated with a unit mass of lactose (g/g).  
Aa
W
ads NS
MSSAC ⋅=    (Eq. 6-2) 
 The calculated amount of fatty acid for a monolayer surface coverage on SV and ML 
will be: 1) stearic acid: 0.71 mg/g and 2.1 mg/g; 2) palmitic acid: 0.64 mg/g and 1.91 
mg/g; 3) myristic acid: 0.57 mg/g and 1.70 mg/g; 4) lauric acid: 0.50 mg/g and 1.50 mg/g. 
 
6.3.2 Fatty Acid Coating of Lactose Monohydrate 
The adsorption-association isotherms for all four acids at the surface of SV and ML are 
shown in Figure 6-3. The GC quantification result is shown in Appendix 6-A. The result 
indicated that at fatty acids equilibrium concentration range between 0.2-0.8 mg/mL, the 
amount of fatty acid coated on the surface of SV or ML was in a range of 4-250 μg/g, 
which was much less than required for a monolayer surface coating, assuming fatty acid 
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stood vertically on the surface of lactose monohydrate. Linear regression of the 
corresponding isotherm gave excellent R2, ranging from 0.9693 to 0.9961. This indicated 
that the adsorption was still in the linear range. There was a trend that the amount coated 
on the unit mass of ML was higher than that of SV, except for stearic acid coating. 
However, considering three times larger of specific surface area of ML, the amount of 
fatty acid coated on the ML was less than expected. The amount of coating seemed to be 
independent of the fatty acid chain length. This was different from an earlier study that 
larger amount of fatty acid coated on the disodium cromoglycate when the fatty acid 
chain length increased.[37] It was reported that the critical micelle concentration (CMC) 
for lauric acid in dichloromethane was ~0.1 M, and the CMC reduced in dichloromethane 
and chloroform mixture due to the reduced dielectric constant of cosolvent (dielectric 
constant at 20 oC for dichloromethane and chloroform are 9.10 and 4.81, respectively).[36] 
The CMC for stearic acid in 1,2-dichloroethane (a solvent having dielectric constant 4.65 
at 20 oC) was ~0.04 M.[48, 49] This indicated that the fatty acids were dissolved in 
dichloromethane in the concentration range studied. Reduced CMC occurred when 
chloroform was added, which drove the adsorption process to coacervation. Unlike the 
surface coating of disodium fluorescein using lauric acid [36], the step adsorption was not 
observed in all studied adsorption isotherm. This is conceivable since the surfaces of SV 
and ML were not yet saturated.  
The surface coating of SV and ML using stearic acid at equilibrium concentrations 
of 0.4 mg/mL (SVlow and MLlow: coated mass ~6 μg/g) and 5 mg/mL (SVhigh and 
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MLhigh: coated mass ~140 μg/g) were chosen for the further studies. 
 
6.3.3 Physicochemical Characterization 
6.3.3.1 Bulk/Tap Density (CCI) 
The flow properties characterized by measuring Carr’s compressibility index were shown 
in Table 6-1. The result indicated that all tap density values for SV were smaller than 
those of ML. The bulk density for SV was strongly influence by solvent treatment and 
coating, whereas ML was less dependent on solvent treatment and coating. When SV was 
treated with solvent, the flow property indicated by CCI was poorer (0.32) than the 
original lactose (0.26). Stearic acid coating greatly ameliorate the flow properties and the 
CCI reduce to 0.22. Surface coating had smaller influence to the CCI of ML. But the 
solvent treatment resulted in the poorest flow property (0.42). 
6.3.3.2 Thermal properties (DSC) 
DSC thermograms of –SVcontrol, –MLcontrol, SVlow, MLlow, SVhigh, MLhigh, and 
their corresponding AS and FP interactive physical mixtures at 5 oC/min heating rate are 
shown in Figure 6-4. The analysis of the dehydration of the SV sample indicates that the 
water contents were reduced when increasing concentrations of stearic acid were used. 
While comparing the dehydration peak of +SVcontrol (original SV) with –SVcontrol 
(solvent treated SV), the enthalpies are comparable. It indicated that stearic acid may 
participate in the dehydration on the SV lactose surface. The fusing peak was reduced as 
well when increasing amount of stearic acid was used, indicating the molecular 
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interactions of fatty acid with anhydrous α-lactose. It means that although very small 
amount of stearic acid exist on the surface of lactose monohydrate, the molecular 
interaction between them could be strong. The reduced dehydration and fusing peak 
intensity due to added stearic acid could also be observed in ML but to a less extent. But 
when the dehydration of –MLcontrol was compared with +MLcontrol, a significant loss 
of bound water was observed. Both dehydration and fusing peaks in +MLcontrol were 
smaller than +SVcontrol. The solution treatment changed the surface molecular disorder, 
as the characteristic exothermic peak disappeared in both ML and SV samples.  
  When AS was blended with SV or ML, there was a distinct broadening of the 
fusing peak, indicated by the smaller onset and larger end temperature. Interestingly, 
when FP was blended with stearic acid coated ML or SV, there was a small peak at 
temperature 235 oC, indicating the fusing of β-lactose. It is not clear if the stearic acid 
may induce the mutarotation that convert the α-lactose to the β form. This phenomenon 
was not observed in all previously studied lactose monohydrate formulations. When FP 
was blended with ML, the exothermic peak became visible again, indicating the disturbed 
surface molecules due to mechanical blending.  
 
6.3.4 In Vitro Aerosolization Performance Assessment (TSLI) 
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The aerosolization performance results are shown in Appendix 6-B and 6-C. The 
performance data were correlated with SET shear stress and PADE non-linear regression 
and linear regression were plotted in Figure 6-5 and 6-6. In all studied systems, the 
solvent treatedment (-SVcontrol and -MLcontrol) resulted in negative influence on the 
aerosolization performance. This is possibly because the solvent (CH2Cl2/CHCl3) 
dissolved the trace surface impurities such as protein and lipid, and exposed more surface 
heterogeneity and high surface energy sites than original lactose monohydrate surface. 
Because lactose monohydrate is a milk product, it is recrystallized with trace residual 
lipids (triglycerides, fatty acids, cholesterol) and protein (casein, lactoalbumin, whey), 
which are present on the surface dry particles. Although existed in tiny quantity, but these 
materials, some are surfactants, could naturally act as surface force control agents (e.g. 
change the surface hydrophobicity) and influence the performance efficiency. In SV-AS 
formulations (Figure 6-5A and 5B), the performance showed high dependency upon the 
amount of stearic acid coating. While the solvent treatment stripped the natural surface 
coating and increased surface heterogeneity, the artificial coating with stearic acid could 
mask surface active sites and increase performance efficiency. When SV surfaces were 
coated with larger amount of stearic acid (SVhigh+AS), there was a trend that the 
performance followed less to the Langmuir type PADE. The drug AS could be 
aerosolized at lower shear and the performance keep increasing at higher shear. This 
implies the surface coating with stearic acid may change the force balance and result in a 
redistribution of surface forces. More data points are necessary to explain this. 
Conversely, ML-AS formulation were less susceptible to the surface coating. While 
solvent treated control gave poor performance, the original ML and stearic acid coated 
ML resulted in similar performance efficiency, as is shown the overlap of PADE 
regression curves (Figure 6-5C and 5D). This implies that the performance efficiency is 
not solely dependent on the surface active sites. Because ML has many surface fines, they 
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may act as the intrinsic ternary component and form drug-fine aggregates. While a 
stronger drug-fine interaction forces will favor larger agglomerates formation, introducing 
fatty acid may not necessary disrupt such agglomerates from forming. The performance 
will be remain the same. It should be noted that ML formulations still gave higher 
performance efficiency than SV formulations. 
  In SV-FP formulations (Figure 6-6A and 6B), the solvent treatment effectively 
reduced both the powder flow properties (ED in a range of 49-56% for SET-A and B) and 
drug aerosolization (FPF in a range of 1.8-4.7%). However, when stearic acid was coated, 
the performance reached closer to the original SV-FP formulation. No further increase in 
performance was observed. This is probably because FP is a hydrophobic molecule (logP 
= 3.46 [50]). The surface coating with stearic acid may not effectively reduce particulate 
interactions between FP and carrier particles. In ML-FP formulation, the increase in FPF 
after coating occurred at low shear and maintained similar FPF at high shear. This implies 
such an increase in performance was not mainly because of agglomeration. 
 
6.4 Summary 
In this chapter, the influence of surface modification of selected lactose monohydrate was 
explored. The surface modification was achieved by adsorption-coacervation of naturally 
occurring fatty acids. Such modification was expected to increase the surface 
hydrophobicity and homogeneity. Four fatty acids were successfully coated at 
submonolayer concentration. The flow properties characterized by CCI indicated that 
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solvent treatment of SV and ML result in poorer powder flow. The coating of fatty acid 
could effectively increase the powder flow. The thermal analysis indicated that surface 
coating with fatty acid in this manner or solvent treatment may result in partial loss of 
bound water of surface molecules. The aerosolization performance indicated that the 
PADE interpretation of heterogeneity by the analogous “surface occupancy” approach 
described by adsorption theory accounted for both proposed “active” site and 
“agglomeration” and without favoring either mechanism. By using a similar expression 
for aerosol performance which was limited only by the data available at various shear 
stresses, from which the hyperbolic curve was derived, it is conceivable that an analogous 
mechanistic approach to the evaluation of particle-particle (drug-drug, drug-excipient 
fines), particle-surface (drug-excipient carrier, excipient fines-excipient carrier) 
interactions might be achieved.  
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Figure 6-1. Proposed deaggregation mechanisms of ternary blends 
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Figure 6-2. Representative Gas Chromatography Standard Peaks and Retention Time.  
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Gas Chromatography Peak Retention Time Based on Fatty Acid Chain Length. 
 
Derivatized 
Fatty Acid 
Chain Length
(Cn) 
Oven/Colume Temp
(oC) 
Retention Time 
(min) 
Stearic acid 18 180 6.17 
Palmitic acid 16 180 3.18 
Myristic acid 14 180 1.71 
Lauric acid 12 160 1.53 
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Figure 6-3. Adsorption-association Isotherm of Fatty Acids with SV and ML Lactose 
Monohydrate. (A) Stearic acid; (B) Palmitic acid; (C) Myristic acid; and (D) Lauric acid. 
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Figure 6-4. Differential Scanning Calorimetry thermograms of Lactose Monohydrate 
after Fatty Acid Surface Coating: (A) -SVcontrol (CH2Cl2/CHCl3 treated); SVlow (~6 
μg/g stearic acid); SVhigh (~140 μg/g stearic acid); (B) -MLcontrol (CH2Cl2/CHCl3 
treated); MLlow; MLhigh; (C) SV-AS; (D) ML-AS; (E) SV-FP; (F) ML-FP . 
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Figure 6-5. PADE Nonlinear Regression and Linear Regression of AS Formulations. 
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Figure 6-6. PADE Nonlinear Regression and Linear Regression of FP Formulations. 
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Table 6-1. Physical Characterization of the Powder Flow Properties (n = 3, mean value) 
 
 
Bulk density
(kg/m3) 
Tap density
(kg/m3) 
Carr’s index 
+SVcontrol 659 890 0.26 
-SVcontrol 589 866 0.32 
SVlow 606 866 0.30 
SVhigh 684 877 0.22 
+MLcontrol 555 925 0.40 
-MLcontrol 548 944 0.42 
MLlow 554 923 0.40 
MLhigh 595 933 0.36 
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CHAPTER 7 GENERAL DISCUSSION 
7.1 Review 
The delivery of aerosol drugs to the respiratory systems greatly improved the treatment of 
many diseases. Inflammatory airway diseases, such as asthma have been successfully treated 
using inhalation aerosols. Of the three types of aerosol delivery methods, dry powder inhalers 
(DPIs) are an alternative to the commercially dominant propellant-driven metered dose 
inhalers (MDIs) for inhalation therapy. With the manufacturing and engineering of inhalation 
particles growing as a research endeavor, the production of dry powders with desired particle 
size distributions, morphology, and other characteristics become possible. The major hurdles 
for effective treatment using DPIs relate to the formulation performance efficiency and 
reproducibility. Current device and formulation combinations often give sub-optimal 
performance and dosing variation. This is partly due to poor understanding of the relationship 
between the physicochemical nature of powder formulation and the behavior of particles in 
the aerosolization process. Some drugs such as β2-agonists are widely accepted for inhalation 
due to their wide therapeutic windows. For these drugs, efficient devices and formulations 
may be a priority since they reduce the loss of drug and are cost effective. But drugs with 
narrower therapeutic windows, such as steroids, require more accurate drug delivery. For 
such drugs, dosing accuracy may be the major concern. From the pharmacological 
classification, five major types of therapeutics are used for the treatment of asthma and 
COPD. The consistent and efficient delivery of a reliable dose to the appropriate parts of the 
respiratory tract using DPIs requires a good understanding of the characteristics of static 
powder, the aerosol generation, the aerodynamic behavior of aerosols, the aerosol deposition 
mechanisms, and site of actions. 
Dry powder formulations are mainly composed of micronized drug particles and 
larger carrier particles, typically lactose monohydrate. The factors that influence 
aerosolization performance are numerous. Great effort has been expended to address 
reproducible aerosolization and efficient performance by manipulating these factors, but with 
limited success. Although the calculated interparticulate adhesive and cohesive forces (van 
der Waals, electrostatic, and capillary forces) between ideal particles have been available for 
many years, these forces, measured experimentally, are not directly predictive of the aerosol 
performance. The difficulty lies in our current poor understanding and prediction of adhesive 
and aerodynamic forces and their effects on heterogeneous and multicomponent powder 
systems. Performance optimization remains a largely empirical process. Moreover, unlike the 
situation with liquid droplets, the particles in the solid state have limited molecular mobility. 
They are rigid and resistant to stress. The surface molecules of the solid cannot immediately 
rearrange to equilibrate with the bulk. Consequently, the surfaces of the particles are highly 
conditioned by their past history such as the method of particle formation, processing 
(milling and blending, filling), and storage conditions (RH and temperature) (Figure 7-1). 
The variation of these interparticulate interactions will subsequently dictate the aerodynamic 
performance of powder aerosols and therapeutic success.[1, 2] An overview of 
pharmaceutical processing that controls interparticulate interactions and performance is 
shown in Table 1-2.[3]. 
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7.1.1 Pharmaceutical Processing 
7.1.1.1 Origins of particles: Milling and spray drying 
Bulk drugs must be prepared in suitable size ranges for aerosol delivery. A variety of 
conventional and innovative research methods have been developed for controlled aerosol 
generation and their theoretical principles have been readily established.[4] Among them, 
two most common methods of aerosol drug particle preparation are milling (destructive) [1] 
and spray drying (constructive).[5] The former involves particle reduction by pressure, 
friction, impact, or shear depending on the types of mills used.[1, 6] Among them, jet mills 
and fluid energy mills are often used for drug particle micronization within the respirable 
range,[7, 8] whereas ball mills are  often used for the treatment of carriers such as α-lactose 
monohydrate.[9, 10] The jet-milling is operated at high pressure. The N2 supply from the 
feed and opposing jets caused the powder to impact with each other and against the sides of 
the milling chamber resulting in micronization of the bulk powder. The centrifugal force in 
the milling chamber and cyclone separation was used to collect micronized powder inside the 
milling chamber, cyclone separator, and the collection vessel. Superfine particles were 
trapped by a collection bag above the cyclone. The yield of micronized particles collected 
was ~ 50-60%. 
Generally, milling has limited control of particle size distribution. The degree of 
surface amorphous content increases with a longer milling time[9, 11] and higher milling 
pressure [11]. Milling is accompanied by surface area and molecular disorder increase, and 
potential surface charge buildup, which may cause particle agglomeration. As processing 
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technologies advance, some specialized milling process may achieve more controllable and 
predictable results. The latter is operated when a pressurized drug solution or suspension is 
atomized to a spray and then in contact with a hot drying airstream, resulting in rapid 
evaporation and drying of the droplet to form solid particle. These methods are relatively 
simple, cost-effective, and suitable for both small- and large-scale processing. From the 
perspective of conventional solid dosage forms such as capsules or tablets, these processes 
share similar intent at enhancing drug dissolution rate, diffusion, and absorption from sites. 
For pulmonary delivery, a more important purpose is to achieve a suitable aerodynamic 
particle size for site-specific aerosol delivery. [1, 12]  
The influence of milling of drugs or carriers on the aerosol performance has been 
studied extensively [8, 9, 13-17]. Aerosol dispersion of mannitol microparticles produced by 
jet milling and spray-drying was compared and greater aerosol dispersion was observed for 
spray-dried particles [8]. This was attributed to reduced van der Waals forces due to particle 
shape and reduced electrostatic forces due to the particle generation [8]. The performance of 
an inhalation peptide, cetrorelix, was also examined using milling and several other particle 
engineering techniques [15]. The fine particle fraction (FPF, particles with aerodynamic 
diameter < 6.8µm sampled at 90L/min) was lower for milled cetrorelix than spray dried or 
spray freeze dried particles. However, in another study, with tuned pearl milling of cetrorelix, 
a substantial increase of FPF (~60%), much higher than spray dried formulation performance 
could be achieved [16]. The study of milling effects of carrier lactose monohydrate on 
formulation performance showed that higher milling intensity and increased mill time 
resulted in higher FPF of a variety of drugs delivered from blends with these lactose batches 
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[9, 13].  A linear relationship was observed when FPF was correlated with mill time [9]. A 
linear relationship between FPF and the intrinsic lactose fines content revealed that the fines 
generated from the milling process served as a ternary component and played a major role in 
improving in vitro performance [9, 13]. 
7.1.1.2 Mixing 
In order to overcome agglomeration and increase powder flow properties, achieve content 
uniformity and accurate dosing, micronized drugs are often mixed with coarser carrier 
particles. Mixing is a statistical process, involves relative displacement of particles of one 
component with another component until a state of uniformity is achieved. [1, 18] In practice, 
the degree of homogeneity can be estimated by evaluating the sample variance ( ) (Eq. 
7-1).[18] 
2
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∑
= −
−=
N
i
si
s N
xx
1
2
2
1
)(σ  (Eq. 7-1) 
where xi (i = 1, 2,…, N) is the composition in the ith sample taken randomly (e.g. employing 
sample thieves [19]); sx is the sample mean. The blend homogeneity is an important 
indicator of uniform mixing. A detailed discussion of sampling methods and homogeneity 
analysis was reviewed by a few research groups.[20-23] The mechanisms of mixing include 
convective (large-scale random motion), diffusive (small-scale random motion) and shear 
(momentum exchange due to velocity distribution) mixing depending on the mixer and 
mixing time.[1, 18] In theory, mixing is a time-dependent process following an exponential 
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rise.[1] The mixing rate can be expressed by a first order kinetics as Eq. 7-2, where the 
mixing index, M, is defined as Eq. 7-3:[1] 
kteM −−=1  (Eq. 7-2) 
s
sM r=  (Eq. 7-3) 
where k is the rate constant (s-1) dependent on the material, mixer geometry and operation; sr 
represents the standard deviation of a series of samples drawn from a random mixture; s is 
the standard deviation of samples drawn from the mixture under examination. In reality, the 
rate constant k is affected appreciably by the material, mixer geometry, and mixing intensity 
and mechanism [1, 24-26]. 
 The micronized drug particles are generally cohesive, which may affect the mixing 
efficiency.[27, 28] The carrier particles are significantly larger than drug particles so that an 
even coating of drug particles may surround the carrier particles to form the so-called ordered 
mixing [29, 30]. Due to the particle size distribution of both respirable drug and carrier 
particles, both randomization and ordering are present in equilibrium [31]. A narrower size 
distribution of carrier particles can greatly increase the mixing efficiency and avoid 
segregation, which is known as the competing mechanism and opposite of mixing [31, 32]. 
Batch to batch variations in blend homogeneity will affect aerosol performance. The effects 
of concentration and material properties on multicomonent mixing of cohesive powders were 
evaluated previously [33]. The variables that can be manipulated to influence drug-carrier 
interaction in mixing process were reviewed [34]. They include the degree of fine particle 
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break-up during mixing, drug distribution, interaction forces, and press-on forces between 
drug and carrier particles [34]. The blending sequence may also influence the powder 
performance [35]. In recent years, there has been great interest in the development of ternary 
mixing systems because the inclusion of ternary component into the carrier-based dry powder 
formulation results in improved formulation performance due to a drug-carrier interaction 
change [36-38]. In the lactose-based DPI formulations, such ternary components can be fines 
of α-lactose monohydrate or alternative sugars [36, 39], or intrinsic fines generated from the 
primary lactose monohydrate particles [40]; or a variety of force control agents such as 
magnesium stearate [41-43], leucine [44] and trileucine [45]; nanoparticles [46, 47]; 
polymers [48] or active drugs [49]. Based on the effect of fines on the aerosolization 
performance, two different hypotheses were proposed to account for performance 
improvement of carrier-based dry powder formulation: the “active” site and agglomeration 
hypotheses (see Figure 6-1).[36]  
7.1.1.3 Filling and storage 
The filling of DPI formulation for aerosol product is a challenging task. This is partly 
because the lack of lung administration safety data restricted the use of many excipients, 
diluents, lubricants, binders, and surfactants in filling that are commonly used in oral 
products. α-Lactose monohydrate acts as excipient, diluent, and carrier. Besides the 
conventional requirement for powder filling including accuracy, consistency, and uniformity 
in standard pharmaceutical dosage forms (capsule, blister, strip, reservoir), the challenges for 
DPI powder filling include low apparent density, particulate cohesion and adhesion, low 
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filling weight, and high-throughput filling. Similar problems encountered in mixing such as 
percolation and trajectory segregation should also be considered. 
 Powder product stability is an issue of storage over time. A thermodynamically unstable 
molecular disorder may be created by the above mentioned processes. The unstable form 
may undergo molecular relaxation such as recrystallization and/or particle fusion resulting in 
poor aerosolization.[50] For example, the recrystallization of amorphous albuterol sulfate can 
happen during the process of milling or blending, leading to particle growth, agglomeration 
and size distribution shift.[51, 52] Moisture adsorption and ingress in the amorphous region 
due to increased water activity and capillary condensation will cause agglomeration and 
particle bridging, resulting in humidity-induced aerodynamic property change in dry powder 
formulations.[53, 54] 
 
7.1.2 Summary of Findings 
This dissertation addressed the frequently encountered problems during DPI development: 
the delivery efficiency and dosing variability. In order to improve performance and optimize 
the DPI formulations, the heterogeneous nature of carrier-based DPI formulations was 
systematically investigated. The physicochemical properties of one-component (drug or 
carrier alone) and two-component (interactive physical mixtures of different drugs and 
carriers) systems, and their aerodynamic performance were characterized.  
For most of the aerosolization performance studies, SETs were applied. The 
mechanisms of particle separation in the SETs include 1) particle entrainment in a laminar or 
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turbulent shear fluidization; 2) particle entrainment in a laminar or turbulent wall boundary 
layer; 3) turbulent deaggregation of agglomerates by aerodynamic forces or turbulent 
transient acceleration (relative motion) and; 4) particle detachment by momentum transfer 
(e.g. impaction and vibration). These mechanisms manifested to a different extent in the 
SETs and all of them are directly related to the fluid energy dissipated per unit volume of the 
flow, ε. The adequate measure of such dissipation is the magnitude of viscous turbulent shear, 
τs. This parameter varies within the flow cross-section and also depends on the flow 
geometry, pressure drop, and Reynolds number. The studies using SETs minimized the 
confounding factors caused by inhaler devices and allowed for studies that could focus on the 
relationship of airflow conditions and formulation performance. 
In order to elucidate the relationship between the dry powder formulations and their 
aerosolization performance, the performance data were correlated with the aerodynamic 
parameters (represented as τs). Excellent correlation results were observed in all studied 
formulations. A novel interpretation using powder aerosol deaggregation (PADE) was 
applied to describe and compare the particulate surface dissociation across a range of shear 
stress.[55-58] Briefly, PADE is a method that developed based on the fundamental 
understanding that the forces acting at the particle interface are analogous to those that the 
molecular level, and that models of molecular surface association described by an adsorption 
expression can be adapted to fit shear displacement observations. In principle, drug particles 
adhere to the carrier surface by fundamental forces including van der Waals, electrostatic and 
capillary interactions. As shear forces apply to the surface of a drug coated carrier particle, 
drug particles are removed with increasing difficulty because of the sites that they occupy 
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until a saturation is reached, when no drug particle can be removed at increasing shear forces 
unless comminution of particles. The analogy from surface adsorption/desorption leads to a 
completely novel way of looking at particle interactions. This method is significant because it 
not only describes the formulation performance across the entire shear stress range, but more 
importantly may reveal the mechanism of drug deaggregation during inhalation. In the PADE 
non-linear regression analysis, the invariable (shear independent) region at high shear has 
important predictive implications for screening (performance evaluation) of existing 
formulations and rationally designing of new formulations. It will be easy to idientify the 
optimum shear required for efficient deaggregation close to the plateau, yet within the 
specific resistance limit for patient’s inhalation. The variable (shear dependent) region at 
lower shear reflected in the specific interfacial and physicochemical properties of drugs and 
carriers in their heterogeneous state. It has the potential to reveal the mechanisms of drug 
deaggregation considering the surface energy heterogeneity and lateral interaction forces. 
This can be achieved by increasing the dataset for PADE non-linear curve fitting of different 
algebraic equivalent surface adsorption models and use statistical thermodynamic approach 
to particle deaggregation studies analogous to those used in adsorption theory. 
  During the development of the PADE method, three apparently similar but 
inherently different surface phenomena, adsorption, protein binding, and particle 
disassociation were compared. These surface phenomena are governed by the same 
fundamental forces but different dimensions and magnitude (i.e. intermolecular, colloidal, 
and interparticulate). They share the same algebraic expression that could be derived 
thermodynamically from the surface energy. The interfacial driving forces also share the 
  257
same unit (N/m2) between adsorption and deaggregation. Real systems of all these surface 
phenomena require the consideration of surface heterogeneity, various binding affinity and 
sites, and lateral interactions. Among them, the adsorption theory (e.g. Langmuir adsorption) 
equates the rates of adsorption and desorption in terms of fraction loading. The dynamic 
equilibrium is time independent. At high pressure, the amount adsorbed reaches the 
saturation capacity to form a monolayer surface coverage. The treatment of heterogeneous 
adsorption is achieved by grouping the similar surface energy sites in a patchwise or random 
manner using statistical thermodynamic approach and applies appropriate isotherm to each 
local adsorption. Similarly, the protein binding is also a time independent equilibrium 
process. The amount of adsorbed and monolayer surface coverage in langmuir adsorption are 
now described as the percentage of drug bound in the total protein and the number of 
independent binding sites, respectively. The number of binding sites determines the 
saturation capacity. If there’re multiple binding sites or binding sites are dependent one 
another (heterogeneity), the treatment is usually to group similar classes of binding sites, 
treat each class of protein binding separately and then add up. As an analogy to the surface 
coverage in adsorption and the number of independent binding sites in protein binding, the 
parameter in deaggregation expression is defined as the maximum achievable fine particle 
fraction (FPFmax). The heterogeneity in particle deaggregation is probably the most 
complicated because geometric, energetic characteristics of both drug particle and carrier 
particle, and the interfacial interaction of both particles contribute to the heterogeneity. The 
analogy to surface adsorption expressions was eventually chosen. 
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  Despite the unifying concepts between these surface phenomena, there are 
fundamental differences between the powder deaggregation and the other two concepts. The 
physical adsorption is a molecular thermodynamic diffusion process. The residence time 
(time required for molecular transport to adsorption sites) is relatively short. However, the 
actuation of dry powder to form aerosols is most likely a different scenario. Because of the 
transient nature of powder entrainment and deaggregation (a short burst of powder), the 
particle deaggregation in this manner should be differentiated from the long-term particle 
diffusion by a time independent “particle desorption/deposition” model which could be 
viewed as a true analogy to adsorption phenomena.[59, 60] The particle entrainment and 
deaggregation, due to the particle size and system dimension, cannot be treated as a 
continuum for continued drug particle adhesion and deaggregation. Furthermore, the particle 
deaggregation in a burst involves rapid system volume expansion and the corresponding net 
gain in entropy. 
  The newly developed PADE method was subjected to several types of evaluation. 
They include the performance evaluation of a variety of carrier-based formulations (different 
drugs or carriers), the performance comparison of SETs vs. DPI devices, the storage effects 
to the performance efficiency. These applications proved PADE as a robust formulation 
optimization and screening tool in the defined shear range. 
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  As an analogy to Langmuir adsorption theory, the PADE method tolerated well in 
the heterogeneous particulate systems containing both drug and carrier particles. It was 
hypothesized that by applying a force control agent (fatty acid) coating, the surface 
heterogeneity could be reduced and the performance efficiency could be improved. The 
surface coating could potentially mask the high surface energy density sites and could serve 
as a probe for mechanistic study of PADE. It was found the analogous “surface occupancy” 
approach described by adsorption theory could potentially account for both proposed 
“active” site (e.g. Langmuir type) and “agglomeration” (e.g. B.E.T. type) and without 
favoring either mechanism. By using similar surface adsorption expression for aerosol 
performance, it is conceivable that an analogous mechanistic approach to the evaluation of 
particle-particle and particle surface interactions might be achieved. 
 
7.2 General Conclusion 
The mechanics of DPIs are complex and not very well understood, largely because of the 
heterogeneous nature of dry powders and the turbulent nature of airflow in which the 
aerosols are entrained and resuspended. Using SETs in which particle separation occurs in 
response to shear stress, we have developed a basic understanding of aerosolization 
performance described by PADE. To our knowledge this is the first time that such an 
approach has been suggested. It is conceivable that particles which can be stripped by shear 
forces may more readily be removed under the influence of impaction and momentum 
transfer, from which it can be inferred that these formulation performance studies may 
extrapolate qualitatively to drug product performance. This observation may serve as a link 
between macroscopic statistical thermodynamics and microscopic individual particle 
deaggregation. Dry powder deaggregation is a very complex process. The surface 
imperfection including geometric and energetic heterogeneity, lateral interaction (drug-drug 
cohesion), the nonideality of the bulk, and the turbulent airflow conditions, all influence the 
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macroscopic aerosolization. But this complex deaggregation process can now simply be 
described by adapting surface adsorption theories and fitting the shear displacement using 
SETs. The PADE method is served to open a new window for the novel interpretation of 
aerosol formulation development. 
 
7.3 Future Work 
A broad range of future studies may be conducted to support the general application of the 
PADE.  
1) The Langmuir adsorption isotherm is the cornerstone of nearly all the surface adsorption 
expressions and has been most widely used. However, in many cases, the experimental 
results require adjustment that with respect to surface heterogeneity and lateral interactions. 
From a historical perspective, theoretical and semi-empirical expressions were based on 
experimental data and statistical thermodynamic derivation considering various influences 
such as affinity constant change (e.g. Volmer isotherm [61]), surface heterogeneity (e.g. 
Freundlich [62], Sips [63], Toth [64], Unilan [61] equation), and lateral interaction (e.g. 
Fowler-Guggenheim equation [61]). Likewise, the PADE (Langmuir equivalent) method 
tolerated the surface heterogeneity and lateral interactions. But elaborating such an approach 
would have the benefit of describing more accurately the magnitude of the interaction and the 
likely underlying mechanisms, based on inflections in FPF with respect to shear that could 
be probed, subsequently, by controlled experiments (highly engineered particles: e.g. narrow 
span, porous, smooth, etc).  
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2) One of the difficulties in the development of PADE (Langmuir equivalent) was definition 
of the deaggregation constant k. As an energy function, this parameter could be affected by a 
variety of factors, such as the heat of adhesion, the energy density distribution of drugs and 
carriers. It remains to be seen if this parameter could be related to the surface energy or the 
adhesive and cohesive forces. Future research should employ surface analytical techniques 
such as AFM and IGC to account for the influence of formulation to the aerosolization 
performance. The fluid dynamic methods could also be an alternative technique for adhesive 
force measurement since it involves adhesion in a particle-fluid system. 
3) In the previous studies, the experiments were designed to account for the influences of 
drug, carrier, and SET shear stress, while the drug concentration (drug to carrier ratio), which 
could be important, was omitted. But this factor should be included in the future studies. 
Expressions describing surface adsorption were intended to allow elucidation of mechanisms 
including using the Brunauer classification for reference, lateral interactions, multilayers and 
capillary condensation.[65] The evolution of the Brunauer Emmett Teller (BET) equation 
encompassed the Langmuir expression as a special case with the assumptions that the 
successive heat of adsorption for all layers except the first are equal to the heat of 
condensation of the adsorbate (energetically homogeneous).[66, 67] Similar approaches were 
described by Giles et al. for solute adsorption at solid surfaces from solution resulting in a 
range of isotherms equivalent to the Brunauer classification.[68, 69]  
  262
4) From the ACI experimental data, it indicated that an exponential decay relationship could 
fit the data (analysis was not shown) when another fundamental parameter, MMAD, was 
correlated with shear stress. This was consistent with the earlier findings.[70] It was 
conceivable that a complete deaggregation of drug particles would produce an MMAD value 
equivalent to the aerodynamic diameter of the primary drug particles. 
5) In addition to the turbulent shear forces which are the principal mechanism of powder 
entrainment and drug deaggregation, the impaction and momentum transfer are perhaps the 
most important mechanisms for deaggregation. Besides, frictional forces should be 
considered at initiation of powder entrainment. Their roles should be considered in the future. 
A computational fluid dynamics study of the SETs may be helpful. 
6) It is worth investigating if the PADE method could be applied to other aerosol systems 
because only carrier-based formulations were evaluated. Further investigations of other 
aerosol systems such as carrier-free formulations, porous particle formulations, drug-carrier 
composite formulations, or even pMDI and nebulizer formulations are necessary. 
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Figure 7-1 Pharmaceutical Dry Powder Aerosol Processing and Variables Associated with 
Each Process. 
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               surface & bulk properties, stability (moisture adsorption), particulate interaction
Mixing: Type of drug and carrier, type of mixer, mixing time, type of mixture: surface 
              properties, bulk properties, content uniformity, drug/carrier ratio, coating or 
              surface treatment, ternary component, stability, particulate interaction
Filling: Type of mixture, type of filler, packing method, stability
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Appendix 1-A. Selected Dry Powder Inhalers (DPIs) and Their Characteristics 
Inhaler Company Drug Carrier Powder supply Dosing
Fluidization / 
Deaggregation Diseases
First generation: passive DPIs, single unit dose 
Rotahaler GSK AS, BDP, SS+BDP Lactose Capsule 1 
Mechanical/ 
turbulence Asthma
Inhalator BI FE, IPB Glucose Capsule 1 or 6 Capillary/ Shear force Asthma
Spinhaler Aventis DSCG None Capsule 1 Capillary/ Shear force Asthma
Cyclohaler Pharmachemie 
SS, BDP, 
IB, BUD - Capsule 1 - Asthma
Handihaler BI TI Lactose Capsule 1 - COPD 
Aerolizer Novartis FO  Capsule 1 or 6 Capillary/ Shear force 
Asthma, 
COPD 
FlowCaps Hovione -  Capsule 1 - Asthma
TwinCaps Hovione NI  Capsule 1 - Influenza
Second generation: passive DPIs, multi-unit or multiple doses 
Turbuhaler AZ AS, TS, BUD None Reservoir 200 
Shear,  capillary 
/ shear force Asthma
Diskhaler GSK SX, BDP, FP, ZM Lactose Blister 4, 8 
Shear force / 
turbulence 
Asthma, 
Influenza
Diskus GSK 
AS, SX, 
FP, 
SX+FP 
Lactose Strip 60 Shear force / turbulence Asthma
Aerohaler BI IPB - Capsule 6  Asthma
Easyhaler Orion Pharma AS, BDP Lactose Reservoir 200 
Shear force / 
turbulence Asthma
Ultrahaler Aventis - - Reservoir - - Asthma
Pulvinal Chiesi AS, BDP - Reservoir - - Asthma
Novolizer ASTA BUD Lactose Reservoir cartridge   
Asthma, 
COPD 
MAGhaler BI AS Lactose Reservoir 200-500 
Mechanical / 
Mechanical Asthma
Taifun Focus Inhal AS  Reservoir   Asthma
Eclipse Aventis DSCG  Capsule   Asthma
Clickhaler Innoveta Biomed AS, BDP  Reservoir   Asthma
Twisthaler SP MF - Reservoir   Asthma
Third generation: active DPIs, single or multi-dose 
Exubera Pfizer Insulin  Blister   Diabete
Airmax 
Norton 
Healthcar
e 
FO, BUD  Reservoir   Asthma, COPD 
Continued… 
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Inhaler Company Drug Carrier Powder supply Dosing
Fluidization / 
Deaggregation Diseases
Next generation DPIs (approved or in development stage) 
Aspirair Vectura Apomorphine hydrochloride - Powder Multi Active 
Erectile 
dysfunction
Omnihaler Innoveta Biomed  - - -  Active  
Actispire Britania Pumactant  Powder 1 Active - 
NEXTTM 
DPI Chiesi - - Reservoir
Multi-
unit - 
Asthma / 
COPD 
DirectHaler Direct-Haler - - Premetered 1 - Asthma / COPD 
JAGO SkyPharma AS - Reservoir Multi - Asthma 
Turbospin PH & T - - Capsule 1 - Asthma 
AIR Alkermes - - Capsule 1  - 
MicroDose MDT/3M 
Insulin, β-
agonists, 
steroids 
- blister 
1 or 
Multi-
unit 
Electronic 
/breath  
Multi 
purpose 
Cyclovent Pharma-chemie Opioids - Reservoir Multi - 
Dyspnea, 
pain 
Dispohaler AC Pharma - - - Multi - - 
CONIX 
ONE 
Cambridge 
Consultant 
Vaccines, 
anti-asthma - blister 1 - 
Avian flu, 
Asthma 
Microhaler Harris Pharm DSCG - Capsule 1 Passive Asthma 
Technohaler Innoveta Biomed - - Blister 
Multi-
unit Passive Asthma 
Spiros Dura AS Lactose Blister 1, 16, 30 
Mechan, Turbul. 
Shear, impaction Asthma 
Bulkhaler Asta Medica - - Reservoir Multi-unit Passive Asthma 
Miat-Haler MiatSpA FO, FP, BUD - Reservoir
Multi-
unit Passive 
Asthma, 
COPD 
Prohaler Valois TS, SKF-104353-Q Mannitol Blister 
Multi-
unit 
Gas assisted / 
turbul., shear Asthma 
Ostuka DPI Otsuka Pharma - - 
Compact 
cake 
Multi-
unit Gas assisted Asthma 
Acu-Breath Respirics FP - Powder Multi - Asthma 
MF-DPI - MF - Reservoir Multi-unit - Asthma 
Swinhaler Otsuka Pharma 
Procaterol, 
BUD - Powder Multi - Asthma 
Dynamic Powder 
Disperser 
Pfeiffer 
GmbH - Lactose Powder 12 Gas assisted Asthma 
Certihaler Novartis/Skye FO - Powder Multi Gas assisted Asthma 
Source: Adapted from [38, 41, 43, 46, 82, 197]. 
Glossary: MF: mometasone furoate; AS: albuterol sulfate; SX: salmeterol xinafoate; FP: fluticasone propionate; 
BUD: budesonide; TS: terbutaline sulfate; FE: fenoterol; FO: formoterol; IPB: ipratropium bromide; TI: 
tiotropium; DSCG: disodium cromoglycate; BDP: beclomethasone dipropionate; EFD: eformoterol fumarate 
dihydrate; ZM: zanamivir; NI: neuraminidase inhibitors; Lactose: α-lactose monohydrate; GSK: 
GlaxoSmithKline; BI: Boehringer Ingelheim; AZ: AstraZeneca; SP: Schering-Plough; MDT: MicroDose 
Technologies. Dashline (-) denotes information not available. 
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Appendix 2-A. TSLI performance data (The order has been sorted for the ease of data 
analyses; airflow rate Q = 60 L/min; actuation duration 10s; with solenoid switch; the 
response data (ED, FPFTD, and FPFED) mean value, standard deviation in parentheses, 
replication n = 3. 
SETs Sample 
Blend Conc 
(w/w) 
Dose 
(μg) ED      (%) 
FPF in TD 
(%) 
FPF in ED 
(%) 
A SV131 2.0% 505.3 90.9 (1.2) 25.9 (0.9) 28.5 (1.2) 
C SV131 2.0% 500.7 91.6 (2.3) 14.3 (1.0) 15.6 (0.8) 
D SV131 2.0% 499.3 93.4 (0.1) 9.9 (1.2) 10.6 (1.3) 
A SV131 0.5% 252.3 89.2 (4.3) 17.3 (2.7) 19.3 (2.1) 
C SV131 0.5% 250.2 95.0 (0.2) 10.5 (1.1) 11.1 (1.2) 
D SV131 0.5% 250.7 91.1 (2.6) 10.0 (1.5) 11.0 (2.0) 
A ML058 2.0% 501.3 74.0 (4.7) 35.2 (2.7) 47.6 (2.7) 
C ML058 2.0% 500.0 87.2 (1.0) 30.4 (2.5) 34.8 (3.0) 
D ML058 2.0% 501.3 88.4 (1.4) 22.4 (4.2) 25.4 (4.7) 
A ML058 0.5% 251.4 76.6 (4.1) 33.7 (2.6) 43.9 (1.3) 
C ML058 0.5% 250.3 88.6 (2.3) 24.4 (5.3) 27.5 (5.3) 
D ML058 0.5% 251.3 90.9 (1.5) 23.7 (3.5) 26.0 (3.5) 
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Appendix 2-B 
Experimental design of albuterol sulfate - lactose monohydrate blends for performance study: 
Factors: Lactose (SV473, ML780); concentration (0.5%, 2%); SETs (D, A) 
Response: ED, FPFTD, FPFED 
 
Run Factor B: Lactose 
Factor C:
Tube 
Factor D
Conc % 
Response 
ED % 
Response 
FPF in TD% 
Response 
FPF in ED% 
1 SV473 D 2 91.8 8.9 9.7 
2 ML780 D 2 84.7 23.0 27.1 
3 SV473 A 2 77.8 23.4 30.1 
4 SV473 D 0.5 84.8 8.9 10.5 
5 SV473 A 0.5 87.8 17.6 20.0 
6 ML780 D 0.5 87.5 18.3 21.0 
7 ML780 A 2 81.2 45.4 56.0 
8 ML780 A 0.5 80.8 34.8 43.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
DESIGN-EXPERT Plot
FPF in TD 
A: Carrier 
B: Conc 
C: Tube 
Half Normal % probability
Half Normal plot
Effect
0.00 3.92 7.84 11.76 15.67
0
20
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60
70
80
85
90
95
97
99
A
C
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DESIGN-EXPERT Plot
Response 3
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Appendix 2-C 
Experimental design of albuterol sulfate - lactose monohydrate blends for performance study: 
Factors: Lactose (SV131, ML058); concentration (0.5%, 2%); SETs (D, A) 
Response: ED, FPFTD, FPFED 
 
Run Factor B: Lactose 
Factor C:
Tube 
Factor D
Conc % 
Response 
ED % 
Response 
FPF in TD% 
Response 
FPF in ED% 
1 SV131 D 0.5 91.1 10.0 11.0 
2 ML058 A 0.5 76.6 33.7 43.9 
3 SV131 D 2 93.4 9.9 10.6 
4 SV131 A 2 90.9 25.9 28.5 
5 ML058 D 2 88.4 22.4 25.4 
6 SV131 A 0.5 89.2 17.3 19.3 
7 ML058 A 2 74.0 35.2 47.6 
8 ML058 D 0.5 90.9 23.7 26.0 
 
 
 
 
 
 
 
 
 
 
Summary of finding from Appendix-B and C: The notable contributing variables for the 
FPFTD and FPFED were lactose and applied shear (SETs), while the drug concentration 
contribution was not statistically significant. The contributing variables for the ED were not 
significant. 
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APPENDIX 3-A1. – TSLI performance data of albuterol sulfate (AS) and disodium 
cromoglycate (DSCG) (The order has been sorted for the ease of data analyses; drug conc 
2%(w/w); airflow rate Q = 60 L/min; actuation duration 10 s; with solenoid switch) 
Drug Carrier SET ED 
(%) 
FPFTD
(%) 
FPFED
 (%) 
FPM   
(μg) 
Drug Carrier SET ED 
(%) 
FPFTD
(%) 
FPFED
 (%) 
FPM   
(μg) 
AS SV208 A 77.02 14.22 18.47 68.91 DSCG SV208 A 75.40 38.26 50.74 185.42
AS SV208 A 87.88 16.12 18.34 74.43 DSCG SV208 A 75.69 33.52 44.29 157.53
AS SV208 A 83.67 13.89 16.60 69.73 DSCG SV208 A 73.32 28.88 39.39 146.63
AS SV208 B 81.02 9.43 11.64 46.13 DSCG SV208 B 81.18 33.19 40.88 159.48
AS SV208 B 84.01 11.89 14.15 57.05 DSCG SV208 B 83.63 35.02 41.87 183.22
AS SV208 B 86.64 13.16 15.19 71.59 DSCG SV208 B 77.76 29.70 38.19 143.92
AS SV208 C 92.09 9.13 9.91 44.66 DSCG SV208 C 91.01 33.97 37.33 161.39
AS SV208 C 93.54 8.71 9.31 41.02 DSCG SV208 C 90.98 34.08 37.46 167.36
AS SV208 C 91.04 11.85 13.02 57.74 DSCG SV208 C 87.94 32.11 36.52 158.53
AS SV208 D 87.98 8.92 10.14 45.47 DSCG SV208 D 94.75 22.80 24.07 111.99
AS SV208 D 93.38 6.65 7.13 31.36 DSCG SV208 D 92.72 22.83 24.62 108.67
AS SV208 D 88.80 6.68 7.52 35.23 DSCG SV208 D 86.33 20.89 24.19 104.76
AS SV473 A 77.80 23.39 30.06 114.70 DSCG ML058 A 71.48 39.58 55.37 189.54
AS SV473 A 91.05 13.65 14.99 66.70 DSCG ML058 A 80.47 48.01 59.66 225.75
AS SV473 A 88.83 12.64 14.23 68.75 DSCG ML058 A 79.54 42.42 53.33 211.19
AS SV473 B 88.60 9.80 11.06 47.48 DSCG ML058 B 69.82 38.54 55.20 186.56
AS SV473 B 93.50 9.14 9.78 45.11 DSCG ML058 B 71.29 35.95 50.42 175.88
AS SV473 B 90.33 12.47 13.81 67.27 DSCG ML058 B 70.40 36.95 52.48 186.98
AS SV473 C 93.80 11.13 11.86 54.02 DSCG ML058 C 85.74 34.38 40.10 167.83
AS SV473 C 95.44 8.54 8.95 42.73 DSCG ML058 C 83.75 30.98 37.00 150.00
AS SV473 C 95.59 10.26 10.74 52.39 DSCG ML058 C 83.79 33.31 39.76 166.34
AS SV473 D 91.84 8.89 9.68 44.21 DSCG ML058 D 86.76 26.87 30.98 134.02
AS SV473 D 96.25 5.68 5.91 28.18 DSCG ML058 D 80.97 18.40 22.73 89.22
AS SV473 D 91.36 5.87 6.43 30.34 DSCG ML058 D 84.62 17.35 20.51 88.99
AS ML058 A 81.16 45.43 55.98 236.28 DSCG SV473 A 79.00 43.63 55.23 214.12
AS ML058 A 85.64 42.92 50.12 210.57 DSCG SV473 A 75.51 31.02 41.08 143.62
AS ML058 A 83.82 40.28 48.05 220.68 DSCG SV473 A 75.42 32.57 43.19 163.30
AS ML058 B 77.23 36.19 46.86 177.41 DSCG SV473 B 83.36 39.08 46.87 191.69
AS ML058 B 73.64 35.24 47.86 177.95 DSCG SV473 B 81.40 34.81 42.76 162.52
AS ML058 B 76.59 36.40 47.52 191.28 DSCG SV473 B 79.53 30.12 37.88 149.88
AS ML058 C 88.30 31.43 35.59 160.26 DSCG SV473 C 91.89 33.70 36.67 154.83
AS ML058 C 87.14 31.03 35.61 160.00 DSCG SV473 C 90.85 36.99 40.72 169.74
AS ML058 C 84.99 28.60 33.66 142.44 DSCG SV473 C 89.43 36.14 40.41 174.04
AS ML058 D 84.66 22.96 27.12 114.70 DSCG SV473 D 92.43 27.12 29.34 129.07
AS ML058 D 80.74 17.70 21.92 88.07 DSCG SV473 D 91.17 25.78 28.28 120.30
AS ML058 D 84.86 23.53 27.72 127.05 DSCG SV473 D 88.45 23.18 26.21 114.99
AS ML780 A 80.22 27.39 34.15 151.76 DSCG ML780 A 82.61 47.26 57.21 231.87
AS ML780 A 82.79 38.30 46.26 191.70 DSCG ML780 A 81.35 50.00 61.46 232.35
AS ML780 A 76.32 36.31 47.57 194.66 DSCG ML780 A 79.00 41.66 52.74 209.40
AS ML780 B 72.39 28.53 39.42 142.22 DSCG ML780 B 68.76 42.51 61.82 204.21
AS ML780 B 69.62 35.47 50.95 182.50 DSCG ML780 B 67.11 39.37 58.66 187.04
AS ML780 B 79.50 35.10 44.15 200.23 DSCG ML780 B 72.73 38.93 53.53 194.73
AS ML780 C 81.52 17.50 21.46 83.57 DSCG ML780 C 85.31 39.23 45.99 189.42
AS ML780 C 87.49 18.70 21.37 98.75 DSCG ML780 C 82.57 34.30 41.54 163.72
AS ML780 C 85.43 26.25 30.73 135.23 DSCG ML780 C 83.13 37.05 44.57 185.55
AS ML780 D 89.99 13.03 14.48 74.88 DSCG ML780 D 85.46 23.58 27.60 112.65
AS ML780 D 86.46 16.26 18.80 81.25 DSCG ML780 D 88.70 23.82 26.85 116.69
AS ML780 D 76.52 11.14 14.56 58.48 DSCG ML780 D 83.92 17.51 20.87 90.12
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APPENDIX 3-A2. – TSLI performance data of ipratropium bromide monohydrate (IPB) and 
fluticasone propionate (FP) (The order has been sorted for the ease of data analyses; drug 
conc 2%(w/w); airflow rate Q = 60 L/min; actuation duration 10 s; with solenoid switch) 
Drug Carrier SET ED 
(%) 
FPFTD
(%) 
FPFED
 (%) 
FPM   
(μg) 
Drug Carrier SET ED 
(%) 
FPFTD
(%) 
FPFED
 (%) 
FPM   
(μg) 
IPB SV208 A 71.95 33.06 45.95 173.38 FP SV208 A 72.21 15.64 21.65 78.03
IPB SV208 A 69.57 29.12 41.85 148.92 FP SV208 A 68.70 14.98 21.80 78.42
IPB SV208 A 71.25 32.91 46.19 170.62 FP SV208 A 69.07 14.75 21.36 78.34
IPB SV208 B 72.84 31.96 43.87 151.23 FP SV208 B 68.72 13.47 19.59 65.05
IPB SV208 B 71.54 32.77 45.81 158.46 FP SV208 B 68.79 13.53 19.67 65.83
IPB SV208 B 71.83 33.60 46.77 157.69 FP SV208 B 68.80 13.56 19.71 66.61
IPB SV208 C 87.06 31.91 36.65 145.38 FP SV208 C 84.37 15.86 18.79 80.83
IPB SV208 C 88.07 36.14 41.04 157.23 FP SV208 C 88.05 15.12 17.17 79.97
IPB SV208 C 88.63 33.63 37.94 160.15 FP SV208 C 89.52 16.23 18.13 81.76
IPB SV208 D 91.04 29.48 32.38 161.23 FP SV208 D 86.90 10.55 12.14 50.69
IPB SV208 D 89.07 32.23 36.19 159.54 FP SV208 D 88.08 14.41 16.36 74.61
IPB SV208 D 91.83 30.20 32.89 137.38 FP SV208 D 89.23 15.00 16.81 81.68
IPB SV473 A 68.09 33.94 49.84 161.38 FP SV473 A 69.66 17.09 24.53 87.28
IPB SV473 A 67.22 31.26 46.51 146.15 FP SV473 A 70.91 16.27 22.94 82.23
IPB SV473 A 71.40 28.81 40.35 150.15 FP SV473 A 69.97 13.66 19.52 73.45
IPB SV473 B 73.26 24.74 33.77 132.92 FP SV473 B 70.59 14.30 20.26 71.74
IPB SV473 B 72.71 29.34 40.36 136.15 FP SV473 B 73.72 16.01 21.72 82.38
IPB SV473 B 67.05 23.51 35.07 120.31 FP SV473 B 70.91 13.99 19.73 69.87
IPB SV473 C 83.46 36.27 43.46 193.38 FP SV473 C 86.45 14.88 17.21 79.04
IPB SV473 C 81.02 34.04 42.01 169.23 FP SV473 C 86.77 14.80 17.06 73.06
IPB SV473 C 86.59 33.20 38.34 163.85 FP SV473 C 85.94 13.63 15.86 68.91
IPB SV473 D 87.76 27.46 31.29 144.00 FP SV473 D 90.04 12.16 13.51 55.73
IPB SV473 D 90.32 27.74 30.71 146.62 FP SV473 D 91.48 11.37 12.43 51.37
IPB SV473 D 90.69 28.91 31.87 143.38 FP SV473 D 90.03 8.86 9.85 41.35
IPB ML058 A 72.17 37.74 52.29 190.31 FP ML058 A 67.12 20.84 31.05 112.38
IPB ML058 A 69.50 31.62 45.50 164.92 FP ML058 A 65.62 21.28 32.43 111.68
IPB ML058 A 71.97 28.00 38.90 149.38 FP ML058 A 64.22 18.90 29.44 100.80
IPB ML058 B 70.00 27.41 39.16 147.85 FP ML058 B 50.75 20.29 39.99 94.21
IPB ML058 B 63.54 37.05 58.31 179.08 FP ML058 B 52.51 16.01 30.49 74.81
IPB ML058 B 66.81 36.65 54.86 187.38 FP ML058 B 51.19 20.09 39.25 86.66
IPB ML058 C 83.84 35.12 41.89 187.08 FP ML058 C 82.88 13.97 16.85 69.02
IPB ML058 C 77.60 29.63 38.18 176.00 FP ML058 C 79.87 11.46 14.35 59.66
IPB ML058 C 80.31 29.98 37.33 155.85 FP ML058 C 83.24 12.53 15.05 67.54
IPB ML058 D 85.39 21.44 25.11 116.15 FP ML058 D 82.08 15.94 19.42 74.53
IPB ML058 D 88.31 29.02 32.87 150.00 FP ML058 D 88.20 13.78 15.62 66.84
IPB ML058 D 89.99 27.04 30.05 131.38 FP ML058 D 81.73 17.00 20.79 72.98
IPB ML780 A 66.89 37.49 56.04 186.46 FP ML780 A 70.90 25.76 36.34 131.89
IPB ML780 A 70.17 36.44 51.93 196.62 FP ML780 A 68.83 25.46 36.98 134.38
IPB ML780 A 70.02 34.93 49.89 181.38 FP ML780 A 65.53 21.48 32.77 112.54
IPB ML780 B 67.12 31.56 47.02 167.85 FP ML780 B 58.40 22.70 38.87 109.81
IPB ML780 B 70.04 38.25 54.61 188.92 FP ML780 B 62.27 25.95 41.67 135.16
IPB ML780 B 63.66 38.58 60.60 182.31 FP ML780 B 60.19 25.19 41.85 123.73
IPB ML780 C 84.59 26.85 31.74 124.92 FP ML780 C 78.74 20.08 25.50 107.88
IPB ML780 C 84.13 27.18 32.30 139.08 FP ML780 C 79.26 19.76 24.93 107.41
IPB ML780 C 79.05 28.86 36.51 129.08 FP ML780 C 84.69 27.09 31.98 146.58
IPB ML780 D 88.47 21.07 23.82 102.46 FP ML780 D 88.20 21.46 24.34 104.38
IPB ML780 D 82.19 23.16 28.18 124.31 FP ML780 D 87.48 22.14 25.31 110.91
IPB ML780 D 83.46 23.37 28.00 129.23 FP ML780 D 82.89 22.35 26.96 108.11
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Appendix. 4-A. TSLI Performance Data Using SET (2% (w/w) drug conc., 10 s actuation) 
 
Drug Lactose Tube ED (%) FPFTD (%) FPFED (%) 
AS Treh A 86.0 13.9 16.1 
AS Treh A 93.0 12.1 13.0 
AS Treh A 91.7 12.5 13.6 
AS Treh B 94.5 9.0 9.6 
AS Treh B 94.2 8.4 8.9 
AS Treh B 92.4 11.2 12.1 
AS Treh C 95.4 7.4 7.8 
AS Treh C 95.1 6.4 6.7 
AS Treh C 95.8 9.4 9.8 
AS Treh D 95.3 6.3 6.6 
AS Treh D 89.9 4.1 4.5 
AS Treh D 94.0 5.7 6.1 
AS Mann A 88.0 12.2 13.8 
AS Mann A 94.1 10.2 10.8 
AS Mann A 89.9 9.9 11.0 
AS Mann B 93.9 9.3 10.0 
AS Mann B 94.3 6.6 7.0 
AS Mann B 91.2 7.4 8.1 
AS Mann C 94.8 8.8 9.3 
AS Mann C 95.7 5.7 6.0 
AS Mann C 94.0 8.0 8.5 
AS Mann D 90.1 5.0 5.6 
AS Mann D 97.3 5.2 5.4 
AS Mann D 93.0 5.2 5.6 
DSCG Treh A 86.9 22.1 25.4 
DSCG Treh A 85.6 15.3 17.9 
DSCG Treh A 83.2 11.8 14.2 
DSCG Treh B 88.4 17.4 19.7 
DSCG Treh B 95.2 17.3 18.2 
DSCG Treh B 86.4 17.5 20.3 
DSCG Treh C 94.2 16.8 17.8 
DSCG Treh C 94.4 16.6 17.6 
DSCG Treh C 95.4 16.5 17.3 
DSCG Treh D 95.4 11.2 11.7 
DSCG Treh D 97.2 11.4 11.7 
DSCG Treh D 93.9 10.4 11.1 
DSCG Mann A 88.1 27.0 30.7 
DSCG Mann A 86.8 20.4 23.5 
DSCG Mann A 85.0 19.0 22.4 
DSCG Mann B 90.0 17.1 19.0 
DSCG Mann B 88.6 17.6 19.9 
DSCG Mann B 86.3 15.4 17.8 
DSCG Mann C 93.7 15.9 17.0 
DSCG Mann C 92.5 18.2 19.7 
DSCG Mann C 89.8 14.0 15.5 
DSCG Mann D 94.7 12.9 13.6 
DSCG Mann D 90.0 7.4 8.2 
DSCG Mann D 86.5 9.4 10.9 
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Drug Lactose Tube ED (%) FPFTD (%) FPFED (%) 
IPR Treh A 76.7 12.3 16.1 
IPR Treh A 80.5 16.5 20.5 
IPR Treh A 81.0 16.3 20.2 
IPR Treh B 80.8 16.3 20.1 
IPR Treh B 84.3 15.5 18.4 
IPR Treh B 83.8 14.7 17.6 
IPR Treh C 88.0 9.8 11.1 
IPR Treh C 92.0 12.1 13.1 
IPR Treh C 91.6 10.3 11.3 
IPR Treh D 90.8 4.2 4.6 
IPR Treh D 93.3 5.0 5.4 
IPR Treh D 93.7 6.4 6.9 
IPR Mann A 75.0 8.3 11.1 
IPR Mann A 78.4 9.5 12.1 
IPR Mann A 72.9 9.5 13.0 
IPR Mann B 77.7 12.6 16.2 
IPR Mann B 74.3 11.4 15.3 
IPR Mann B 79.0 10.2 12.9 
IPR Mann C 92.3 10.0 10.3 
IPR Mann C 90.4 8.7 9.7 
IPR Mann C 86.7 5.3 6.1 
IPR Mann D 84.8 3.2 3.8 
IPR Mann D 74.6 1.8 2.4 
IPR Mann D 72.9 3.7 5.1 
FLUT Treh A 64.9  7.9  12.1  
FLUT Treh A 67.3  8.1  12.1  
FLUT Treh A 65.7  11.0  16.7  
FLUT Treh B 66.6  4.9  7.3  
FLUT Treh B 64.7  5.4  8.3  
FLUT Treh B 65.8  5.2  7.9  
FLUT Treh C 87.6  8.3  9.4  
FLUT Treh C 86.2  11.4  13.2  
FLUT Treh C 86.9  8.8  10.2  
FLUT Treh D 91.7  7.1  7.7  
FLUT Treh D 88.4  6.5  7.4  
FLUT Treh D 90.6  6.7  7.4  
FLUT Mann A 67.5  11.8  17.5  
FLUT Mann A 68.9  11.6  16.8  
FLUT Mann A 71.8  14.6  20.3  
FLUT Mann B 73.6  15.2  20.7  
FLUT Mann B 77.4  13.9  17.9  
FLUT Mann B 76.2  14.6  19.1  
FLUT Mann C 90.5  13.9  15.4  
FLUT Mann C 84.4  14.7  17.4  
FLUT Mann C 86.9  14.4  16.5  
FLUT Mann D 89.7  9.7  10.8  
FLUT Mann D 91.6  9.8  10.7  
FLUT Mann D 90.6  10.2  11.2  
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Appendix 5-A. The Schematic Calculation of Aerodynamic Parameters of Extra SETs. 
 
Aerosol 
Device 
Reynold’s No., 
Re, 
Shear Stress τs 
(N/m2) 
Power 
(Nm/s) 
Pressure drop, 
∆P (N/m2) 
SET A 18443 13.143 6.9194 6919.38 
SET A1 16196 8.742   
SET B 13440 4.342 1.4915 1491.55 
SET B1 12583 3.270   
SET C 11066 2.199 0.7470 747.01 
SET C1 10126 1.412   
SET D 7720 0.624 0.1557 155.69 
 
Inhalator 25865 42.934 5.3410 5340.98 
Rotahaler 10810 2.026 0.4575 457.53 
Aerolizer 8881 8.248 1.8500 1850.00 
 
1) The SET parameter 
New SET A1, B1, C1 have mean shear stress between SET A and B, SET B and C, and SET C and  
D, respectively, which are 1.412, 3.270, 8.742 N/m2. 
2) The shear stress determined by Re-τ1/4 linear regression. 
 
Shear^0.25 vs Re
τ1/4
0.0 0.5 1.0 1.5 2.0
R
e
0
5000
10000
15000
20000
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The linear regression equation was y = 9635x – 376.21, R2 = 0.9964.  
The Re was then determined accordingly: 10126, 12583, and 16196. From equation below, the inlet  
 
inner diameter d can be determined: 8.3, 6.7, and 5.2 
25
3
4
11081.1
10120.1
d
d
A
QdVdeR
××××
×××===
−
−
πη
ρ
η
ρ
 
3) SET-A1 and SET-B1 use I-peripherally-located dosage table, 
 
4) SET-C1 uses II-centrally-located dosage table. (Fig.1 below) 
 
 
 
SET External outlet 
length (a) 
Inlet 
length (b)
Internal outlet 
length (c) 
Powder dosage 
length (d) 
Inlet outer 
diameter (e) 
Inlet inner 
diameter (f)
A 150 300 140 10 6.3 4.5 
A1 144 300 134 10 7.0 5.2 
B 135 300 125 10 8.0 6.2 
B1 133 300 123 10 8.5 6.7 
C 127 600 117 10 9.5 7.7 
C1 121 600 111 10 10.1 8.3 
D 99 600 90 10 12.7 11.0 
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Appendix 5-B. TSLI Performance Data: Aerosolization Performance Using Three Extra SETs. 
 
Drug Run SET τs (N/m2)
ED 
(%) 
FPFTD   
(%) 
FPFED   
(%) 
τs/FPFTD*102 
(N/m2/%*102) 
DSCG ML780 A1 8.742 75.9 40.17 52.9  21.76 
DSCG ML780 A1 8.742 75.4 43.88 58.2  19.92 
DSCG ML780 A1 8.742 74.0 37.34 50.4  23.41 
DSCG ML780 B1 2.775 65.5 31.33 47.8  8.86 
DSCG ML780 B1 2.775 64.3 30.05 46.7  9.23 
DSCG ML780 B1 2.775 62.7 30.69 48.9  9.04 
DSCG ML780 C1 1.412 80.9 29.09 36.0  4.85 
DSCG ML780 C1 1.412 78.4 26.42 33.7  5.34 
DSCG ML780 C1 1.412 80.7 27.88 34.6  5.06 
AS Mann A1 8.742 91.3 8.7 9.5  100.72 
AS Mann A1 8.742 91.9 13.6 14.8  64.32 
AS Mann A1 8.742 92.7 9.1 9.8  95.98 
AS Mann B1 2.775 92.2 6.77 7.3  41.02 
AS Mann B1 2.775 92.9 5.74 6.2  48.34 
AS Mann B1 2.775 90.4 5.76 6.4  48.21 
AS Mann C1 1.412 94.0 5.5 5.8  25.89 
AS Mann C1 1.412 95.3 8.7 9.1  16.21 
AS Mann C1 1.412 93.7 4.9 5.2  28.73 
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Appendix 5-C. Schematic Calculation of Aerodynamic Shear Stress of DPI devices: e.g. Aerolizer® 
1) The mouthpiece length (L = 4.7×10-3 m) of the Aerolizer® was determined using a caliper. The 
length was confirmed in the literature. (Pharm. Res., 2007, 24, 1450-1456). 
2) The device pressure drop can be measured using a manometer. The airflow rate was set at Q = 60 
L/min. This parameter was also reported in literature (ΔP = 1850 N/m2 at 60 L/min). (Pharm. 
Res.,2005, 22, 1445-1453). 
3) The airflow velocity (umean) that was volume-averaged throughout the whole device was 14.1 m/s 
at 60 L/min. (Pharm. Res., 2005, 22, 1445-1453). 
4) The critical diameter (d) of the device can be calculated according to Poiseuille’s law: (Hickey, 
A.J., Ganderton, D., Fluid flow: in Pharmaceutical Process Engineering, 2001, Marcel Dekker, Inc., 
New York, NY, pp. 1-35). 
2
32
d
LuP meanμ=Δ   ; 　 is the air dynamic viscosity 1.81 × 10-5 kg/(m s);    
The critical diameter, d = 1.44 × 10-4 m 
5) The viscous shear stress (τs) was calculated according to Kolmogorov theory. (see Chapter 1, 
section 1.4.2).  
νεν
εμτ ;/1.14)2.0(22
332/1
smuVwhere
d
V
d
V
where means ==≈≅⎟⎠
⎞⎜⎝
⎛= is the air kinematic 
viscosity 1.5 × 10-6 m2/s. 
τs = 8.248 N/m2. 
It would be easy to calculate the other two aerodynamic parameters, Re and power: 
== μ
ρ VDaRe 8881, where D was the diameter of the tube with grid, calculated from Q and V. 
power = 1.850 Nm/s. 
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Appendix 5-D. TSLI Performance Data: Aerosolization Performance Using Rotahaler® and 
Aerolizer®. 
Factor A Factor B Factor C ED% FPFTD% FPFED% FPM
ASMann Gelatin Rotahaler 54.9 4.9 8.9 24.4 
ASMann Gelatin Rotahaler 77.7 10.2 13.2 51.2 
ASMann Gelatin Rotahaler 73.8 7.3 9.8 36.3 
ASMann HPMC Rotahaler 83.4 13.0 15.6 65.2 
ASMann HPMC Rotahaler 76.7 8.0 10.4 40.3 
ASMann HPMC Rotahaler 78.8 7.7 9.8 38.7 
DSCGML780 Gelatin Rotahaler 60.4 28.4 47.1 142.8
DSCGML780 Gelatin Rotahaler 59.1 32.6 55.2 163.2
DSCGML780 Gelatin Rotahaler 52.4 27.6 52.7 137.9
DSCGML780 HPMC Rotahaler 55.1 25.6 46.4 127.3
DSCGML780 HPMC Rotahaler 62.6 21.6 34.5 108.2
DSCGML780 HPMC Rotahaler 60.4 33.5 55.5 166.3
ASMann Gelatin Aerolizer 85.3 9.2 10.7 45.6 
ASMann Gelatin Aerolizer 86.4 10.9 12.6 54.8 
ASMann Gelatin Aerolizer 77.0 12.4 16.2 62.2 
ASMann HPMC Aerolizer 66.7 6.3 9.4 31.3 
ASMann HPMC Aerolizer 66.6 9.0 13.5 44.9 
ASMann HPMC Aerolizer 79.2 8.7 11.0 43.4 
DSCGML780 Gelatin Aerolizer 77.5 33.4 43.1 163.6
DSCGML780 Gelatin Aerolizer 75.9 38.6 50.8 192.9
DSCGML780 Gelatin Aerolizer 80.6 40.5 50.2 198.4
DSCGML780 HPMC Aerolizer 82.6 37.7 45.6 186.1
DSCGML780 HPMC Aerolizer 76.1 31.4 41.2 155.5
DSCGML780 HPMC Aerolizer 82.2 36.6 44.6 179.6
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Appendix 5-E. Performance data of FP-Treh Before and After Storage in the Desiccator. 
 
Drug Lactose Tube ED FPFTD FPFED 
Before Storage* 
FP Treh A 64.9  7.9  12.1  
FP Treh A 67.3  8.1  12.1  
FP Treh A 65.7  11.0  16.7  
FP Treh B 66.6  4.9  7.3  
FP Treh B 64.7  5.4  8.3  
FP Treh B 65.8  5.2  7.9  
FP Treh C 87.6  8.3  9.4  
FP Treh C 86.2  11.4  13.2  
FP Treh C 86.9  8.8  10.2  
FP Treh D 91.7  7.1  7.7  
FP Treh D 88.4  6.5  7.4  
FP Treh D 90.6  6.7  7.4  
After Storage**  
FP Treh A 66.6  6.3  9.5  
FP Treh A 63.0  6.9  11.0  
FP Treh A 58.3  5.1  8.8  
FP Treh A1 67.6  6.7  10.0  
FP Treh A1 58.9  6.0  10.1  
FP Treh A1 60.5  3.9  6.5  
FP Treh B 67.3  5.0  7.4  
FP Treh B 67.6  6.7  10.0  
FP Treh B 60.1  4.2  7.0  
FP Treh B1 63.9  3.9  6.2  
FP Treh B1 66.2  4.0  6.0  
FP Treh B1 70.0  4.8  6.9  
FP Treh C 85.1  4.8  5.6  
FP Treh C 89.0  5.2  5.8  
FP Treh C 84.4  4.4  5.3  
FP Treh C1 79.7  4.9  6.2  
FP Treh C1 79.9  3.0  3.8  
FP Treh C1 75.3  3.1  4.1  
FP Treh D 87.9  2.5  2.9  
FP Treh D 85.3  1.9  2.2  
FP Treh D 87.9  5.3  6.0  
 
*   Data adapted from Chapter 4 
** Newly generated data 
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Appendix 6-A. The Amount of Fatty Acid Associated on the Surface of Lactose 
Monohydrate Powder Treated with Stearic Acid (SA), Palmitic Acid (PA), Myristic Acid 
(MA) and Lauric Acid (LA). 
 
Equil. 
Conc. 
SA/SV 
(μg/g) 
SA/ML 
(μg/g) 
PA/SV
(μg/g)
PA/ML
(μg/g) 
MA/SV
(μg/g) 
MA/ML 
(μg/g) 
LA/SV 
(μg/g) 
LA/ML
(μg/g) 
0.2 -- 4.14 6.22 9.92 12.92 14.05 6.08 - 
0.4 7.16 12.80 7.29 12.19 17.76 19.03 8.17 15.92 
0.6 7.59 13.17 12.00 14.73 23.03 21.91 20.14 22.67 
0.8 9.89 13.17 17.58 23.55 23.92 30.19 41.66 44.48 
1.6 33.37 41.88 28.33 47.94 39.18 26.94 57.22 71.78 
2.4 63.71 67.92 41.42 73.32 61.39 67.01 74.17 102.39
3.2 91.87 91.63 77.47 84.47 70.19 99.46 104.26 147.34
4.8 143.29 131.98 116.97 126.05 114.52 126.76 167.01 216.16
6.0 166.40 194.05 143.30 159.60 107.37 178.87 183.85 246.32
8.0 242.40 197.56 183.65 236.14 185.86 226.02 217.56 - 
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Appendix 6-B. The Aerosolization Performance after Stearic Acid Coating (AS formulation) 
 
Drug Carrier Tube Conc (%) ED (%) FPFTD (%) FPFED (%)
AS SV473-control A 2.0  76.75 12.4  16.1  
AS SV473-control A 2.0  75.36 11.9  15.8  
AS SV473-control A 2.0  80.25 12.0  15.0  
AS SV473-control B 2.0  84 8.7  10.4  
AS SV473-control B 2.0  81.4 8.8  10.8  
AS SV473-control B 2.0  77.24 7.5  9.7  
AS SV473-control C 2.0  84.63 7.8  9.3  
AS SV473-control C 2.0  84.77 8.1  9.5  
AS SV473-control C 2.0  86.89 8.6  9.9  
AS SV473-control D 2.0  82.45 3.8  4.6  
AS SV473-control D 2.0  86.32 6.1  7.1  
AS SV473-control D 2.0  90.8  7.2  8.0  
AS SV473-lowSA A 2.0  90.1  14.6  16.2  
AS SV473-lowSA A 2.0  91.9  17.0  18.5  
AS SV473-lowSA A 2.0  87.1  13.2  15.2  
AS SV473-lowSA B 2.0  88.2  11.4  12.9  
AS SV473-lowSA B 2.0  84.9  10.9  12.9  
AS SV473-lowSA B 2.0  85.9  9.1  10.6  
AS SV473-lowSA C 2.0  90.4  9.1  10.1  
AS SV473-lowSA C 2.0  88.0  10.5  12.0  
AS SV473-lowSA C 2.0  91.1  10.0  11.0  
AS SV473-lowSA D 2.0  91.4  7.2  7.9  
AS SV473-lowSA D 2.0  84.6  5.1  6.1  
AS SV473-lowSA D 2.0  92.3  5.6  6.1  
AS SV473-highSA A 2.0  83.1  20.5  24.7  
AS SV473-highSA A 2.0  82.4  18.5  22.5  
AS SV473-highSA A 2.0  79.5  16.7  21.0  
AS SV473-highSA B 2.0  85.3  9.1  10.7  
AS SV473-highSA B 2.0  82.5  10.8  13.1  
AS SV473-highSA B 2.0  86.7  15.8  18.2  
AS SV473-highSA C 2.0  83.0  8.1  9.8  
AS SV473-highSA C 2.0  92.2  10.5  11.4  
AS SV473-highSA C 2.0  83.9  8.5  10.1  
AS SV473-highSA D 2.0  89.5  9.7  10.9  
AS SV473-highSA D 2.0  90.4  7.8  8.6  
AS SV473-highSA D 2.0  91.0  7.9  8.6  
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Appendix 6-B’ (continued). 
 
Drug Carrier Tube Conc (%) ED (%) FPFTD (%) FPFED (%)
AS ML058-control A 2.0  78.4 35.3  45.0  
AS ML058-control A 2.0  77.1 33.4  43.3  
AS ML058-control A 2.0  76.1 33.2  43.6  
AS ML058-control B 2.0  76.6 31.3  40.9  
AS ML058-control B 2.0  76.3 31.6  41.4  
AS ML058-control B 2.0  74.6 28.7  38.4  
AS ML058-control C 2.0  78.3 24.8  31.7  
AS ML058-control C 2.0  77.8 24.3  31.2  
AS ML058-control C 2.0  79 23.7  29.9  
AS ML058-control D 2.0  83.4 20.0  23.9  
AS ML058-control D 2.0  83.1 18.5  22.3  
AS ML058-control D 2.0  84.1 19.6  23.3  
AS ML058-lowSA A 2.0  80.5  35.9  44.6  
AS ML058-lowSA A 2.0  80.0  39.3  49.1  
AS ML058-lowSA A 2.0  84.1  42.5  50.6  
AS ML058-lowSA D 2.0  84.5  21.6  25.5  
AS ML058-lowSA D 2.0  80.8  20.7  25.7  
AS ML058-lowSA D 2.0  82.1  19.2  23.4  
AS ML058-highSA A 2.0  81.5  42.2  51.7  
AS ML058-highSA A 2.0  79.9  39.2  49.0  
AS ML058-highSA A 2.0  80.2  40.6  50.7  
AS ML058-highSA B 2.0  74.2  33.7  45.3  
AS ML058-highSA B 2.0  77.3  34.2  44.3  
AS ML058-highSA B 2.0  77.4  37.7  48.7  
AS ML058-highSA C 2.0  86.8  31.1  35.8  
AS ML058-highSA C 2.0  85.4  33.0  38.7  
AS ML058-highSA C 2.0  87.5  33.4  38.1  
AS ML058-highSA D 2.0  88.0  20.7  23.6  
AS ML058-highSA D 2.0  87.5  22.9  26.2  
AS ML058-highSA D 2.0  86.1  23.0  26.7  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  288
Appendix 6-C. The Aerosolization Performance after Stearic Acid Coating (FP formulation) 
 
Drug Carrier Tube Conc (%) ED (%) FPFTD (%) FPFED (%) 
FP SV473-control A 2.0 49.5 4.7 9.6 
FP SV473-control A 2.0 55.5 3.6 6.5 
FP SV473-control A 2.0 54.8 5.1 9.2 
FP SV473-control B 2.0 51.0 4.1 8.1 
FP SV473-control B 2.0 53.4 4.2 7.8 
FP SV473-control B 2.0 50.6 3.4 6.7 
FP SV473-control C 2.0 83.3 1.9 2.3 
FP SV473-control C 2.0 82.5 2.2 2.7 
FP SV473-control C 2.0 81.7 3.9 4.7 
FP SV473-control D 2.0 75.4 1.4 1.8 
FP SV473-control D 2.0 74.3 1.5 2.0 
FP SV473-control D 2.0 77.2 1.8 2.3 
FP ML058-control A 2.0 54.5 15.0 27.5 
FP ML058-control A 2.0 51.8 13.6 26.3 
FP ML058-control A 2.0 54.1 13.8 25.4 
FP ML058-control B 2.0 44.2 9.6 21.6 
FP ML058-control B 2.0 45.9 9.5 20.8 
FP ML058-control B 2.0 50.7 12.1 23.9 
FP ML058-control C 2.0 80.1 11.9 14.8 
FP ML058-control C 2.0 80.4 11.2 14.0 
FP ML058-control C 2.0 78.2 9.7 12.4 
FP ML058-control D 2.0 81.4 10.3 12.6 
FP ML058-control D 2.0 80.0 9.7 12.1 
FP ML058-control D 2.0 81.3 8.8 10.8 
FP SV473-lowSA A 2.0 63.4 11.8 18.7 
FP SV473-lowSA A 2.0 63.1 11.0 17.5 
FP SV473-lowSA D 2.0 81.6 6.1 7.5 
FP SV473-lowSA D 2.0 81.4 5.7 7.0 
FP SV473-highSA A 2.0 66.9 14.9 22.3 
FP SV473-highSA A 2.0 68.5 17.6 25.7 
FP SV473-highSA D 2.0 84.3 7.0 8.3 
FP SV473-highSA D 2.0 83.2 6.7 8.1 
FP ML058-lowSA A 2.0 58.8 21.9 37.2 
FP ML058-lowSA A 2.0 59.1 22.0 37.3 
FP ML058-lowSA D 2.0 82.8 20.5 24.7 
FP ML058-lowSA D 2.0 83.5 20.8 24.9 
FP ML058-highSA A 2.0 67.3 26.6 39.5 
FP ML058-highSA A 2.0 67.2 24.5 36.5 
FP ML058-highSA D 2.0 81.6 16.6 20.3 
FP ML058-highSA D 2.0 84.0 22.1 26.3 
